
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Exploring the metabolic signaling network of GFPT in cancer - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE533A9B8AF33243053A9B004C4EA1A3.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="cddiscover">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365115/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Cell Death Discovery">
<meta name="citation_title" content="Exploring the metabolic signaling network of GFPT in cancer">
<meta name="citation_author" content="Chibuzo Sampson">
<meta name="citation_author_institution" content="Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 110042 Shenyang, China">
<meta name="citation_author_institution" content="Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China">
<meta name="citation_author" content="Pengfei Li">
<meta name="citation_author_institution" content="Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 110042 Shenyang, China">
<meta name="citation_author" content="Yiqian Wang">
<meta name="citation_author_institution" content="Department of Radiotherapy, The First Affiliated Hospital of Dalian Medical University, 116000 Dalian, China">
<meta name="citation_author" content="Jing Liu">
<meta name="citation_author_institution" content="Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China">
<meta name="citation_author" content="Jing Lv">
<meta name="citation_author_institution" content="Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China">
<meta name="citation_author" content="Tian Xia">
<meta name="citation_author_institution" content="Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China">
<meta name="citation_author" content="Hai-long Piao">
<meta name="citation_author_institution" content="Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 110042 Shenyang, China">
<meta name="citation_author_institution" content="Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China">
<meta name="citation_author" content="Yegang Ma">
<meta name="citation_author_institution" content="Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 110042 Shenyang, China">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="11">
<meta name="citation_firstpage" content="388">
<meta name="citation_doi" content="10.1038/s41420-025-02687-3">
<meta name="citation_pmid" content="40830088">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365115/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365115/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365115/pdf/41420_2025_Article_2687.pdf">
<meta name="description" content="Metabolic homeostasis is essential for cellular function in living organisms. In cancer cells, metabolic processes are reprogrammed to meet the energy demands and biosynthetic needs for rapid growth. This reprogramming enhances nutrient flux through ...">
<meta name="og:title" content="Exploring the metabolic signaling network of GFPT in cancer">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Metabolic homeostasis is essential for cellular function in living organisms. In cancer cells, metabolic processes are reprogrammed to meet the energy demands and biosynthetic needs for rapid growth. This reprogramming enhances nutrient flux through ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365115/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12365115">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1038/s41420-025-02687-3"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/41420_2025_Article_2687.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365115%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12365115/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12365115/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365115/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-cddiscover.jpg" alt="Cell Death Discovery logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Cell Death Discovery" title="Link to Cell Death Discovery" shape="default" href="http://www.nature.com/cddiscovery/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Cell Death Discov</button></div>. 2025 Aug 19;11:388. doi: <a href="https://doi.org/10.1038/s41420-025-02687-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1038/s41420-025-02687-3</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cell%20Death%20Discov%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell%20Death%20Discov%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cell%20Death%20Discov%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Cell%20Death%20Discov%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Exploring the metabolic signaling network of GFPT in cancer</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sampson%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Chibuzo Sampson</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Chibuzo Sampson</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 110042 Shenyang, China </div>
<div class="p">
<sup>2</sup>Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sampson%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chibuzo Sampson</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Pengfei Li</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Pengfei Li</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 110042 Shenyang, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Pengfei Li</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Yiqian Wang</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Yiqian Wang</span></h3>
<div class="p">
<sup>3</sup>Department of Radiotherapy, The First Affiliated Hospital of Dalian Medical University, 116000 Dalian, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yiqian Wang</span></a>
</div>
</div>
<sup>3,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Jing Liu</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Jing Liu</span></h3>
<div class="p">
<sup>2</sup>Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jing Liu</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lv%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Jing Lv</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Jing Lv</span></h3>
<div class="p">
<sup>2</sup>Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lv%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jing Lv</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xia%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Tian Xia</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Tian Xia</span></h3>
<div class="p">
<sup>2</sup>Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xia%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tian Xia</span></a>
</div>
</div>
<sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Piao%20HL%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Hai-long Piao</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Hai-long Piao</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 110042 Shenyang, China </div>
<div class="p">
<sup>2</sup>Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Piao%20HL%22%5BAuthor%5D" class="usa-link"><span class="name western">Hai-long Piao</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ma%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Yegang Ma</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Yegang Ma</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 110042 Shenyang, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ma%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yegang Ma</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 110042 Shenyang, China </div>
<div id="Aff2">
<sup>2</sup>Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, China </div>
<div id="Aff3">
<sup>3</sup>Department of Radiotherapy, The First Affiliated Hospital of Dalian Medical University, 116000 Dalian, China </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Nov 28; Revised 2025 Jul 16; Accepted 2025 Aug 7; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12365115  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40830088/" class="usa-link">40830088</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Metabolic homeostasis is essential for cellular function in living organisms. In cancer cells, metabolic processes are reprogrammed to meet the energy demands and biosynthetic needs for rapid growth. This reprogramming enhances nutrient flux through the glycolytic pathway, supporting ATP production and branching into pathways that synthesize macromolecules required for cell proliferation. One critical branching pathway is the hexosamine biosynthesis pathway (HBP), which, driven by metabolic reprogramming, facilitates the synthesis of uridine-5’-diphospho-N-acetylglucosamine (UDP-GlcNAc), a glycosylation substrate. This pathway is regulated by the rate-limiting enzyme glutamine-fructose-6-phosphate transaminase (GFPT), a key controller of cellular UDP-GlcNAc levels and protein glycosylation. Dysregulation of GFPT is linked to metabolic disorders, like in diabetes, and it is also frequently upregulated in cancers. Given that GFPT plays a pivotal role in cancer metabolism, elucidating its regulatory interactions with other metabolic signaling pathways under metabolic stress is crucial to identifying therapeutic vulnerabilities in cancer. This review discusses the interaction network of GFPT with other metabolic pathways, its role in nutrient sensing, and the implications of GFPT deregulation in cancer.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Subject terms:</strong> Cancer metabolism, Cancer microenvironment</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Facts</h2>
<ul class="list" style="list-style-type:disc">
<li><p id="Par3">The rate-limiting enzyme of hexosamkine biosynthetic pathway (HBP), GFPT, plays important roles in cellular signaling by controlling the level of HBP product UDP-GlcNAc to regulate protein glycosylation.</p></li>
<li><p id="Par4">The abnormal expression of GFPT has been detected in different cancer types, and GFPT participates in cancer progression through various manners.</p></li>
<li><p id="Par5">By promoting the flux of HBP, GFPT acts as a sensor of diverse cellular nutrients, and is involved in cancer metabolic reprogramming.</p></li>
<li><p id="Par6">According to its functions in cancer progression, targeting GFPT has been recognized as a promising strategy in cancer treatment.</p></li>
</ul></section><section id="Sec2"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par7">Metabolic reprogramming is a hallmark of cancer, characterized by the metabolic alterations that malignant cells undergo to support rapid proliferation. First described by Otto Warburg, this phenomenon, known as “Warburg effect,” is marked by elevated glycolysis and glycolytic ATP production in normoxia, a process termed aerobic glycolysis [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. Beyond glycolysis, cancer cells exhibit modifications in mitochondrial function that shift metabolism towards anabolic biosynthesis rather than ATP generation via the tricarboxylic acid (TCA) cycle. In contrast to quiescent cells, proliferating cancer cells must adapt to the challenging tumor microenvironment (TME), which is often marked by fluctuating oxygen levels, making the reliance on oxidative phosphorylation (OXPHOS) for ATP production less feasible [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. Hence, cancer cells prioritize aerobic glycolysis to meet the energy demands and produce metabolic intermediates essential for the synthesis of macromolecules needed for cellular proliferation [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. To sustain this metabolic shift, cancer cells frequently acquire mutations that enhance nutrient uptake, particularly of glucose and glutamine [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>, <a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. These nutrients supply carbon and nitrogen for biomass production; for example, glutamine provides a carbon source and amino groups crucial for nucleotide and protein synthesis, and it also fuels the hexosamine biosynthetic pathway (HBP). Furthermore, glutaminolysis contributes anaplerotic inputs to the TCA cycle and drives several biosynthetic pathways branching from the TCA [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>]. Enhanced glucose uptake likewise promotes flux into anabolic pathways, including the HBP, pentose phosphate pathway, and serine biosynthetic pathway, all of which are vital for the anabolic synthesis of macromolecules in proliferating cancer cells [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>].</p>
<p id="Par8">The hexosamine biosynthetic pathway (HBP) branches from glycolysis, beginning with the glycolytic intermediate fructose-6-phosphate. This nutrient-sensitive pathway, activated during metabolic reprogramming, is essential for supporting anabolic biosynthesis [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. Approximately 2–5% of cellular glucose enters the HBP, leading to the production of uridine-5’-diphospho-N-acetylglucosamine (UDP-GlcNAc), a key glycosylation substrate. The HBP utilizes glucose, glutamine, acetyl-CoA, and UTP to produce UDP-GlcNAc, which is the precursor for both N-glycosylation and O-glycosylation of cellular proteins (Fig. <a href="#Fig1" class="usa-link">1</a>). Glycosylation plays a crucial role in protein folding, cell signaling, immune response, inflammation, and epithelial-to-mesenchymal transition (EMT) [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>, <a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. N- and O-glycosylation primarily occur in the secretory pathways of the endoplasmic reticulum and Golgi apparatus, involving the addition of complex glycans to proteins. In contrast, O-GlcNAcylation is a post-translational modification affecting nuclear and cytoplasmic proteins. Analogous to phosphorylation, O-GlcNAcylation is a dynamic process that transfers a single O-linked β-N-acetylglucosamine (O-GlcNAc) moiety to the hydroxyl groups of serine and threonine residues on proteins. Since O-GlcNAcylation often occurs on the same sites as phosphorylation, it directly or indirectly influences protein phosphorylation [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>, <a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. Studies indicate that many phosphorylated proteins are also O-GlcNAcylated, highlighting a regulatory crosstalk between these modifications that modulates cellular signaling [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>]. Nevertheless, while phosphorylation is mediated by multiple kinases, O-GlcNAcylation is cycled by a single enzyme pair: O-GlcNAc transferase (OGT), which adds the GlcNAc group, and O-GlcNAcase (OGA), which removes it. O-GlcNAcylation regulates various intracellular processes, and in cancer, it has been shown to modulate metabolic enzymes, nutrient transporters, as well as several oncoproteins and tumor suppressors involved in metabolic reprogramming [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>–<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>].</p>
<figure class="fig xbox font-sm" id="Fig1"><h3 class="obj_head">Fig. 1. Hexosamine biosynthetic pathway (HBP).</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365115_41420_2025_2687_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab9/12365115/a946a850886b/41420_2025_2687_Fig1_HTML.jpg" loading="lazy" id="d33e309" height="518" width="785" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The HBP branches from glycolysis, utilizing ~2–5% of the glucose entering the cell. The enzyme GFPT, which has two catalytic domains (N-terminal and C-terminal), catalyzes the committed step of the HBP by converting fructose-6-phosphate (Fru-6-P) and glutamine (Gln) into glucosamine-6-phosphate (GlcN-6-P) and glutamate (Glu) as by-products. GlcN-6-P is then acetylated by glucosamine-6-phosphate N-acetyltransferase (GNPAT) to form N-acetylglucosamine-6-phosphate (GlcNAc-6-P), which is subsequently converted into GlcNAc-1-P by phosphoglucomutase (PGM3). Using UTP from nucleotide metabolism, uridine diphosphate N-acetylhexosamine pyrophosphorylase (UAP) catalyzes the conversion of GlcNAc-1-P to uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), a substrate for O-GlcNAcylation (a post-translational modification) mediated by O-GlcNAc transferase (OGT), as well as for N- and O-linked glycosylation.</p></figcaption></figure><p id="Par9">The rate-limiting step in HBP is catalyzed by glutamine transaminase (GFPT), which is also known as GFAT, GFA (fungi ortholog), and GlmS (bacteria ortholog). GFPT mediates the transfer of an amino group from glutamine to fructose-6-phosphate (Fru-6-P), forming glucosamine-6-phosphate (GlcN-6-P), which is subsequently processed by downstream enzymes to produce UDP-GlcNAc (Fig. <a href="#Fig1" class="usa-link">1</a>) [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. The catalytic reaction is initiated by the binding of fructose-6-phosphate, which enhances the binding affinity for the second substrate, glutamine, and opens the hydrophobic ammonia channel [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>–<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>], through which the ammonia released through glutamine hydrolysis is transported to the catalytic acceptor site within the isomerase domain (Fig. <a href="#Fig1" class="usa-link">1</a>)[<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>].</p></section><section id="Sec3"><h2 class="pmc_sec_title">Featuers of glutamine-fructose-6-phosphate transaminase (GFPT)</h2>
<p id="Par10">GFPT is regulated by feedback inhibition from its end product, UDP-GlcNAc, whereas the bacterial ortholog is not susceptible to this inhibition [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>, <a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. Additionally, the first catalytic product, GlcN-6-P, acts as a competitive inhibitor at the Fru-6-P binding site of GFPT [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]. In the hexosamine biosynthetic pathway, GFPT plays a pivotal role in controlling UDP-GlcNAc flux and cellular protein O-GlcNAcylation. Dysregulation of GFPT has been implicated in the metabolic disorders of many diseases, including cancer, diabetes, and neurodegeneration [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>–<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. Structurally, GFPT contains two catalytic domains: the N-terminal glutamine amidotransferase type 2 (GATase-2) domain, which hydrolyzes glutamine to glutamate and ammonia, and the C-terminal sugar isomerase (SIS) domain, which facilitates the amination and isomerization of Fru-6-P to GlcN-6-P (Fig. <a href="#Fig2" class="usa-link">2</a>) [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. Mutations in <em>GFPT1</em> are associated with congenital myasthenic syndrome, a hereditary neuromuscular junction disorder [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>, <a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>], while gain-of-function mutations in GFPT1 have been linked to extended lifespan in <em>C.elegans</em> [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]. Studies indicate that cancer cells upregulate GFPT1 to increase HBP flux, promoting abnormal protein O-GlcNAcylation [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. Therefore, understanding the regulatory network associated with GFPT in metabolic reprogramming is crucial for identifying targetable metabolic vulnerabilities in therapeutic strategy development. In metazoans, there are two GFPT isoforms: GFPT1 and GFPT2, each with distinct tissue expression profiles [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. GFPT1 is widely expressed, particularly in the pancreas, placenta, muscle, and testis, while GFPT2 is primarily found in the central nervous system [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]. A distinct GFPT1 isoform, featuring an 18-amino acid insertion at position 229, is specifically expressed in muscle tissue [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]. GFPT1 and GFPT2 share ~79% sequence identity, and human GFPT1 and GFPT2 are consisted of 681 and 682 amino acids, respectively (Fig. <a href="#Fig2" class="usa-link">2</a>) [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]. However, GFPT2 has lower sensitivity to UDP-GlcNAc feedback inhibition and does not strictly follow the bi-bi order of reaction, as it can hydrolyze glutamine even without Fru-6-P [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]. Throughout this review, we specify GFPT1 or GFPT2 when discussing individual isoforms and use “GFPT” to refer generically when the specific isoform is not indicated.</p>
<figure class="fig xbox font-sm" id="Fig2"><h3 class="obj_head">Fig. 2. Structure domain and upstream activators of GFPT.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365115_41420_2025_2687_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab9/12365115/f4b4594474c1/41420_2025_2687_Fig2_HTML.jpg" loading="lazy" id="d33e405" height="520" width="789" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>GFPT contains two catalytic domains: the N-terminal glutamine amidotransferase type 2 (GATase-2) domain and the C-terminal sugar isomerase (SIS) domain, which functions as the synthase site. Several upstream regulators, including AMPK, PKA and mTORC2, modulate GFPT activity via phosphorylation.</p></figcaption></figure></section><section id="Sec4"><h2 class="pmc_sec_title">GFPT-transcription factor regulatory network</h2>
<p id="Par11">The enzymatic activity of GFPT is primarily regulated by protein kinases, while its mRNA and protein levels are controlled through transcriptional regulation (Fig. <a href="#Fig3" class="usa-link">3</a>). As previously discussed, cellular stress triggers signaling pathways that induce GFPT expression by upregulating its transcription activators, to support metabolic adaptability under stress. Multiple studies have shown an intricate regulatory interplay between GFPT and transcription factors (Table <a href="#Tab1" class="usa-link">1</a>).</p>
<figure class="fig xbox font-sm" id="Fig3"><h3 class="obj_head">Fig. 3. Transcriptional regulation of GFPT.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365115_41420_2025_2687_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab9/12365115/74f4f574c499/41420_2025_2687_Fig3_HTML.jpg" loading="lazy" id="d33e423" height="333" width="725" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Certain transcription factors drive the transcriptional upregulation of both GFPT1 and GFPT2, while others specifically target either GFPT1 or GFPT2 individually.</p></figcaption></figure><section class="tw xbox font-sm" id="Tab1"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>GFPT and metabolic signaling interaction.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">Signaling pathway</th>
<th colspan="1" rowspan="1">GFPT isoform</th>
<th colspan="1" rowspan="1">Interacting protein</th>
<th colspan="1" rowspan="1">Outcome</th>
<th colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="3" colspan="1">PI3/mTOR</td>
<td rowspan="3" colspan="1">GFPT1</td>
<td colspan="1" rowspan="1">mTORC2</td>
<td colspan="1" rowspan="1">
<p>Maintain GFPT1 Phosphorylation.</p>
<p>Promote GFPT1 expression.</p>
</td>
<td colspan="1" rowspan="1">[<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>, <a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">C-myc</td>
<td colspan="1" rowspan="1">Transcriptional upregulation of GFTP1.</td>
<td colspan="1" rowspan="1">[<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PTEN</td>
<td colspan="1" rowspan="1">O-GlcNAcylation of PTEN leading to its Ubiquitination and degradation.</td>
<td colspan="1" rowspan="1">[<a href="#CR97" class="usa-link" aria-describedby="CR97">97</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PI3/AKT/Mtor</td>
<td colspan="1" rowspan="1">GFPT1 and GFPT2</td>
<td colspan="1" rowspan="1">AKT</td>
<td colspan="1" rowspan="1">Activation of AKT and mTOR signaling Leading to cardiomyocyte hypertrophy.</td>
<td colspan="1" rowspan="1">[<a href="#CR95" class="usa-link" aria-describedby="CR95">95</a>, <a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>]</td>
</tr>
<tr>
<td rowspan="2" colspan="1">RAS/MAPK</td>
<td rowspan="2" colspan="1">GFPT1</td>
<td colspan="1" rowspan="1">MAPK/C-myc</td>
<td colspan="1" rowspan="1">Modulate the expression and protein level of GFPT1 to stimulate HBP flux.</td>
<td colspan="1" rowspan="1">[<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TAB1 and TLLS</td>
<td colspan="1" rowspan="1">Activation of p38 MAPK signaling to promote cell survival upon nutrient stress.</td>
<td colspan="1" rowspan="1">[<a href="#CR114" class="usa-link" aria-describedby="CR114">114</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">LKB1/AMPK</td>
<td colspan="1" rowspan="1">GFPT1</td>
<td colspan="1" rowspan="1">AMPK</td>
<td colspan="1" rowspan="1">
<p>Ser-243 Phosphorylation of GFPT1</p>
<p>and modulation of GFPT1 enzyme activity.</p>
</td>
<td colspan="1" rowspan="1">[<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR109" class="usa-link" aria-describedby="CR109">109</a>]</td>
</tr>
<tr>
<td rowspan="2" colspan="1">cAMP/PKA</td>
<td colspan="1" rowspan="1">GFPT1</td>
<td colspan="1" rowspan="1">PKA</td>
<td colspan="1" rowspan="1">Ser 205 Phosphorylation of GFPT and modulation of GFPT1 enzyme activity.</td>
<td colspan="1" rowspan="1">[<a href="#CR123" class="usa-link" aria-describedby="CR123">123</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT2</td>
<td colspan="1" rowspan="1">PKA</td>
<td colspan="1" rowspan="1">Ser 202 phosphorylation and enhanced GFPT2 activity.</td>
<td colspan="1" rowspan="1">[<a href="#CR125" class="usa-link" aria-describedby="CR125">125</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">UPR</td>
<td colspan="1" rowspan="1">GFPT1 and GFPT2</td>
<td colspan="1" rowspan="1">XBP1</td>
<td colspan="1" rowspan="1">Induces GFPT expression and cell survival in response to stress.</td>
<td colspan="1" rowspan="1">[<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">UPR</td>
<td colspan="1" rowspan="1">GFPT1 and GFPT2</td>
<td colspan="1" rowspan="1">ATF4</td>
<td colspan="1" rowspan="1">Induces GFPT expression and cell survival in response to stress.</td>
<td colspan="1" rowspan="1">[<a href="#CR118" class="usa-link" aria-describedby="CR118">118</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">NF-κB</td>
<td colspan="1" rowspan="1">GFPT2</td>
<td colspan="1" rowspan="1">NF-κB</td>
<td colspan="1" rowspan="1">Transcriptional expression of GFPT2 and feedback regulation of NF-κB.</td>
<td colspan="1" rowspan="1">[<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">WNT/β-catenin</td>
<td colspan="1" rowspan="1">GFPT1</td>
<td colspan="1" rowspan="1">β-catenin</td>
<td colspan="1" rowspan="1">GlcNAcylation and nuclear translocation and expression of β-catenin.</td>
<td colspan="1" rowspan="1">[<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>, <a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">HIF-1</td>
<td colspan="1" rowspan="1">GFPT1</td>
<td colspan="1" rowspan="1">HIF-1α</td>
<td colspan="1" rowspan="1">Increase HIF-1α expression and leading to HIF-1 signaling activation.</td>
<td colspan="1" rowspan="1">[<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">HIF-1</td>
<td colspan="1" rowspan="1">Not specified</td>
<td colspan="1" rowspan="1">HIF-1α</td>
<td colspan="1" rowspan="1">Augment the expression and activation of GFPT during hypoxic stress.</td>
<td colspan="1" rowspan="1">[<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">YBX-1</td>
<td colspan="1" rowspan="1">GFPT2</td>
<td colspan="1" rowspan="1">YBX-1</td>
<td colspan="1" rowspan="1">Promote YBX-1 O- GlcNAcylation, nuclear localization, and target gene expression.</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Hippo pathway</td>
<td colspan="1" rowspan="1">GFPT1</td>
<td colspan="1" rowspan="1">YAP</td>
<td colspan="1" rowspan="1">Promote YAP O- GlcNAcylation, activation, and nuclear localization.</td>
<td colspan="1" rowspan="1">[<a href="#CR214" class="usa-link" aria-describedby="CR214">214</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p20"><p>The relationship of GFPT proteins with defferent pathways that have been reported are summarized here, including the interacting proteins, outcomes and references.</p></div></div></section><p id="Par12">Metabolic remodeling enhances GFPT1-driven O-GlcNAcylation of key transcription factors, including NF-κB, HIFα, β-catenin, STAT3 and C-myc which play significant roles in cancer progression [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>–<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]. Conversely, transcription factors modulate the HBP and protein O-GlcNAcylation through GFPT expression. For example, hypoxic stress increases HBP flux by activating HIF-1α, which controls GFPT1 transcription [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>, <a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]. Similarly, endoplasmic reticulum (ER) stress initiates the unfolded protein response (UPR) via XBP1, a known transcriptional activator of GFPT [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. Notably, while UPR signaling often upregulates GFPT2 expression in response to viral infection in human small airway epithelial cells [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>], it specifically promotes GFPT1 expression in cardiomyocytes [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. The reasons for this isoform-specific regulation remain unclear. However, it is proposed that GFPT2’s unique resistance to the UDP-GlcNAc feedback inhibition may contribute to the increased accumulation of UDP-GlcNAc post-infection. Moreover, the established association between GFPT2 and EMT could explain the preferential induction of GFPT2, as evidenced that GFPT2 is coexpressed with EMT-related proteins [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>, <a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. In parallel, UPR-related transcription factor, Tisp40, has been shown to regulate GFPT1 expression and enhance protein O-GlcNAcylation thereby modulating cardiac dysfunction following ER stress or myocardial injury [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>].</p>
<p id="Par13">In cancer cells, chemotherapy resistance has been linked to the regulation of GFPT isoforms by specific transcription factors. For instance, the Forkhead box transcription factor FOXA2 promotes HBP-driven O-GlcNAcylation by transcriptionally activating GFPT1, consequently doxorubicin-induced apoptosis in hepatocellular carcinoma [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]. Several other oncogenic transcription factors, including NF-κB, HIF-1α, and c-Myc, also upregulate GFPT expression, which correlates with cancer progression. Notably, GFPT2 and NF-κB form a positive feedback loop by mutually enhancing each other to promote tumor development [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>, <a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]. In pancreatic ductal adenocarcinoma (PDAC) cells, the hypoxic microenvironment fosters metabolic adaptability and cell survival via HIF-1α-mediated GFPT1 expression [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]. Additionally, active GFPT2 expression is associated with c-Myc target genes, suggesting that HBP-induced O-GlcNAcylation stabilizes c-Myc in leiomyosarcoma [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]. Furthermore, c-Myc targets various enzymes in anabolic biosynthetic pathways, including GFPT, to support metabolic reprogramming and tumor growth [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>, <a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. In glioblastoma, c-Myc-dependent activation of GFPT1 is linked to cancer cell proliferation, invasion, and metastasis [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. Collectively, the regulatory interactions between transcription factors and GFPT1 are essential for reprogramming cellular metabolism to sustain growth under stress conditions.</p></section><section id="Sec5"><h2 class="pmc_sec_title">GFPT network in nutrient response</h2>
<p id="Par14">HBP integrates signals from various metabolic inputs—amino acid metabolism (glutamine), carbohydrate metabolism (glucose), lipid oxidation (acetyl-CoA), and nucleotide biosynthesis (UTP)—to produce UDP-GlcNAc, a critical substrate for protein glycosylation. As the rate-limiting enzyme of HBP, GFPT senses these nutrients to regulate pathway flux (Fig. <a href="#Fig1" class="usa-link">1</a>). Nutrient fluctuations alter cellular metabolism and microenvironmental conditions, leading to adaptive changes in GFPT1 activity. For instance, elevated glucose levels are linked to increased GFPT activity (Fig. <a href="#Fig1" class="usa-link">1</a>) [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>, <a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. Hyperglycemia-induced pathologies, including diabetes and cardiovascular complications, have been associated with GFPT activation within the HBP pathway [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>–<a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]. In cancer cells, glucose-fueled tumor progression and invasion have been linked to aberrant glycosylation resulting from heightened GFPT expression and increased HBP flux [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>–<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]. GFPT level, activity, and mRNA expression are regulated by nutrient-sensing kinases, growth factors, and transcription factors in response to nutrient availability. For example, under nutrient deprivation, AMPK and mTORC2 phosphorylate GFPT1 at serine 243 [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>–<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. This regulation underscores the role GFPT as a nutrient sensor, which couples signals from metabolites to modulate HBP flux and cellular adaptation to metabolic stress.</p>
<p id="Par15">Glutamine, an essential nutrient for cell growth, drives the HBP in rapidly proliferating cells. As a GFPT1 substrate, glutamine availability enhances GFPT1 activity, leading to increased GlcNAc levels and subsequent protein glycosylation (Fig. <a href="#Fig1" class="usa-link">1</a>). The interaction between mTORC2 and GFPT1 is sensitive to glutamine levels [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]. Prolonged glutamine deprivation reduces mTORC2 activation and GFPT1 expression, while short-term glutamine withdrawal increases mTORC2 activity and sustains GFPT1 expression, highlighting the role of mTORC2 in modulating GFPT1 in response to glutamine homeostasis [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]. Glutamine thus sustains HBP flux during glucose limitation through an mTORC2-dependent mechanism [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. In parallel, coordinated glucose and glutamine uptake fuels cell growth during metabolic reprogramming [<a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>]. Notably, deprivation of glucose and glutamine, key substrates of the HBP pathway reduces UDP-GlcNAc levels and N-glycan branching, thereby skewing T cell differentiation toward pro-inflammatory TH17 cells at the expense of anti-inflammatory Treg cells [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>].</p>
<p id="Par16">GFPT1 is also responsive to lipid levels in addition to glucose and glutamine availability. Lipid metabolism generates acetyl-CoA, a crucial input into the HBP pathway (Fig. <a href="#Fig1" class="usa-link">1</a>). Acetyl-CoA, a key component in fatty acid synthesis, drives lipid storage following excessive caloric intake. Overexpression of fatty acid synthase (FASN), a key enzyme in fatty acid synthesis, correlates with GFPT1 upregulation and enhanced colorectal cancer proliferation [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>]. Thus, diets high in carbohydrates and fats stimulate GFPT1 expression and enhance HBP flux. Studies indicate that lipid consumption raises cellular O-glycosylation levels, likely linked to GFPT1-driven HBP flux [<a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>–<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>]. Consistently, high-fat diet-induced obesity is associated with increased levels of O-GlcNAc-related proteins, including GFPT1 and OGT [<a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>]. For instance, conjugated linoleic acid intake has been shown to elevate GFPT1 mRNA expression in porcine muscle, while palmitate and stearate boost protein O-glycosylation by upregulating GFPT1 [<a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>, <a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>]. Moreover, saturated fat intake promotes GFPT2 expression in the mouse retina in an NR4A1-dependent manner [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>].</p>
<p id="Par17">Interestingly, nutrient stress, such as glucose or glutamine deprivation, can also enhance GFPT expression [<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>, <a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>]. Under such conditions, the unfolded protein response (UPR) is activated, upregulating GFPT as part of a stress adaptation mechanism [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>]. Reduced HBP-driven UDP-GlcNAc levels during nutrient stress typically impair glycosylation and glycan synthesis, leading to protein misfolding and UPR activation [<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>]. The resulting increase in GFPT1 enables cells to survive nutrient scarcity by enhancing their stress resilience. Additionally, HBP-induced O-GlcNAcylation regulates the expression of stress-responsive proteins, including specificity protein 1 (Sp1) and heat shock proteins [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>, <a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>]. Overall, GFPT is directly and indirectly influenced by cellular nutrient levels and its nutrient response is critical for promoting cell growth.</p></section><section id="Sec6"><h2 class="pmc_sec_title">GFPT1 and cellular signaling network</h2>
<p id="Par18">Anabolic processes are fundamental to cancer progression, with the hexosamine biosynthetic pathway (HBP) playing a key role in driving protein glycosylation through its association with various oncogenic signaling networks. As the rate-limiting enzyme of the HBP, GFPT1 serves as a pivotal mediator, bridging oncogenic signals with metabolic pathways to support cellular anabolism. GFPT1 interacts with a range of molecular communicators, including kinases, immune checkpoint regulators, growth factors, and transcription factors, forming an extensive signaling network as outlined in Figs. <a href="#Fig4" class="usa-link">4</a> and <a href="#Fig5" class="usa-link">5</a> and summarized in Table <a href="#Tab1" class="usa-link">1</a>.</p>
<figure class="fig xbox font-sm" id="Fig4"><h3 class="obj_head">Fig. 4. GFPT in metabolic signaling interaction network.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365115_41420_2025_2687_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab9/12365115/c391c313f44b/41420_2025_2687_Fig4_HTML.jpg" loading="lazy" id="d33e888" height="397" width="705" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>GFPT interacts with multiple metabolic signaling pathways, including PI3K/mTOR, RAS/MAPK, Wnt/β-catenin, LKB1/AMPK, cAMP/PKA, and the Hippo pathway. Regulatory phosphorylation of GFPT by AMPK, PKA, and mTORC2 can either promote or inhibit its activity. GFPT-driven activation of transcription factors subsequently regulates the expression of their target genes.</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig5"><h3 class="obj_head">Fig. 5. Regulatory interactions among AMPK, mTOR, and GFPT during acute and prolonged nutrient stress.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365115_41420_2025_2687_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab9/12365115/6b69ebfd0313/41420_2025_2687_Fig5_HTML.jpg" loading="lazy" id="d33e896" height="572" width="699" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Short nutrient starvation potentially inhibits GFPT1 directly via AMPK. In prolonged nutrient stress, GFPT1 activity is potentially maintained directly by mTORC2 and indirectly by AMPK.</p></figcaption></figure></section><section id="Sec7"><h2 class="pmc_sec_title">GFPT1 and the PI3K/AKT/mTOR pathway</h2>
<p id="Par19">The PI3K/AKT/mTOR pathway is a prominent oncogenic pathway that orchestrates cellular metabolic reprogramming and nutrient sensing [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>, <a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>]. Activated by growth factors, this pathway facilitates metabolic remodeling in cancer by transmitting signals from PI3K (Phosphoinositide 3-kinase) through AKT (Protein Kinase B) to mTOR (mammalian target of rapamycin) and subsequently to downstream effectors and transcription factors, all of which drive cell growth [<a href="#CR84" class="usa-link" aria-describedby="CR84">84</a>]. Notably, GFPT1 has been implicated in interacting with PI3K/AKT/mTOR signaling, to impact the metabolic reprogramming associated with cancer as well as diabetic and cardiac diseases (Fig. <a href="#Fig4" class="usa-link">4</a>) [<a href="#CR85" class="usa-link" aria-describedby="CR85">85</a>–<a href="#CR87" class="usa-link" aria-describedby="CR87">87</a>].</p>
<p id="Par20">In glioblastoma, GFPT1 and mTORC2 form a regulatory network that adapts cancer metabolism to cellular nutrient levels [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. Mechanistically, nutrient abundance activates mTORC2, which via c-Myc, enhances GFPT1 transcription and enzymatic activity. This upregulation increases HBP flux, promotes protein glycosylation, and reprograms cellular metabolism, collectively driving glioblastoma progression [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. Acting as a glutamine sensor, mTORC2 responds to intracellular glutamine availability and promotes hexosamine biosynthetic pathway (HBP) flux by targeting GFPT1 through Ser243 phosphorylation [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. Notably, this mTORC2-mediated GFPT1 phosphorylation at Ser243 persists at a prolonged but reduced amplitude during glucose starvation, which sustains GFPT1 expression and HBP activity even under nutrient limitation [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. However, findings regarding this phosphorylation event are complex: Ser243 phosphorylation maintains the activity of GFPT1, which was not entirely abolished in SIN<sup>-/-</sup> (a component of mTORC2) HeLa and MEF cells or in TORIN-treated cells under glucose starvation, suggesting that other kinases may also contribute to this regulation [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. Additionally, basal phosphorylation at GFPT1 Ser243 continued even with limited AMPK activity, further implying alternative regulatory kinases [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>].</p>
<p id="Par21">Emerging evidence indicates that mTORC2 enhances GFPT1 expression through transcription factors like X-box binding protein 1 (XBP1) and c-Myc [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>, <a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]. Furthermore, AKT, a direct target of mTORC2 and upstream regulator of mTORC1, has been linked to GFPT1 expression and HBP activation via the AKT/XBP1 pathway, particularly in contributing to chemoresistance against agents like doxorubicin and camptothecin [<a href="#CR88" class="usa-link" aria-describedby="CR88">88</a>]. Intriguingly, GFPT1-driven O-GlcNAcylation also modulates AKT activation [<a href="#CR89" class="usa-link" aria-describedby="CR89">89</a>, <a href="#CR90" class="usa-link" aria-describedby="CR90">90</a>], as lower O-GlcNAcylation levels, induced by pharmacological inhibition of GFPT1 or OGT, correlate with heightened AKT phosphorylation at Ser473 and Thr308 in acute myeloid leukemia (AML) cells [<a href="#CR91" class="usa-link" aria-describedby="CR91">91</a>]. This inverse correlation between O-GlcNAcylation and AKT activation has similarly been observed in pancreatic beta cells, kidney, adipocytes, and neurons [<a href="#CR92" class="usa-link" aria-describedby="CR92">92</a>–<a href="#CR94" class="usa-link" aria-describedby="CR94">94</a>]. In contrast, a direct correlation between GFPT-induced O-GlcNAcylation and AKT activation has been found in cardiomyocytes during hypertrophy, where increased O-GlcNAcylation driven by GFPT1 and GFPT2 promotes AKT-mediated hypertrophic growth [<a href="#CR95" class="usa-link" aria-describedby="CR95">95</a>, <a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>]. Additionally, GFPT1 acts as a negative regulator of the phosphatase and tensin homolog (PTEN), a known PI3K/mTOR inhibitor. Mechanistically, GFPT1 increases HBP flux and PTEN O-GlcNAc, which promotes PTEN ubiquitination and degradation, thereby stimulating PI3K/mTOR signaling and promoting the proliferation of cervical cancer cells [<a href="#CR97" class="usa-link" aria-describedby="CR97">97</a>]. This regulatory network positions GFPT1 as a key modulator in the interplay between nutrient sensing and oncogenic signaling, linking it to cancer growth and therapeutic resistance.</p></section><section id="Sec8"><h2 class="pmc_sec_title">GFPT-LKB1/AMPK pathway</h2>
<p id="Par22">AMPK (Adenosine Monophosphate-Activated Protein Kinase) is a central energy and nutrient sensor that regulates the cellular balance of ATP through the activation of catabolic pathways, including glycolysis, the TCA cycle, and fatty acid oxidation, in response to low glucose or ATP levels [<a href="#CR98" class="usa-link" aria-describedby="CR98">98</a>]. AMPK is a heterotrimeric kinase composed of three subunits: a catalytic α subunit, a scaffolding β subunit, and an AMP-sensing γ subunit [<a href="#CR99" class="usa-link" aria-describedby="CR99">99</a>]. Under nutrient scarcity, elevated AMP/ATP ratio leads AMP to bind the γ subunit, promoting phosphorylation of the α subunit at threonine 172 (Thr172) by upstream regulators such as LKB1 for AMPK activation [<a href="#CR99" class="usa-link" aria-describedby="CR99">99</a>, <a href="#CR100" class="usa-link" aria-describedby="CR100">100</a>]. As a metabolic checkpoint, AMPK coordinates with other nutrient-sensing pathways to uphold metabolic homeostasis during nutrient stress [<a href="#CR101" class="usa-link" aria-describedby="CR101">101</a>].</p>
<p id="Par23">The LKB1/AMPK-GFPT1 pathway was initially explored in adipocytes, where increased HBP flux via GFPT1 overexpression enhances AMPK phosphorylation and activation and consequently promots fatty acid oxidation (Fig. <a href="#Fig4" class="usa-link">4</a>) [<a href="#CR102" class="usa-link" aria-describedby="CR102">102</a>]. This effect is mediated by O-GlcNAcylation of AMPK in adipocytes. However, reports on AMPK activation through O-GlcNAcylation are mixed: while O-GlcNAcylation has been linked to increased AMPK activity, acute inhibition of O-GlcNAc cycling—leading to higher O-GlcNAc levels—appears to suppress AMPK activation [<a href="#CR103" class="usa-link" aria-describedby="CR103">103</a>–<a href="#CR106" class="usa-link" aria-describedby="CR106">106</a>]. Interestingly, inhibiting GFPT1-mediated O-GlcNAcylation in bladder cancer cells enhances AMPK activation and induces autophagy [<a href="#CR104" class="usa-link" aria-describedby="CR104">104</a>]. These varied findings suggest additional regulatory factors or context-specific roles for O-GlcNAcylation in AMPK regulation.</p>
<p id="Par24">The direct interaction between AMPK and GFPT1 shows that glucose scarcity activates the LKB1/AMPK pathway, leading to AMPK-mediated phosphorylation of GFPT1 at Ser243 (Fig. <a href="#Fig2" class="usa-link">2</a>) [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>]. This phosphorylation reportedly inhibits GFPT1 activity and reduces HBP flux, impacting processes like VEGF-induced angiogenesis [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>], ER-induced apoptosis [<a href="#CR107" class="usa-link" aria-describedby="CR107">107</a>], and anti-hypertrophic responses [<a href="#CR108" class="usa-link" aria-describedby="CR108">108</a>]. Conversely, another study suggests that Ser243 phosphorylation enhances GFPT1 activity [<a href="#CR109" class="usa-link" aria-describedby="CR109">109</a>], aligning with mTORC2-mediated GFPT1 regulation under nutrient stress. The discrepancy underscores a complex regulatory network that demands further exploration, discussed in detail in the following sections.</p></section><section id="Sec9"><h2 class="pmc_sec_title">GFPT1-KRAS/MAPK pathway</h2>
<p id="Par25">KRAS (Kirsten Rat Sarcoma virus), a well-known proto-oncogene, is frequently mutated and activated in several cancers [<a href="#CR110" class="usa-link" aria-describedby="CR110">110</a>]. KRAS signaling drives tumor proliferation, survival, and aggressiveness through downstream activation of MAPK (Mitogen-Activated Protein Kinase) and PI3K pathways [<a href="#CR111" class="usa-link" aria-describedby="CR111">111</a>, <a href="#CR112" class="usa-link" aria-describedby="CR112">112</a>]. A major outcome of KRAS activation is metabolic reprogramming, which enhances nutrient uptake and anabolic biosynthetic pathways in cancer cells [<a href="#CR113" class="usa-link" aria-describedby="CR113">113</a>]. One key metabolic shift in KRAS-mutant cancers is the increased hexosamine biosynthetic pathway (HBP) flux, which boosts protein O-GlcNAcylation and N-glycan biosynthesis.</p>
<p id="Par26">Oncogenic KRAS is pivotal in directing glycolytic intermediates into anabolic pathways, specifically the pentose phosphate and HBP pathways [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>, <a href="#CR112" class="usa-link" aria-describedby="CR112">112</a>]. KRAS signaling modulates GFPT1 expression, thereby increasing HBP flux and protein glycosylation in pancreatic ductal adenocarcinoma (PDA) cells [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. The transcription factor Myc, a downstream effector of KRAS, is known to regulate GFPT1 and other metabolic genes in PDA cells [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. Importantly, GFPT1 has been shown to modulate p38 MAPK activation independently of the HBP-mediated glycosylation pathway. Specifically, GFPT1 interacts with and glutamylates TAB1 (Transforming Growth Factor-β-Activated Kinase 1 Binding Protein 1), thereby promoting the recruitment and activation of p38 MAPK to support lung cancer cell survival under conditions of glucose deprivation (Fig. <a href="#Fig4" class="usa-link">4</a>) [<a href="#CR114" class="usa-link" aria-describedby="CR114">114</a>]. Furthermore, KRAS-induced lung cancer aggressiveness is associated with GFPT2 expression [<a href="#CR115" class="usa-link" aria-describedby="CR115">115</a>]. The transcription factors Snai1 and Twist1, both working as key regulators of epithelial-mesenchymal transition (EMT), are implicated in upregulating HBP enzymes, especially GFPT2, in KRAS-mutant lung cancer [<a href="#CR115" class="usa-link" aria-describedby="CR115">115</a>]. Similarly, KRAS and LKB1 co-mutations in non-small cell lung cancer (NSCLC) promote GFPT2 expression, which correlates with poor prognosis [<a href="#CR116" class="usa-link" aria-describedby="CR116">116</a>]. The potential mechanism is that since the LKB1/AMPK axis generally inhibits HBP flux, loss of LKB1 indirectly promotes HBP activation via GFPT2, whose expression and activated is maintained by KRAS [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR116" class="usa-link" aria-describedby="CR116">116</a>].</p>
<p id="Par27">KRAS also responds to glutamine availability by regulating genes involved in amino acid metabolism, including those mediating glutamine utilization such as GFPT1, especially in nutrient-limited NSCLC [<a href="#CR117" class="usa-link" aria-describedby="CR117">117</a>]. This regulation involves the transcription factor ATF4 (Activating Transcription Factor 4), which targets GFPT expression in response to endoplasmic reticulum stress [<a href="#CR118" class="usa-link" aria-describedby="CR118">118</a>]. The enrichment of unfolded protein response (UPR) genes regulated by KRAS under low-glutamine conditions may explain ATF4 activation during nutrient stress [<a href="#CR117" class="usa-link" aria-describedby="CR117">117</a>]. Given that KRAS-mutant tumors with elevated HBP activity rely on this pathway for survival, HBP enzymes, particularly GFPT, present a promising targetable vulnerability in KRAS-driven cancers [<a href="#CR119" class="usa-link" aria-describedby="CR119">119</a>].</p></section><section id="Sec10"><h2 class="pmc_sec_title">GFPT-cAMP/PKA pathway</h2>
<p id="Par28">Protein kinase A (PKA), or cAMP-dependent protein kinase, is activated directly by cAMP and subsequently promotes the release of glucose and free fatty acids through gluconeogenesis, glycogenolysis, and lipolysis to support cellular energy requirements and is associated with metabolic reprogramming and cancer cell survival under nutrient stress, suggesting its potential interplay with the glucose-sensing HBP pathway (Fig. <a href="#Fig4" class="usa-link">4</a>) [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>, <a href="#CR120" class="usa-link" aria-describedby="CR120">120</a>–<a href="#CR122" class="usa-link" aria-describedby="CR122">122</a>].</p>
<p id="Par29">Two consensus PKA phosphorylation sites, RRGS for Ser205 and KKGS for Ser235 have been identified in human GFPT1 (Fig. <a href="#Fig2" class="usa-link">2</a>) [<a href="#CR123" class="usa-link" aria-describedby="CR123">123</a>, <a href="#CR124" class="usa-link" aria-describedby="CR124">124</a>]. The RRGS motif, conserved across eukaryotes, corresponds to the Ser202 site in GFPT2, while the KKGS motif is not conserved and does not exist in GFPT2 [<a href="#CR124" class="usa-link" aria-describedby="CR124">124</a>–<a href="#CR126" class="usa-link" aria-describedby="CR126">126</a>]. Phosphorylation at Ser205 in GFPT1 or Ser202 in GFPT2 by PKA has been shown to modify GFPT activity, while no significant impact was observed for phosphorylation at Ser235 (Fig. <a href="#Fig2" class="usa-link">2</a>) [<a href="#CR123" class="usa-link" aria-describedby="CR123">123</a>–<a href="#CR125" class="usa-link" aria-describedby="CR125">125</a>]. Specifically, phosphorylation at GFPT2 Ser202 is known to enhance GFPT2 activity, yet reports on GFPT1 Ser205 phosphorylation have been inconsistent, showing both inhibition and activation effects [<a href="#CR123" class="usa-link" aria-describedby="CR123">123</a>, <a href="#CR124" class="usa-link" aria-describedby="CR124">124</a>]. A study addressing this discrepancy with a phospho-mimic S205D mutant and an R203H gain-of-function mutant in GFPT1, finding that phosphorylation at Ser205 disrupts UDP-GlcNAc feedback inhibition, thereby sustaining GFPT1 activity [<a href="#CR127" class="usa-link" aria-describedby="CR127">127</a>]. This regulation suggests that PKA-dependent Ser205 phosphorylation positions the glutaminase and isomerase domains of GFPT1 in a configuration that prevents UDP-GlcNAc-mediated inhibition. Thus, at high UDP-GlcNAc concentrations, Ser205 phosphorylation serves as an activating mechanism by disrupting feedback inhibition, while at low concentrations, it reduces GFPT1 catalytic activity, acting as an inhibitory regulation [<a href="#CR127" class="usa-link" aria-describedby="CR127">127</a>].</p>
<p id="Par30">Since PKA typically promotes glucose availability by inducing glycogenolysis and gluconeogenesis [<a href="#CR121" class="usa-link" aria-describedby="CR121">121</a>], it is plausible that PKA could also negatively regulate GFPT1 to sustain cellular glucose homeostasis. However, in nutrient-deprived cancer cells, PKA activity is linked to protein N-glycosylation and glutamine metabolism, which are crucial for cancer cell survival, suggesting a positive association with HBP flux and potentially GFPT activation [<a href="#CR122" class="usa-link" aria-describedby="CR122">122</a>]. Additional studies are required to elucidate the role of PKA-mediated GFPT1 phosphorylation and to determine if this function exhibits tissue specificity.</p></section><section id="Sec11"><h2 class="pmc_sec_title">Dissecting the regulatory crosstalk of mTORC2 and AMPK on GFPT</h2>
<p id="Par31">The regulation of GFPT1 by mTORC2 and AMPK under nutrient starvation conditions is complex and involves nuanced control via Ser243 phosphorylation. While both mTORC2 and AMPK phosphorylate GFPT1 at this site, the functional outcome of this modification remains contentious. Eguchi et al. and Zibrova et al. observed that AMPK-mediated phosphorylation at Ser243 suppresses GFPT1 activity [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>]. In contrast, Li and colleagues reported that AMPK phosphorylation boosts the synthesis of GlcN-6-P by GFPT1, even though the glutaminase activity is reduced, suggesting that Ser243 phosphorylation may not necessarily result in a decrease in overall GFPT1 function [<a href="#CR109" class="usa-link" aria-describedby="CR109">109</a>]. Supporting this, recent findings indicate that mTORC2-mediated Ser243 phosphorylation enhances GFPT1 activity, and sustains hexosamine biosynthetic pathway (HBP) flux during nutrient scarcity [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. Additionally, while Eguchi et al. noted an activity reduction with AMPK-mediated phosphorylation, this suppression persisted in a GFPT1 S243A mutant, suggesting that AMPK-dependent inhibition of GFPT1 activity may not be solely due to Ser243 phosphorylation [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>].</p>
<p id="Par32">Studies indicate that AMPK negatively regulates O-GlcNAcylation [<a href="#CR108" class="usa-link" aria-describedby="CR108">108</a>, <a href="#CR128" class="usa-link" aria-describedby="CR128">128</a>], possibly due to its impact on UTP levels. For example, 2-deoxyglucose treatment, which activates AMPK, results in a pronounced reduction of UTP during nutrient stress, yet elevated GlcNAc-P levels suggest GFPT1 remains active under these conditions [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. Additionally, since HBP flux could be affected by other downstream enzymes within the pathway, these factors should be considered when using O-GlcNAcylation levels to assess GFPT1 activity. GFPT is known as a critical stress-response protein that supports cell survival during nutrient deprivation, and its activity is expected to increase under nutrient stress.</p>
<p id="Par33">During acute glucose deprivation, GFPT1 may be downregulated via AMPK to curb anabolic processes, while prolonged nutrient stress likely upregulates GFPT1 to support cell survival (Fig. <a href="#Fig5" class="usa-link">5</a>) [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>, <a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>]. Notably, AMPK facilitates mTORC2 activation to promote cell survival under glucose-starved conditions [<a href="#CR129" class="usa-link" aria-describedby="CR129">129</a>]. Although mTORC2 activation is initially measured during acute glucose withdrawal, its expression and activity are even higher under prolonged starvation and are linked with UPR activation, leading to increased GFPT1 expression [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>, <a href="#CR129" class="usa-link" aria-describedby="CR129">129</a>]. Thus, an AMPK-dependent signal may support sustained GFPT1 expression during nutrient deprivation. Although protein expression alone does not always equate to increased activity, elevated GFPT1 levels during nutrient stress have been correlated with tumor progression and poor patient prognosis, indicating that GFPT1 expression is crucial for its role in promoting cancer growth and survival [<a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>]. Overall, GFPT1 is also regulated by additional kinases, metabolites, and feedback inhibition, making it essential to dissect the combined effects of these regulatory mechanisms on GFPT1 activity during short-term and prolonged nutrient stress, as well as their variability across different cell lines.</p></section><section id="Sec12"><h2 class="pmc_sec_title">GFPT and cancer</h2>
<section id="Sec13"><h3 class="pmc_sec_title">Dysregulation of GFPT in cancer</h3>
<p id="Par34">The tumor microenvironment is characterized by multiple stress factors, such as nutrient depletion and hypoxia, which drive metabolic rewiring to support cancer cell growth, survival, and progression. With the emerging focus on cancer metabolic reprogramming, the HBP has gained attention due to its critical role in stress response. Aberrant HBP flux in cancer, driven by dysregulation of GFPT, is associated with various aspects of cancer progression, including enhanced proliferation, survival, self-renewal, and metastasis (Fig. <a href="#Fig6" class="usa-link">6</a> and Table <a href="#Tab2" class="usa-link">2</a>).</p>
<figure class="fig xbox font-sm" id="Fig6"><h4 class="obj_head">Fig. 6. Dysregulation of GFPT in cancer.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365115_41420_2025_2687_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab9/12365115/efa7a8bdcae8/41420_2025_2687_Fig6_HTML.jpg" loading="lazy" id="d33e1243" height="551" width="700" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>GFPT acts as a nutrient and stress-responsive protein, activated under conditions of nutrient abundance and cellular stress. In cancer, GFPT upregulation is closely linked to tumor progression and metastasis.</p></figcaption></figure><section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Dysregulation of GFPT1 in Cancer.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">GFPT isoform</th>
<th colspan="1" rowspan="1">Cancer type</th>
<th colspan="1" rowspan="1">Expression status</th>
<th colspan="1" rowspan="1">Role in cancer</th>
<th colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">GFPT1/GFPT2</td>
<td colspan="1" rowspan="1">Lung cancer</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Tumor growth and survival. Associated with EMT, tumor invasion, migration and metastasis.</td>
<td colspan="1" rowspan="1">[<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>, <a href="#CR114" class="usa-link" aria-describedby="CR114">114</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT1/GFPT2</td>
<td colspan="1" rowspan="1">Colon Cancer</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Promote EMT tumor growth, invasion and metastasis. Associated with tumor microenvironment and immune infiltration.</td>
<td colspan="1" rowspan="1">[<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>, <a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>, <a href="#CR131" class="usa-link" aria-describedby="CR131">131</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT1/GFP2</td>
<td colspan="1" rowspan="1">Pancreatic ductal Adenocarcinoma (PDA)</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Promote tumor aggressiveness lymph node metastasis and stemness. Associated with poor overall survival.</td>
<td colspan="1" rowspan="1">[<a href="#CR132" class="usa-link" aria-describedby="CR132">132</a>, <a href="#CR134" class="usa-link" aria-describedby="CR134">134</a>, <a href="#CR142" class="usa-link" aria-describedby="CR142">142</a>, <a href="#CR171" class="usa-link" aria-describedby="CR171">171</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT1</td>
<td colspan="1" rowspan="1">Glioblastoma</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Accelerate growth of tumor and proliferation.</td>
<td colspan="1" rowspan="1">[<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT1</td>
<td colspan="1" rowspan="1">Prostate Cancer</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Tumor proliferation.</td>
<td colspan="1" rowspan="1">[<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT1</td>
<td colspan="1" rowspan="1">Cervical Cancer</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Enhances tumor proliferation.</td>
<td colspan="1" rowspan="1">[<a href="#CR97" class="usa-link" aria-describedby="CR97">97</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT1</td>
<td colspan="1" rowspan="1">Acute Myeloid Leukemia (AML)</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Promote proliferation and inhibit cancer cell death.</td>
<td colspan="1" rowspan="1">[<a href="#CR91" class="usa-link" aria-describedby="CR91">91</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT1</td>
<td colspan="1" rowspan="1">Hepatocellular Carcinoma</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Promote proliferation, Migration and invasion. Critical for TNM stage and poor overall survival.</td>
<td colspan="1" rowspan="1">[<a href="#CR133" class="usa-link" aria-describedby="CR133">133</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT1</td>
<td colspan="1" rowspan="1">Gastric Cancer</td>
<td colspan="1" rowspan="1">Downregulation</td>
<td colspan="1" rowspan="1">Associated with EMT, invasion and migration.</td>
<td colspan="1" rowspan="1">[<a href="#CR162" class="usa-link" aria-describedby="CR162">162</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT2</td>
<td colspan="1" rowspan="1">Gastric Cancer</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Promote tumor invasion and pathological stage. Associated with immune infiltration and poor prognosis.</td>
<td colspan="1" rowspan="1">[<a href="#CR148" class="usa-link" aria-describedby="CR148">148</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT2</td>
<td colspan="1" rowspan="1">Serous Ovarian Cancer</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Promote EMT, Cell invasion and migration.</td>
<td colspan="1" rowspan="1">[<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT2</td>
<td colspan="1" rowspan="1">leiomyosarcoma</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Associated with enhanced glucose uptake, c-MYC stability and poor patient outcome.</td>
<td colspan="1" rowspan="1">[<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT2</td>
<td colspan="1" rowspan="1">Urinary Bladder Cancer (UBC)</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Associated with immune infiltration tumor pathological grade and metastasis.</td>
<td colspan="1" rowspan="1">[<a href="#CR163" class="usa-link" aria-describedby="CR163">163</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GFPT2</td>
<td colspan="1" rowspan="1">Breast Cancer</td>
<td colspan="1" rowspan="1">Upregulation</td>
<td colspan="1" rowspan="1">Promote tumor growth, EMT, and stemness. Associated with Claudin low breast cancer.</td>
<td colspan="1" rowspan="1">[<a href="#CR140" class="usa-link" aria-describedby="CR140">140</a>, <a href="#CR154" class="usa-link" aria-describedby="CR154">154</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Not specified</td>
<td colspan="1" rowspan="1">Cholangiocarcinoma</td>
<td colspan="1" rowspan="1">upregulation</td>
<td colspan="1" rowspan="1">Increases tumor invasion, migration, and EMT.</td>
<td colspan="1" rowspan="1">[<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p48"><p>GFPT1 has been reported to participate in the progression of different cancer types. Here we list the expression alterations of GFPT1 in diverse cancer types as well as its function in cancer development.</p></div></div></section></section><section id="Sec14"><h3 class="pmc_sec_title">GFPT in cancer cell proliferation and stemness</h3>
<p id="Par35">The growing interest in the role of HBP and glycosylation in tumors has led to a focus on GFPT, though its precise role in cancer is still indistinct. Several evidences support the essential role of GFPT in cancer metabolic reprogramming [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. Elevated glycolysis and the Warburg effect in proliferating cells increase the diversion of glycolytic intermediates into the HBP for enhanced glycosylation. This process relies on the upregulated expression and activation of GFPT, which catalyzes the committed step of the HBP pathway [<a href="#CR130" class="usa-link" aria-describedby="CR130">130</a>]. Consequently, abnormal glycosylation due to dysregulated GFPT gives cancer cells a proliferative edge.</p>
<p id="Par36">The expression of GFPT is elevated in many malignancies [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>, <a href="#CR131" class="usa-link" aria-describedby="CR131">131</a>–<a href="#CR133" class="usa-link" aria-describedby="CR133">133</a>] and correlates with tumor growth and poor prognosis, making it a promising therapeutic target. Both in vivo and in vitro studies have demonstrated that GFPT is essential for cancer cell proliferation [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>, <a href="#CR97" class="usa-link" aria-describedby="CR97">97</a>], and pharmacological inhibition of GFPT has been shown to suppress tumor growth and cell viability [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>, <a href="#CR119" class="usa-link" aria-describedby="CR119">119</a>, <a href="#CR134" class="usa-link" aria-describedby="CR134">134</a>]. Similarly, GFPT depletion in cancer cells reduces proliferation and progression [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>, <a href="#CR135" class="usa-link" aria-describedby="CR135">135</a>]. Specifically, GFPT1 has been identified as a key metabolic driver in PDAC cells [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>] and as a prognostic marker linked to tumor size in triple-negative breast cancer [<a href="#CR136" class="usa-link" aria-describedby="CR136">136</a>]. Meanwhile, GFPT2 plays a critical role in tumor metabolic reprogramming in lung cancer [<a href="#CR137" class="usa-link" aria-describedby="CR137">137</a>], acts as a neoplastic marker in tenosynovial giant cell tumors (TGCT) [<a href="#CR138" class="usa-link" aria-describedby="CR138">138</a>], and functions as an androgen receptor-inducible target involved in prostate cancer metabolic reprogramming [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>].</p>
<p id="Par37">GFPT has been implicated in cellular protection and defense against oxidative stress-induced cell death [<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>, <a href="#CR139" class="usa-link" aria-describedby="CR139">139</a>, <a href="#CR140" class="usa-link" aria-describedby="CR140">140</a>]. It has been observed that UDP-GlcNAc addition mitigates UPR-induced cell death and aids the survival of KRAS-transformed cells during glucose deprivation [<a href="#CR141" class="usa-link" aria-describedby="CR141">141</a>]. This protective mechanism is propagated through GFPT-mediated HBP activity, leading to increased glycosylation, improved protein folding, and subsequent inhibition of UPR activation. Thus, targeting the GFPT1/HBP pathway appears a promising manner for promoting cell death in proliferating cancer cells experiencing nutrient stress.</p>
<p id="Par38">Furthermore, GFPT1 plays a significant role in promoting self-renewal and stemness of cancer cells. High GFPT1 expression has been observed in cancer stem cells (CSCs) within pancreatic cancer [<a href="#CR142" class="usa-link" aria-describedby="CR142">142</a>] and hepatocellular carcinoma stem cell-like populations [<a href="#CR143" class="usa-link" aria-describedby="CR143">143</a>]. Interleukin-8-induced CSC development in colon and lung cancer cells relies on GFPT1-mediated O-GlcNAc modifications, demonstrating the critical involvement of the HBP pathway in cancer stemness [<a href="#CR144" class="usa-link" aria-describedby="CR144">144</a>]. Besides, GFPT-driven HBP activation is associated with cancer chemoresistance [<a href="#CR88" class="usa-link" aria-describedby="CR88">88</a>]. Upregulation of GFPT influences the efficacy of doxorubicin and cisplatin in inducing cancer cell apoptosis [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>, <a href="#CR145" class="usa-link" aria-describedby="CR145">145</a>]. A proteomic study identified GFPT1 as a predictive marker for tamoxifen resistance in estrogen receptor-positive breast cancer [<a href="#CR146" class="usa-link" aria-describedby="CR146">146</a>]. A recent study demonstrates that gemcitabine administration induces GFPT2 expression and thereby promotes the invasion of pancreatic cancer [<a href="#CR147" class="usa-link" aria-describedby="CR147">147</a>]. Meanwhile, GFPT2 expression has been linked to increased sensitivity to certain classes of chemotherapeutic agents [<a href="#CR148" class="usa-link" aria-describedby="CR148">148</a>], suggesting that GFPT expression could serve as a predictive marker for drug response. In summary, GFPT is a central player in cancer metabolic reprogramming, supporting cancer cell proliferation, survival, stemness, and drug resistance.</p></section><section id="Sec15"><h3 class="pmc_sec_title">GFPT in epithelial-mesenchymal transition in cancer cell</h3>
<p id="Par39">Epithelial-mesenchymal transition (EMT) is a hallmark of cancer metastasis that promotes invasive and aggressive phenotypes in tumor cells. During EMT, the epithelial marker E-cadherin (CDH1) is downregulated, leading to a loss of cell-cell adhesion, while mesenchymal markers, such as N-cadherin (CDH2), are upregulated to enhance cell migration [<a href="#CR149" class="usa-link" aria-describedby="CR149">149</a>]. This metabolic reprogramming, which supports the transformational phenotype in cancer, is closely tied to the GFPT-driven HBP flux [<a href="#CR150" class="usa-link" aria-describedby="CR150">150</a>].</p>
<p id="Par40">Several studies have demonstrated a substantial link between the HBP pathway and EMT [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>, <a href="#CR151" class="usa-link" aria-describedby="CR151">151</a>]. The EMT-HBP connection is implicated in the metastasis of various cancers, including lung cancer [<a href="#CR152" class="usa-link" aria-describedby="CR152">152</a>], melanoma [<a href="#CR153" class="usa-link" aria-describedby="CR153">153</a>], ovarian cancer [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>], colorectal cancer [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], and breast cancer [<a href="#CR154" class="usa-link" aria-describedby="CR154">154</a>]. Since the HBP pathway supplies the UDP-GlcNAc required for the synthesis of glycan, which plays a fundamental role in cell adhesion and communication, changes in HBP flux affect glycan structures and consequently influence epithelial morphology and EMT [<a href="#CR155" class="usa-link" aria-describedby="CR155">155</a>, <a href="#CR156" class="usa-link" aria-describedby="CR156">156</a>]. GFPT-mediated O-GlcNAcylation and glycan synthesis are crucial for regulating the expression of both epithelial and mesenchymal markers [<a href="#CR157" class="usa-link" aria-describedby="CR157">157</a>–<a href="#CR159" class="usa-link" aria-describedby="CR159">159</a>]. Gene expression profiling reveals that GFPT2 is a metabolic signature of mesenchymal cancer cell lines, upregulated in EMT and prominent in metastatic tumors exhibiting EMT [<a href="#CR160" class="usa-link" aria-describedby="CR160">160</a>]. Furthermore, GFPT2 expression positively correlated with markers of cancer-associated fibroblasts (CAF) [<a href="#CR137" class="usa-link" aria-describedby="CR137">137</a>, <a href="#CR148" class="usa-link" aria-describedby="CR148">148</a>], which play a role in cancer cell migration and invasion. In metastatic tumors, GFPT2 expression is also favorably associated with EMT-promoting transcription factors, including SNAIL, TWIST, and VIMENTIN [<a href="#CR115" class="usa-link" aria-describedby="CR115">115</a>, <a href="#CR131" class="usa-link" aria-describedby="CR131">131</a>].</p>
<p id="Par41">Transcriptomics profiling reveals upregulation of GFPT2 in mesenchymal stem cells within KRAS-driven lung cancer models [<a href="#CR115" class="usa-link" aria-describedby="CR115">115</a>]. GFPT has been linked to the aggressive and metastatic phenotype of cholangiocarcinoma [<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>], and in breast cancer, GFPT2 is highly expressed in mesenchymal cells and is notably associated with the claudin-low subtype [<a href="#CR140" class="usa-link" aria-describedby="CR140">140</a>]. Elevated GFPT2 levels are consistently observed from primary to metastatic leiomyosarcoma, underscoring its critical role in cancer metastasis [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]. GFPT2 is also implicated in stomatin-like protein 1 (STOML1)-driven liver metastasis of pancreatic cancer [<a href="#CR161" class="usa-link" aria-describedby="CR161">161</a>]. In gastric cancer, recent studies show that high GFPT2 expression correlates with increased tumor invasion and poor patient outcomes [<a href="#CR148" class="usa-link" aria-describedby="CR148">148</a>], while downregulation of GFPT1 in the same cancer type is similarly associated with EMT, invasion, and adverse prognosis [<a href="#CR162" class="usa-link" aria-describedby="CR162">162</a>]. Given the established links between GFPT isoforms and tumor progression, the contrasting roles of GFPT1 and GFPT2 in gastric cancer warrant further investigation.</p></section><section id="Sec16"><h3 class="pmc_sec_title">GFPT in cancer immune response and inflammatory signaling</h3>
<p id="Par42">The HBP serves as a critical communication axis between immune-inflammatory signaling and metabolism, with GFPT acting as a key player linking immune signaling and glucose metabolism, making it a potential target in immunotherapy. Recent studies reveal a direct relationship between GFPT expression and immune cell infiltration in tumors, where GFPT has been shown to promote T-cell exhaustion and increase inhibitory immune checkpoints such as PD-L1/PD-1 in the tumor microenvironment, suggesting an immunosuppressive role [<a href="#CR131" class="usa-link" aria-describedby="CR131">131</a>, <a href="#CR148" class="usa-link" aria-describedby="CR148">148</a>, <a href="#CR163" class="usa-link" aria-describedby="CR163">163</a>–<a href="#CR165" class="usa-link" aria-describedby="CR165">165</a>]. GFPT2, specifically, is associated with immunosuppressive cells like M2 macrophages and cancer-associated fibroblasts, contributing to immune evasion. For example, GFPT2-driven glutamine consumption disrupts mitochondrial function in macrophages and reduces their phagocytic activity. In EGFR-mutated NSCLC, targeted GFPT2 inhibition restores anti-tumor immunity by enhancing CD8 + T cell infiltration and reducing immune checkpoint activity [<a href="#CR166" class="usa-link" aria-describedby="CR166">166</a>]. Likewise, GFPT1 stabilizes PD-L1 via O-GlcNAcylation, which promotes IFNγ-induced PD-L1 activation and reduces T-cell and NK-cell efficacy against lung cancer cells [<a href="#CR167" class="usa-link" aria-describedby="CR167">167</a>]. Pharmacological GFPT1 inhibition, or blockade of glutamine utilization through DON treatment, heightens PDA sensitivity to anti-PD-1 therapy by diminishing hyaluronan levels and altering the extracellular matrix (ECM) [<a href="#CR165" class="usa-link" aria-describedby="CR165">165</a>]. These immunosuppressive functions of GFPT explain the correlation between high GFPT expression and poor patient outcomes.</p>
<p id="Par43">In colorectal cancer, GFPT1 is connected to mitochondrial antiviral-signaling protein (MAVS) from early to late stages, supporting reprogrammed metabolic states seen in viral immune responses [<a href="#CR168" class="usa-link" aria-describedby="CR168">168</a>, <a href="#CR169" class="usa-link" aria-describedby="CR169">169</a>]. Viral infections, such as respiratory syncytial virus (RSV), stimulate GFPT2 to drive HBP, leading to increased UDP-GlcNAc synthesis and viral glycoprotein production [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>, <a href="#CR170" class="usa-link" aria-describedby="CR170">170</a>]. Moreover, GFPT2 contributes to M2 macrophage polarization in PDA cells through the GFPT2-O-GlcNAcylation-YBX1 axis [<a href="#CR171" class="usa-link" aria-describedby="CR171">171</a>], and LPS-triggered inflammatory signaling induces GFPT2 expression via TLR4-FoxO1 in macrophages and TNF-NF-κB in NSCLC [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>, <a href="#CR172" class="usa-link" aria-describedby="CR172">172</a>]. These findings underscore the immunosuppressive and pro-inflammatory roles of GFPT in cancer, with therapeutic potential in modulating immune and inflammatory responses.</p></section><section id="Sec17"><h3 class="pmc_sec_title">Targeting GFPT in cancer</h3>
<p id="Par44">GFPT, the rate-limiting enzyme of the HBP and a central regulator of cellular UDP-GlcNAc levels, plays a pivotal role in cancer metabolism. Due to its essential function in glycosylation, GFPT has attracted increasing interest as a potential therapeutic target, particularly in cancer and metabolic diseases such as diabetes. A range of GFPT inhibitors—both synthetic and naturally derived—have been investigated, initially in the context of antimicrobial and antidiabetic therapies [<a href="#CR173" class="usa-link" aria-describedby="CR173">173</a>, <a href="#CR174" class="usa-link" aria-describedby="CR174">174</a>]. These include analogs of fructose-6-phosphate or glucosamine-6-phosphate that target the isomerase domain, glutamine analogs that inhibit the glutaminase domain, and compounds that mimic the enzyme transition state [<a href="#CR175" class="usa-link" aria-describedby="CR175">175</a>–<a href="#CR178" class="usa-link" aria-describedby="CR178">178</a>]. Among these, glutamine analog N³-(4-methoxyfumaroyl)-2,3-diaminopropanoic acid (FMDP) demonstrates high selectivity for GFPT [<a href="#CR179" class="usa-link" aria-describedby="CR179">179</a>], whereas others such as DON (6-diazo-5-oxo-L-norluecin) and Azaserine (O-diazoacetyl-L-serine) exhibit broader activity against glutamine-dependent enzymes [<a href="#CR180" class="usa-link" aria-describedby="CR180">180</a>].</p>
<p id="Par45">In cancer, therapeutic strategies targeting GFPT1 primarily involve glutamine analogs that inhibit glutamine-utilizing amidotransferases. Although multiple analogs have been evaluated for anticancer potential, only a subset—most notably DON and Azaserine—have been shown to directly inhibit GFPT activity [<a href="#CR180" class="usa-link" aria-describedby="CR180">180</a>, <a href="#CR181" class="usa-link" aria-describedby="CR181">181</a>].</p></section><section id="Sec18"><h3 class="pmc_sec_title">Early GFPT1-targeting therapies in cancer</h3>
<p id="Par46">Among the earliest glutamine analogs explored for anticancer therapy, DON and Azaserine stand out as notable compounds that target glutamine-utilizing enzymes, including GFPT1. Both are naturally derived from <em>Streptomyces species</em> [<a href="#CR182" class="usa-link" aria-describedby="CR182">182</a>] and were identified over half a century ago during the intensive search for antibiotic compounds with antitumor properties [<a href="#CR183" class="usa-link" aria-describedby="CR183">183</a>, <a href="#CR184" class="usa-link" aria-describedby="CR184">184</a>]. Structurally, DON and Azaserine are analogs of L-glutamine and differ only at the fourth atomic position: DON contains a carbon atom, whereas Azaserine features an oxygen atom (Fig. <a href="#Fig7" class="usa-link">7</a>). DON is chemically synthesized through diazotization of the γ-carboxyl group of protected L-glutamic acid, following selective masking of its amino and carboxyl groups [<a href="#CR185" class="usa-link" aria-describedby="CR185">185</a>, <a href="#CR186" class="usa-link" aria-describedby="CR186">186</a>]. In contrast, Azaserine is synthesized via O-diazoacetylation of L-serine [<a href="#CR187" class="usa-link" aria-describedby="CR187">187</a>, <a href="#CR188" class="usa-link" aria-describedby="CR188">188</a>]. Early studies revealed that both compounds are highly polar, thermally unstable, and prone to degradation, necessitating stringent conditions to ensure reliable synthesis and yield [<a href="#CR189" class="usa-link" aria-describedby="CR189">189</a>, <a href="#CR190" class="usa-link" aria-describedby="CR190">190</a>]. Moreover, the safety concerns associated with diazo compound synthesis have historically limited their commercial availability [<a href="#CR191" class="usa-link" aria-describedby="CR191">191</a>, <a href="#CR192" class="usa-link" aria-describedby="CR192">192</a>]. However, recent breakthroughs in microbial genomics have identified the biosynthetic gene clusters responsible for DON and Azaserine production in <em>Streptomyces albus</em> and <em>Glycomyces harbinensis</em>, respectively [<a href="#CR193" class="usa-link" aria-describedby="CR193">193</a>, <a href="#CR194" class="usa-link" aria-describedby="CR194">194</a>]. These findings open new avenues for sustainable, fermentation-based production of these diazo-containing glutamine analogs, offering a scalable and potentially safer alternative to chemical synthesis.</p>
<figure class="fig xbox font-sm" id="Fig7"><h4 class="obj_head">Fig. 7. Inhibitors of GFPT.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365115_41420_2025_2687_Fig7_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab9/12365115/311b4053a1bb/41420_2025_2687_Fig7_HTML.jpg" loading="lazy" id="d33e1852" height="432" width="672" alt="Fig. 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>GFPT-targeting inhibitors investigated in cancer studies include the glutamine analogs Azaserine, DON, Azotomycin, and various DON-based prodrugs. In prodrug design, the α-carboxyl and amino groups of DON are masked with nonpolar, hydrophobic moieties to yield an initially inactive compound, which is subsequently bioactivated in vivo to release DON.</p></figcaption></figure><p id="Par47">The diazo functional groups of DON and Azaserine confer high electrophilicity, a property central to their biological activity as irreversible inhibitors of glutamine-dependent amidotransferases [<a href="#CR195" class="usa-link" aria-describedby="CR195">195</a>]. These compounds covalently bind to the substrate-binding pockets of their target enzymes, resulting in permanent inactivation [<a href="#CR196" class="usa-link" aria-describedby="CR196">196</a>, <a href="#CR197" class="usa-link" aria-describedby="CR197">197</a>]. Mechanistic studies suggest that, within the GFPT glutaminase domain, the inhibitor undergoes protonation—potentially facilitated by the thiol group of the catalytic Cys1 residue. This protonation event initiates a nucleophilic attack by the thiolate on the electrophilic diazonium group of the inhibitor, forming a covalent adduct and releasing molecular nitrogen (N<sub>2</sub>) [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. The potent inhibitory properties of DON and Azaserine have demonstrated significant anticancer effects in multiple preclinical models. However, their acid lability and poor lipophilicity limit their pharmacokinetic properties—particularly their ability to cross the blood–brain barrier—thereby restricting their therapeutic efficacy against brain tumors such as glioblastoma [<a href="#CR189" class="usa-link" aria-describedby="CR189">189</a>].</p>
<p id="Par48">Following promising preclinical results, DON and Azaserine entered clinical trials as early as the 1950s [<a href="#CR198" class="usa-link" aria-describedby="CR198">198</a>, <a href="#CR199" class="usa-link" aria-describedby="CR199">199</a>]. Despite initial indications of therapeutic efficacy, clinical development was halted due to dose-limiting gastrointestinal toxicities, including nausea, vomiting, diarrhea, and mucositis, which were difficult to manage [<a href="#CR184" class="usa-link" aria-describedby="CR184">184</a>, <a href="#CR200" class="usa-link" aria-describedby="CR200">200</a>]. Interest in DON resurfaced in the 1980s, spurred by the clinical success of Azotomycin—a naturally occurring compound composed of two DON molecules linked via an amide bond and a single glutamine moiety attached through its terminal amine group (Fig. <a href="#Fig7" class="usa-link">7</a>) [<a href="#CR184" class="usa-link" aria-describedby="CR184">184</a>, <a href="#CR201" class="usa-link" aria-describedby="CR201">201</a>]. Subsequent clinical studies showed that DON was generally well-tolerated in pediatric populations and exhibited promising outcomes when used in combination with pegylated glutaminase in adults with advanced, treatment-refractory solid tumor [<a href="#CR202" class="usa-link" aria-describedby="CR202">202</a>, <a href="#CR203" class="usa-link" aria-describedby="CR203">203</a>]. However, clinical development was ultimately discontinued due to challenges in optimizing treatment regimens and dosing schedules, as DON-induced toxicity was found to be highly schedule-dependent and difficult to predict [<a href="#CR199" class="usa-link" aria-describedby="CR199">199</a>, <a href="#CR204" class="usa-link" aria-describedby="CR204">204</a>].</p></section><section id="Sec19"><h3 class="pmc_sec_title">DON prodrugs</h3>
<p id="Par49">The recent recognition of cancer glutamine addiction, coupled with the notable antitumor potential of DON, has reignited efforts to repurpose DON with an improved therapeutic index. To address previous limitations—including poor plasma stability, low bioavailability, systemic toxicity, and inadequate lipophilicity for brain penetration—new DON prodrugs have been developed. These prodrugs are designed by masking both the carboxylate and amine functional groups of DON with various promoieties, such as alkyl esters, amino acids, or bulky hydrophobic groups, enabling in vivo bioactivation to release active DON [<a href="#CR205" class="usa-link" aria-describedby="CR205">205</a>]. The first generation of these optimized prodrugs, such as compound 5c, was engineered to enhance stability and facilitate delivery to the central nervous system (CNS) for potential treatment of brain tumors [<a href="#CR205" class="usa-link" aria-describedby="CR205">205</a>]. Building on this foundation, second-generation DON prodrugs—including JHU395, JHU083, and compound 6—incorporated tumor-targeting features and tumor-specific bioactivation, minimizing DON exposure in normal tissues, especially the gastrointestinal tract [<a href="#CR198" class="usa-link" aria-describedby="CR198">198</a>, <a href="#CR206" class="usa-link" aria-describedby="CR206">206</a>–<a href="#CR208" class="usa-link" aria-describedby="CR208">208</a>]. This specificity was achieved by integrating promoieties cleavable by tumor-enriched enzymes, thereby restricting DON release to the tumor microenvironment. Given their robust preclinical efficacy (summarized in Table <a href="#Tab3" class="usa-link">3</a>), several of these prodrugs have advanced toward clinical application. Notably, DRP-104, one of the most promising candidates, is currently undergoing clinical evaluation as both a monotherapy and in combination regimens for advanced solid tumors (<a href="https://clinicaltrials.gov/ct2/show/NCT04471415" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04471415</a>) [<a href="#CR209" class="usa-link" aria-describedby="CR209">209</a>]. Furthermore, a recent study has introduced a hypoxia-activated DON prodrug, tailored to selectively target hypoxic tumor regions [<a href="#CR210" class="usa-link" aria-describedby="CR210">210</a>]. Intriguingly, combining this prodrug with a hypoxia-enhancing agent improved antitumor efficacy even in tumors with low baseline hypoxia, suggesting broader therapeutic potential irrespective of tumor microenvironmental oxygenation.</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Preclinical Features of DON Prodrug.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">DON prodrug</th>
<th colspan="1" rowspan="1">Plasma stability</th>
<th colspan="1" rowspan="1">Distribution to tumor /CNS</th>
<th colspan="1" rowspan="1">Effect and activation</th>
<th colspan="1" rowspan="1">Tolerability and toxicity</th>
<th colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Compound 5</td>
<td colspan="1" rowspan="1">Specie-specific stability</td>
<td colspan="1" rowspan="1">Specific for brain delivery. 10-fold higher than DON</td>
<td colspan="1" rowspan="1">Promising antitumor activity in brain tumors</td>
<td colspan="1" rowspan="1">Not Determined</td>
<td colspan="1" rowspan="1">[<a href="#CR205" class="usa-link" aria-describedby="CR205">205</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">JHU083</td>
<td colspan="1" rowspan="1">Stable</td>
<td colspan="1" rowspan="1">Tumor-specific and CNS delivery with micromolar brain concentration</td>
<td colspan="1" rowspan="1">Robust antitumor activity, immune activation, and apoptotic induction</td>
<td colspan="1" rowspan="1">
<p>Orally bioavailable and very tolerable.</p>
<p>No significant gastrointestinal toxicity at the therapeutic dose</p>
</td>
<td colspan="1" rowspan="1">[<a href="#CR208" class="usa-link" aria-describedby="CR208">208</a>, <a href="#CR215" class="usa-link" aria-describedby="CR215">215</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">JHU395</td>
<td colspan="1" rowspan="1">Stable</td>
<td colspan="1" rowspan="1">
<p>Tumor-specific and CNS delivery</p>
<p>&gt;2-fold tumor/plasma ratio compared to DON</p>
</td>
<td colspan="1" rowspan="1">Robust antitumor activity with apoptotic induction</td>
<td colspan="1" rowspan="1">
<p>Orally bioavailable and very tolerable.</p>
<p>No significant gastrointestinal toxicity at the therapeutic dose</p>
</td>
<td colspan="1" rowspan="1">[<a href="#CR207" class="usa-link" aria-describedby="CR207">207</a>, <a href="#CR216" class="usa-link" aria-describedby="CR216">216</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Compound 6</td>
<td colspan="1" rowspan="1">Stable</td>
<td colspan="1" rowspan="1">
<p>Tumor-specific delivery.</p>
<p>6-fold higher tumor exposure of DON than plasma</p>
</td>
<td colspan="1" rowspan="1">Tumor-specific bioactivation with in vitro antiproliferative effect</td>
<td colspan="1" rowspan="1">Very Tolerable. Minimal DON release in G1 tissues and consequent limitation in G1 toxicity</td>
<td colspan="1" rowspan="1">[<a href="#CR206" class="usa-link" aria-describedby="CR206">206</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Prodrug 1/2/3</td>
<td colspan="1" rowspan="1">Stable</td>
<td colspan="1" rowspan="1">Tumor-specific and CNS delivery</td>
<td colspan="1" rowspan="1">Tumor-specific bioactivation with antitumor effect</td>
<td colspan="1" rowspan="1">Tolerable. Minimal DON release in G1 tissues and limited toxicity at the effective therapeutic doses</td>
<td colspan="1" rowspan="1">[<a href="#CR198" class="usa-link" aria-describedby="CR198">198</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">DRP104</td>
<td colspan="1" rowspan="1">Stable in humans and in CES1<sup>-/-</sup> mice</td>
<td colspan="1" rowspan="1">
<p>Preferential tumor delivery.</p>
<p>6-fold higher tumor exposure of DON than plasma</p>
</td>
<td colspan="1" rowspan="1">Tumor-specific bioactivation. Robust antitumor effect with complete tumor regression and immune activation.</td>
<td colspan="1" rowspan="1">Very tolerable. Negligible DON exposure to G1 and plasma. Reduced toxicity</td>
<td colspan="1" rowspan="1">[<a href="#CR209" class="usa-link" aria-describedby="CR209">209</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Compound 11 (Optimized DRP104)</td>
<td colspan="1" rowspan="1">Stable in humans and CES1<sup>-/-</sup> mice</td>
<td colspan="1" rowspan="1">
<p>Preferential tumor delivery.</p>
<p>3.6-fold higher tumor exposure of DON than plasma</p>
</td>
<td colspan="1" rowspan="1">Tumor-specific bioactivation with in vitro antiproliferative effect.</td>
<td colspan="1" rowspan="1">Not Determined</td>
<td colspan="1" rowspan="1">[<a href="#CR217" class="usa-link" aria-describedby="CR217">217</a>]</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Azo-DON</td>
<td colspan="1" rowspan="1">Stable</td>
<td colspan="1" rowspan="1">Tumor-specific delivery</td>
<td colspan="1" rowspan="1">Hypoxia-specific bioactivation. Enhances antitumor immunity and apoptosis.</td>
<td colspan="1" rowspan="1">Dosage-dependent tolerability.</td>
<td colspan="1" rowspan="1">[<a href="#CR210" class="usa-link" aria-describedby="CR210">210</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p78"><p>The chemicals that are detived from DON and considered as prodrug are listed here to demonstrate their properties and activities in cancer treatment.</p></div></div></section><p id="Par50">Overall, compounds targeting GFPT1 exhibit promising therapeutic potential in cancer management. However, many of these agents also inhibit other glutamine-dependent enzymes, resulting in broad perturbations of cellular metabolism. For instance, while the glutamine analog FMDP selectively inhibits microbial GFPT orthologs, its clinical application has so far been restricted to antimicrobial settings. In addition, several small molecules that specifically inhibit the isomerase domain of GFPT or interfere with its interdomain interactions have been primarily explored in the context of diabetes and metabolic disorders [<a href="#CR173" class="usa-link" aria-describedby="CR173">173</a>]. Given their potent inhibitory activity, such compounds may hold untapped anticancer potential—particularly in malignancies characterized by high metabolic plasticity and upregulated hexosamine biosynthetic pathway (HBP) flux. Future efforts aimed at the strategic optimization and repurposing of these inhibitors for oncologic use could provide novel avenues for GFPT-centered translational research, offering new insight into metabolism-targeted cancer therapy.</p></section><section id="Sec20"><h3 class="pmc_sec_title">Differential roles of GFPT isoforms and concerns in translational study</h3>
<p id="Par51">Enzymes of the hexosamine biosynthetic pathway (HBP), yet they exhibit distinct biological roles that bear important implications for clinical and translational research. GFPT1 is ubiquitously expressed across multiple tissues, reflecting its role as the primary isoform mediating basal HBP activity. In contrast, GFPT2 displays tissue-restricted expression, suggesting a more context-specific regulatory function [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]. This divergence is also evident in their regulatory mechanisms. GFPT1, but not GFPT2, is subject to feedback inhibition by UDP-GlcNAc, a key mechanism for maintaining glycosylation homeostasis under steady-state conditions [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>, <a href="#CR211" class="usa-link" aria-describedby="CR211">211</a>]. Conversely, in cells where GFPT2 predominates, AMDHD2—a GlcNAc-6-P deacetylase—is required to regulate intracellular glycosylation flux [<a href="#CR211" class="usa-link" aria-describedby="CR211">211</a>]. The physiological relevance of GFPT1 is further underscored by its critical role in neuromuscular junction function, its association with congenital myasthenic syndromes, the presence of a muscle-specific isoform, and its essentiality for embryonic viability [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>, <a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>, <a href="#CR212" class="usa-link" aria-describedby="CR212">212</a>]. In cancer, the expression of GFPT1 and GFPT2 is differentially regulated under varying cellular stress conditions. For example, ER and nutrient stress induce GFPT1 through the activation of XBP1 and ATF4 [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>], whereas oxidative stress selectively induces GFPT2, potentially via receptor tyrosine kinase (RTK) signaling and NF-κB activation [<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>, <a href="#CR139" class="usa-link" aria-describedby="CR139">139</a>, <a href="#CR140" class="usa-link" aria-describedby="CR140">140</a>]. Although the precise rationale behind the conditional induction of these isoforms remains to be fully elucidated, the ER stress–mediated upregulation of GFPT1 highlights its primary role in maintaining glycosylation for protein folding and stability, whereas GFPT2 may serve stress-adaptive functions under distinct pathological contexts.</p>
<p id="Par52">Comparative analyses of GFPT isoform expression across diverse tumor types reveal that GFPT1 is broadly and constitutively expressed, while GFPT2 exhibits more restricted, tumor-specific expression patterns (Fig. <a href="#Fig8" class="usa-link">8A</a>). This supports the notion of GFPT1 as the basal metabolic isoform, with GFPT2 playing more specialized, context-dependent roles. The differential expression observed in cancer further suggests distinct biological functions for GFPT2 that are not redundant with those of GFPT1. Notably, accumulating evidence indicates that GFPT1 is more closely associated with tumor growth and proliferation, whereas GFPT2 correlates with tumor metastasis and progression [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>, <a href="#CR97" class="usa-link" aria-describedby="CR97">97</a>, <a href="#CR131" class="usa-link" aria-describedby="CR131">131</a>, <a href="#CR161" class="usa-link" aria-describedby="CR161">161</a>]. In support of this, expression analyses show that high GFPT2 levels are positively correlated with advanced tumor stages in multiple cancer types, a trend not observed for GFPT1 (Fig. <a href="#Fig8" class="usa-link">8B</a>). Moreover, GFPT2 expression is enriched in EMT- and ECM-associated cellular populations, including mesenchymal cells, stromal cells, and cancer-associated fibroblasts (CAFs), further underscoring its role in invasion and metastatic dissemination [<a href="#CR137" class="usa-link" aria-describedby="CR137">137</a>, <a href="#CR148" class="usa-link" aria-describedby="CR148">148</a>, <a href="#CR160" class="usa-link" aria-describedby="CR160">160</a>, <a href="#CR213" class="usa-link" aria-describedby="CR213">213</a>]. These isoform-specific functional differences pose a significant challenge for therapeutic strategies targeting GFPT in cancer. While GFPT1’s widespread expression raises concerns about potential off-target effects in normal tissues, GFPT2’s restricted expression profile and association with metastatic phenotypes positions it as a more attractive and potentially safer therapeutic target, particularly in aggressive and oxidative stress-rich tumors. However, the development of isoform-specific inhibitors remains difficult due to the high structural homology between GFPT1 and GFPT2 and the potential for compensatory function between the isoforms.</p>
<figure class="fig xbox font-sm" id="Fig8"><h4 class="obj_head">Fig. 8. Comparative pan-cancer expression and tumor stage correlation of GFPT1 and GFPT2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365115_41420_2025_2687_Fig8_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab9/12365115/f7568a414b56/41420_2025_2687_Fig8_HTML.jpg" loading="lazy" id="d33e2222" height="498" width="699" alt="Fig. 8"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig8/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p><strong>A</strong> Comparative gene expression analysis of GFPT1 and GFPT2 across multiple TCGA tumor types was performed using the Gene Expression Profiling Interactive Analysis (GEPIA) tool [<a href="#CR218" class="usa-link" aria-describedby="CR218">218</a>]. Expression values are represented as Z-scores of the median Log<sub>2</sub>(TPM + 1) across tumor samples for each cancer type. <strong>B</strong> Correlation analysis between GFPT1 and GFPT2 expression levels and tumor stage across TCGA cancers was conducted using TIMER2.0 [<a href="#CR219" class="usa-link" aria-describedby="CR219">219</a>]. The heatmap displays the normalized regression coefficients derived from a Cox proportional hazards model for each gene (GFPT1 or GFPT2), indicating their association with tumor stage.</p></figcaption></figure><p id="Par53">Additionally, the upstream regulatory role of GFPT in protein glycosylation poses a major challenge for its clinical translation as a therapeutic target. Inhibiting GFPT leads to a global suppression of protein glycosylation, a process essential for numerous cellular functions, thereby increasing the risk of off-target effects in normal tissues. Another key concern is the integration of GFPT within broader metabolic networks, including glycolysis and amino acid metabolism. This interconnectedness complicates the ability to isolate the specific contribution of GFPT1, as downstream effects may result from broader metabolic disruptions rather than GFPT inhibition alone. Furthermore, the lack of GFPT-specific inhibitors in preclinical studies raises concerns about misattribution of therapeutic effects, where observed outcomes may be erroneously interpreted as GFPT-specific due to concurrent off-target inhibition. In summary, GFPT plays a central role in cancer growth and progression. While several factors currently limit its feasibility as a direct therapeutic target, the isoform-specific functions of GFPT1 and GFPT2 present an opportunity to develop cancer subtype-specific biomarkers and may inform the design of more selective therapeutic strategies.</p></section></section><section id="Sec21"><h2 class="pmc_sec_title">Conclusion and perspective</h2>
<p id="Par54">The role of GFPT in cancer metabolism is increasingly recognized as a pivotal modulator linking nutrient stress response to tumor progression via the regulation of HBP. While traditionally GFPT has been associated with glycolysis and UDP-GlcNAc synthesis, evidence indicates that GFPT-mediated metabolic adaptation supports cancer cell survival, particularly under stress conditions such as nutrient deprivation and hypoxia. Although GFPT activity can be inhibited in glucose-starved cells, its expression is vital for cancer cell resilience, suggesting its potential as a therapeutic target for tumor types with high HBP dependency.</p>
<p id="Par55">Despite the significant findings, much remains to be understood regarding the roles of GFPT in modulating cancer stemness, chemoresistance, and the interaction with other oncogenic pathways. Importantly, GFPT appears to facilitate EMT, invasion, and metastasis in part by enabling glycosylation of critical proteins. However, these mechanisms may vary by cancer type, highlighting the need for further research to elucidate GFPT’s role across different cellular contexts. Studies on the dysregulation and role of GFPT in cancer are mostly focused on GFPT-induced glycosylation; other non-conventional mechanisms like GFPT-induced glutamylation need to be explored.</p>
<p id="Par56">Targeting GFPT and the HBP offers a promising strategy in cancer therapy, particularly as tumors with high GFPT expression are often more resistant to conventional chemotherapy. While glutamine analogs like DON have shown efficacy by inhibiting GFPT alongside other glutamine-dependent pathways, their broad action limits therapeutic specificity and increases toxicity. Future drug development should focus on optimizing GFPT-specific inhibitors to enhance the selectivity and reduce side effects in cancer treatments. Although prodrugs with better therapeutic index have been developed, their non-selectivity for GFPT still raises concern in translational GFPT research.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>This study was supported by the National Natural Science Foundation of China grants (No. 32470832, No.21907093), Dalian Science and Technology Innovation Funding (2019J12SN52), Liaoning Revitalization Talents Program (XLYC2002035), Liaoning Science and Technology Innovation Funding (20230101-JH2/1013).</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Y.M., H-l.P. and C.S. designed the review, C.S., P.L. and Y.W. drafted the manuscript and prepared the figures, C.S., Jing Liu and Jing Lv collected the related studies, T.X., H-l.P. and Y.M. revised the manuscript. All authors read and approved the final manuscript.</p></section><section id="FPar1"><h2 class="pmc_sec_title">Competing interests</h2>
<p id="Par57">The authors declare no competing interests.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1"><p><strong>Publisher’s note</strong> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div>
<div class="fn p" id="fn2"><p>These authors contributed equally: Chibuzo Sampson, Pengfei Li, Yiqian Wang.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Tian Xia, Email: txia@dicp.ac.cn.</p>
<p>Hai-long Piao, Email: hpiao@dicp.ac.cn.</p>
<p>Yegang Ma, Email: mayegang@cancerhosp-ln-cmu.com.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.
</cite> [<a href="https://doi.org/10.1126/science.1160809" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2849637/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19460998/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vander%20Heiden%20MG,%20Cantley%20LC,%20Thompson%20CB.%20Understanding%20the%20Warburg%20effect:%20the%20metabolic%20requirements%20of%20cell%20proliferation.%20Science.%202009;324:1029%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13:472–82.
</cite> [<a href="https://doi.org/10.1016/j.ccr.2008.05.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18538731/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kroemer%20G,%20Pouyssegur%20J.%20Tumor%20cell%20metabolism:%20cancer%E2%80%99s%20Achilles%E2%80%99%20heel.%20Cancer%20Cell.%202008;13:472%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20.
</cite> [<a href="https://doi.org/10.1016/j.cmet.2007.10.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18177721/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?DeBerardinis%20RJ,%20Lum%20JJ,%20Hatzivassiliou%20G,%20Thompson%20CB.%20The%20biology%20of%20cancer:%20metabolic%20reprogramming%20fuels%20cell%20growth%20and%20proliferation.%20Cell%20Metab.%202008;7:11%E2%80%9320." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev cell Dev Biol. 2011;27:441–64.
</cite> [<a href="https://doi.org/10.1146/annurev-cellbio-092910-154237" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21985671/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lunt%20SY,%20Vander%20Heiden%20MG.%20Aerobic%20glycolysis:%20meeting%20the%20metabolic%20requirements%20of%20cell%20proliferation.%20Annu%20Rev%20cell%20Dev%20Biol.%202011;27:441%E2%80%9364." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21:297–308.
</cite> [<a href="https://doi.org/10.1016/j.ccr.2012.02.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3311998/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22439925/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ward%20PS,%20Thompson%20CB.%20Metabolic%20reprogramming:%20a%20cancer%20hallmark%20even%20warburg%20did%20not%20anticipate.%20Cancer%20Cell.%202012;21:297%E2%80%93308." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Matés JM, Di Paola FJ, Campos-Sandoval JA, Mazurek S, Márquez J. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin cell Dev. Biol 2020;98:34–43.
</cite> [<a href="https://doi.org/10.1016/j.semcdb.2019.05.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31100352/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mat%C3%A9s%20JM,%20Di%20Paola%20FJ,%20Campos-Sandoval%20JA,%20Mazurek%20S,%20M%C3%A1rquez%20J.%20Therapeutic%20targeting%20of%20glutaminolysis%20as%20an%20essential%20strategy%20to%20combat%20cancer.%20Semin%20cell%20Dev.%20Biol%202020;98:34%E2%80%9343." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2:e1600200.</cite> [<a href="https://doi.org/10.1126/sciadv.1600200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4928883/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27386546/" class="usa-link">PubMed</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Swamy M, Pathak S, Grzes KM, Damerow S, Sinclair LV, van Aalten DM, et al. Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. Nat Immunol. 2016;17:712–20.
</cite> [<a href="https://doi.org/10.1038/ni.3439" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4900450/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27111141/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Swamy%20M,%20Pathak%20S,%20Grzes%20KM,%20Damerow%20S,%20Sinclair%20LV,%20van%20Aalten%20DM,%20et%20al.%20Glucose%20and%20glutamine%20fuel%20protein%20O-GlcNAcylation%20to%20control%20T%20cell%20self-renewal%20and%20malignancy.%20Nat%20Immunol.%202016;17:712%E2%80%9320." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Araujo L, Khim P, Mkhikian H, Mortales CL, Demetriou M. Glycolysis and glutaminolysis cooperatively control T cell function by limiting metabolite supply to N-glycosylation. Elife. 2017;6:e21330.</cite> [<a href="https://doi.org/10.7554/eLife.21330" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5257256/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28059703/" class="usa-link">PubMed</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Peric L, Vukadin S, Petrovic A, Kuna L, Puseljic N, Sikora R, et al. Glycosylation alterations in cancer cells, prognostic value of glycan biomarkers and their potential as novel therapeutic targets in breast cancer. Biomedicines. 2022;10:3265.</cite> [<a href="https://doi.org/10.3390/biomedicines10123265" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9775348/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36552021/" class="usa-link">PubMed</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem. 2011;80:825–58.
</cite> [<a href="https://doi.org/10.1146/annurev-biochem-060608-102511" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3294376/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21391816/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hart%20GW,%20Slawson%20C,%20Ramirez-Correa%20G,%20Lagerlof%20O.%20Cross%20talk%20between%20O-GlcNAcylation%20and%20phosphorylation:%20roles%20in%20signaling,%20transcription,%20and%20chronic%20disease.%20Annu%20Rev%20Biochem.%202011;80:825%E2%80%9358." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Nakajima H, Murakami K. O-GlcNAcylation: Implications in normal and malignant hematopoiesis. Exp Hematol. 2021;101-102:16–24.
</cite> [<a href="https://doi.org/10.1016/j.exphem.2021.07.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34302904/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nakajima%20H,%20Murakami%20K.%20O-GlcNAcylation:%20Implications%20in%20normal%20and%20malignant%20hematopoiesis.%20Exp%20Hematol.%202021;101-102:16%E2%80%9324." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Chiaradonna F, Ricciardiello F, Palorini R. The nutrient-sensing hexosamine biosynthetic pathway as the hub of cancer metabolic rewiring. Cells. 2018;7:53.</cite> [<a href="https://doi.org/10.3390/cells7060053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6025041/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29865240/" class="usa-link">PubMed</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Luanpitpong S, Rodboon N, Samart P, Vinayanuwattikun C, Klamkhlai S, Chanvorachote P, et al. A novel TRPM7/O-GlcNAc axis mediates tumour cell motility and metastasis by stabilising c-Myc and caveolin-1 in lung carcinoma. Br J cancer. 2020;123:1289–301.
</cite> [<a href="https://doi.org/10.1038/s41416-020-0991-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7555538/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32684624/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Luanpitpong%20S,%20Rodboon%20N,%20Samart%20P,%20Vinayanuwattikun%20C,%20Klamkhlai%20S,%20Chanvorachote%20P,%20et%20al.%20A%20novel%20TRPM7/O-GlcNAc%20axis%20mediates%20tumour%20cell%20motility%20and%20metastasis%20by%20stabilising%20c-Myc%20and%20caveolin-1%20in%20lung%20carcinoma.%20Br%20J%20cancer.%202020;123:1289%E2%80%93301." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Ferrer CM, Lynch TP, Sodi VL, Falcone JN, Schwab LP, Peacock DL, et al. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol Cell. 2014;54:820–31.
</cite> [<a href="https://doi.org/10.1016/j.molcel.2014.04.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4104413/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24857547/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ferrer%20CM,%20Lynch%20TP,%20Sodi%20VL,%20Falcone%20JN,%20Schwab%20LP,%20Peacock%20DL,%20et%20al.%20O-GlcNAcylation%20regulates%20cancer%20metabolism%20and%20survival%20stress%20signaling%20via%20regulation%20of%20the%20HIF-1%20pathway.%20Mol%20Cell.%202014;54:820%E2%80%9331." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA, et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science. 2012;337:975–80.
</cite> [<a href="https://doi.org/10.1126/science.1222278" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3534962/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22923583/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yi%20W,%20Clark%20PM,%20Mason%20DE,%20Keenan%20MC,%20Hill%20C,%20Goddard%20WA,%20et%20al.%20Phosphofructokinase%201%20glycosylation%20regulates%20cell%20growth%20and%20metabolism.%20Science.%202012;337:975%E2%80%9380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Ghosh S, Blumenthal HJ, Davidson E, Roseman S. Glucosamine metabolism: v. enzymatic synthesis of glucosamine 6-phosphate. J Biol Chem 1960;235:1265–73.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/13827775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ghosh%20S,%20Blumenthal%20HJ,%20Davidson%20E,%20Roseman%20S.%20Glucosamine%20metabolism:%20v.%20enzymatic%20synthesis%20of%20glucosamine%206-phosphate.%20J%20Biol%20Chem%201960;235:1265%E2%80%9373." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Milewski S. Glucosamine-6-phosphate synthase—the multi-facets enzyme. Biochimica Biophysica Acta (BBA) Protein Struct Mol Enzymol. 2002;1597:173–92.</cite> [<a href="https://doi.org/10.1016/s0167-4838(02)00318-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12044898/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Milewski%20S.%20Glucosamine-6-phosphate%20synthase%E2%80%94the%20multi-facets%20enzyme.%20Biochimica%20Biophysica%20Acta%20(BBA)%20Protein%20Struct%20Mol%20Enzymol.%202002;1597:173%E2%80%9392." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Winterburn PJ, Phelps CF. Purification and some kinetic properties of rat liver glucosamine synthetase. Biochem J 1971;121:701–9.
</cite> [<a href="https://doi.org/10.1042/bj1210701" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1176648/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/4255955/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Winterburn%20PJ,%20Phelps%20CF.%20Purification%20and%20some%20kinetic%20properties%20of%20rat%20liver%20glucosamine%20synthetase.%20Biochem%20J%201971;121:701%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Badet B, Vermoote P, Le Goffic F. Glucosamine synthetase from Escherichia coli: kinetic mechanism and inhibition by N3-fumaroyl-L-2,3-diaminopropionic derivatives. Biochemistry. 1988;27:2282–7.
</cite> [<a href="https://doi.org/10.1021/bi00407a006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3132968/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Badet%20B,%20Vermoote%20P,%20Le%20Goffic%20F.%20Glucosamine%20synthetase%20from%20Escherichia%20coli:%20kinetic%20mechanism%20and%20inhibition%20by%20N3-fumaroyl-L-2,3-diaminopropionic%20derivatives.%20Biochemistry.%201988;27:2282%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Raczynska J, Olchowy J, Konariev PV, Svergun DI, Milewski S, Rypniewski W. The crystal and solution studies of glucosamine-6-phosphate synthase from candida albicans. J Mol Biol. 2007;372:672–88.
</cite> [<a href="https://doi.org/10.1016/j.jmb.2007.07.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17681543/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Raczynska%20J,%20Olchowy%20J,%20Konariev%20PV,%20Svergun%20DI,%20Milewski%20S,%20Rypniewski%20W.%20The%20crystal%20and%20solution%20studies%20of%20glucosamine-6-phosphate%20synthase%20from%20candida%20albicans.%20J%20Mol%20Biol.%202007;372:672%E2%80%9388." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Teplyakov A, Obmolova G, Badet B, Badet-Denisot MA. Channeling of ammonia in glucosamine-6-phosphate synthase. J Mol Biol. 2001;313:1093–102.
</cite> [<a href="https://doi.org/10.1006/jmbi.2001.5094" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11700065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Teplyakov%20A,%20Obmolova%20G,%20Badet%20B,%20Badet-Denisot%20MA.%20Channeling%20of%20ammonia%20in%20glucosamine-6-phosphate%20synthase.%20J%20Mol%20Biol.%202001;313:1093%E2%80%93102." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Kornfeld R. Studies on l-glutamine d-fructose 6-phosphate amidotransferase: I. Feedback inhibition by uridine diphosphate-N-acetylglucosamine. J Biol Chem. 1967;242:3135–41.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/4961641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kornfeld%20R.%20Studies%20on%20l-glutamine%20d-fructose%206-phosphate%20amidotransferase:%20I.%20Feedback%20inhibition%20by%20uridine%20diphosphate-N-acetylglucosamine.%20J%20Biol%20Chem.%201967;242:3135%E2%80%9341." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Broschat KO, Gorka C, Page JD, Martin-Berger CL, Davies MS, Huang H-c, et al. Kinetic characterization of human glutamine-fructose-6-phosphate amidotransferase I: potent feedback inhibition by glucosamine 6-phosphate*. J Biol Chem. 2002;277:14764–70.
</cite> [<a href="https://doi.org/10.1074/jbc.M201056200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11842094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Broschat%20KO,%20Gorka%20C,%20Page%20JD,%20Martin-Berger%20CL,%20Davies%20MS,%20Huang%20H-c,%20et%20al.%20Kinetic%20characterization%20of%20human%20glutamine-fructose-6-phosphate%20amidotransferase%20I:%20potent%20feedback%20inhibition%20by%20glucosamine%206-phosphate*.%20J%20Biol%20Chem.%202002;277:14764%E2%80%9370." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Crook ED, Daniels MC, Smith TM, McClain DA. Regulation of insulin-stimulated glycogen synthase activity by overexpression of glutamine: fructose-6-phosphate amidotransferase in rat-1 fibroblasts. Diabetes. 1993;42:1289–96.
</cite> [<a href="https://doi.org/10.2337/diab.42.9.1289" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8349040/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Crook%20ED,%20Daniels%20MC,%20Smith%20TM,%20McClain%20DA.%20Regulation%20of%20insulin-stimulated%20glycogen%20synthase%20activity%20by%20overexpression%20of%20glutamine:%20fructose-6-phosphate%20amidotransferase%20in%20rat-1%20fibroblasts.%20Diabetes.%201993;42:1289%E2%80%9396." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Veerababu G, Tang J, Hoffman RT, Daniels MC, Hebert LF Jr, Crook ED, et al. Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes. 2000;49:2070–8.
</cite> [<a href="https://doi.org/10.2337/diabetes.49.12.2070" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11118009/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Veerababu%20G,%20Tang%20J,%20Hoffman%20RT,%20Daniels%20MC,%20Hebert%20LF%20Jr,%20Crook%20ED,%20et%20al.%20Overexpression%20of%20glutamine:%20fructose-6-phosphate%20amidotransferase%20in%20the%20liver%20of%20transgenic%20mice%20results%20in%20enhanced%20glycogen%20storage,%20hyperlipidemia,%20obesity,%20and%20impaired%20glucose%20tolerance.%20Diabetes.%202000;49:2070%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Paneque A, Fortus H, Zheng J, Werlen G, Jacinto E. The hexosamine biosynthesis pathway: regulation and function. Genes. 2023;14:933.</cite> [<a href="https://doi.org/10.3390/genes14040933" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10138107/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37107691/" class="usa-link">PubMed</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Mouilleron S, Badet-Denisot M-A, Badet B, Golinelli-Pimpaneau B. Dynamics of glucosamine-6-phosphate synthase catalysis. Arch Biochem Biophys. 2011;505:1–12.
</cite> [<a href="https://doi.org/10.1016/j.abb.2010.08.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20709015/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mouilleron%20S,%20Badet-Denisot%20M-A,%20Badet%20B,%20Golinelli-Pimpaneau%20B.%20Dynamics%20of%20glucosamine-6-phosphate%20synthase%20catalysis.%20Arch%20Biochem%20Biophys.%202011;505:1%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Guergueltcheva V, Müller JS, Dusl M, Senderek J, Oldfors A, Lindbergh C, et al. Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations. J Neurol. 2012;259:838–50.
</cite> [<a href="https://doi.org/10.1007/s00415-011-6262-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21975507/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guergueltcheva%20V,%20M%C3%BCller%20JS,%20Dusl%20M,%20Senderek%20J,%20Oldfors%20A,%20Lindbergh%20C,%20et%20al.%20Congenital%20myasthenic%20syndrome%20with%20tubular%20aggregates%20caused%20by%20GFPT1%20mutations.%20J%20Neurol.%202012;259:838%E2%80%9350." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Senderek J, Müller JS, Dusl M, Strom TM, Guergueltcheva V, Diepolder I, et al. Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. Am J Hum Genet. 2011;88:162–72.
</cite> [<a href="https://doi.org/10.1016/j.ajhg.2011.01.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3035713/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21310273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Senderek%20J,%20M%C3%BCller%20JS,%20Dusl%20M,%20Strom%20TM,%20Guergueltcheva%20V,%20Diepolder%20I,%20et%20al.%20Hexosamine%20biosynthetic%20pathway%20mutations%20cause%20neuromuscular%20transmission%20defect.%20Am%20J%20Hum%20Genet.%202011;88:162%E2%80%9372." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Denzel MartinS, Storm NadiaJ, Gutschmidt A, Baddi R, Hinze Y, Jarosch E, et al. Hexosamine pathway metabolites enhance protein quality control and prolong life. Cell. 2014;156:1167–78.
</cite> [<a href="https://doi.org/10.1016/j.cell.2014.01.061" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24630720/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Denzel%20MartinS,%20Storm%20NadiaJ,%20Gutschmidt%20A,%20Baddi%20R,%20Hinze%20Y,%20Jarosch%20E,%20et%20al.%20Hexosamine%20pathway%20metabolites%20enhance%20protein%20quality%20control%20and%20prolong%20life.%20Cell.%202014;156:1167%E2%80%9378." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Akella NM, Ciraku L, Reginato MJ. Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer. BMC Biol 2019;17:52.
</cite> [<a href="https://doi.org/10.1186/s12915-019-0671-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6610925/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31272438/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Akella%20NM,%20Ciraku%20L,%20Reginato%20MJ.%20Fueling%20the%20fire:%20emerging%20role%20of%20the%20hexosamine%20biosynthetic%20pathway%20in%20cancer.%20BMC%20Biol%202019;17:52." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Oki T, Yamazaki K, Kuromitsu J, Okada M, Tanaka I. cDNA cloning and mapping of a novel subtype of glutamine:fructose-6-phosphate amidotransferase (gfat2) in human and mouse. Genomics. 1999;57:227–34.
</cite> [<a href="https://doi.org/10.1006/geno.1999.5785" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10198162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Oki%20T,%20Yamazaki%20K,%20Kuromitsu%20J,%20Okada%20M,%20Tanaka%20I.%20cDNA%20cloning%20and%20mapping%20of%20a%20novel%20subtype%20of%20glutamine:fructose-6-phosphate%20amidotransferase%20(gfat2)%20in%20human%20and%20mouse.%20Genomics.%201999;57:227%E2%80%9334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>McKnight GL, Mudri SL, Mathewes SL, Traxinger RR, Marshall S, Sheppard PO, et al. Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase. J Biol Chem. 1992;267:25208–12.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/1460020/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McKnight%20GL,%20Mudri%20SL,%20Mathewes%20SL,%20Traxinger%20RR,%20Marshall%20S,%20Sheppard%20PO,%20et%20al.%20Molecular%20cloning,%20cDNA%20sequence,%20and%20bacterial%20expression%20of%20human%20glutamine:fructose-6-phosphate%20amidotransferase.%20J%20Biol%20Chem.%201992;267:25208%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Niimi M, Ogawara T, Yamashita T, Yamamoto Y, Ueyama A, Kambe T, et al. Identification of GFAT1-L, a novel splice variant of human glutamine: fructose-6-phosphate amidotransferase (GFAT1) that is expressed abundantly in skeletal muscle. J Hum Genet. 2001;46:566–71.
</cite> [<a href="https://doi.org/10.1007/s100380170022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11587069/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Niimi%20M,%20Ogawara%20T,%20Yamashita%20T,%20Yamamoto%20Y,%20Ueyama%20A,%20Kambe%20T,%20et%20al.%20Identification%20of%20GFAT1-L,%20a%20novel%20splice%20variant%20of%20human%20glutamine:%20fructose-6-phosphate%20amidotransferase%20(GFAT1)%20that%20is%20expressed%20abundantly%20in%20skeletal%20muscle.%20J%20Hum%20Genet.%202001;46:566%E2%80%9371." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>DeHaven JE, Robinson KA, Nelson BA, Buse MG. A novel variant of glutamine: fructose-6-phosphate amidotransferase-1 (GFAT1) mRNA is selectively expressed in striated muscle. Diabetes. 2001;50:2419–24.
</cite> [<a href="https://doi.org/10.2337/diabetes.50.11.2419" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11679416/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?DeHaven%20JE,%20Robinson%20KA,%20Nelson%20BA,%20Buse%20MG.%20A%20novel%20variant%20of%20glutamine:%20fructose-6-phosphate%20amidotransferase-1%20(GFAT1)%20mRNA%20is%20selectively%20expressed%20in%20striated%20muscle.%20Diabetes.%202001;50:2419%E2%80%9324." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Yamazaki K. Glutamine–fructose-6-phosphate transaminase 1,2 (GFPT1,2). In: Taniguchi N, Honke K, Fukuda M, Narimatsu H, Yamaguchi Y, Angata T, editors. Handbook of glycosyltransferases and related genes. Tokyo: Springer Japan; 2014. pp. 1465−79.</cite>
</li>
<li id="CR38">
<span class="label">38.</span><cite>Oliveira IA, Allonso D, Fernandes TVA, Lucena DMS, Ventura GT, Dias WB, et al. Enzymatic and structural properties of human glutamine:fructose-6-phosphate amidotransferase 2 (hGFAT2). J Biol Chem. 2021;296:100180.
</cite> [<a href="https://doi.org/10.1074/jbc.RA120.015189" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7948480/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33303629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Oliveira%20IA,%20Allonso%20D,%20Fernandes%20TVA,%20Lucena%20DMS,%20Ventura%20GT,%20Dias%20WB,%20et%20al.%20Enzymatic%20and%20structural%20properties%20of%20human%20glutamine:fructose-6-phosphate%20amidotransferase%202%20(hGFAT2).%20J%20Biol%20Chem.%202021;296:100180." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Liu L, Pan Y, Ren X, Zeng Z, Sun J, Zhou K, et al. GFPT2 promotes metastasis forms a Posit feedback loop p65 colorectal. Cancer. 2020;10:2510.</cite> [<a href="/articles/PMC7471343/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32905539/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20L,%20Pan%20Y,%20Ren%20X,%20Zeng%20Z,%20Sun%20J,%20Zhou%20K,%20et%20al.%20GFPT2%20promotes%20metastasis%20forms%20a%20Posit%20feedback%20loop%20p65%20colorectal.%20Cancer.%202020;10:2510." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Zhou L, Luo M, Cheng L-j, Li R-n, Liu B, Linghu H. Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) promotes the EMT of serous ovarian cancer by activating the hexosamine biosynthetic pathway to increase the nuclear location of β-catenin. Pathol Res Pract. 2019;215:152681.
</cite> [<a href="https://doi.org/10.1016/j.prp.2019.152681" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31685298/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20L,%20Luo%20M,%20Cheng%20L-j,%20Li%20R-n,%20Liu%20B,%20Linghu%20H.%20Glutamine-fructose-6-phosphate%20transaminase%202%20(GFPT2)%20promotes%20the%20EMT%20of%20serous%20ovarian%20cancer%20by%20activating%20the%20hexosamine%20biosynthetic%20pathway%20to%20increase%20the%20nuclear%20location%20of%20%CE%B2-catenin.%20Pathol%20Res%20Pract.%202019;215:152681." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Chanmee T, Ontong P, Izumikawa T, Higashide M, Mochizuki N, Chokchaitaweesuk C, et al. Hyaluronan production regulates metabolic and cancer stem-like properties of breast cancer cells via hexosamine biosynthetic pathway-coupled hif-1 signaling. J Biol Chem. 2016;291:24105–20.
</cite> [<a href="https://doi.org/10.1074/jbc.M116.751263" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5104936/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27758869/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chanmee%20T,%20Ontong%20P,%20Izumikawa%20T,%20Higashide%20M,%20Mochizuki%20N,%20Chokchaitaweesuk%20C,%20et%20al.%20Hyaluronan%20production%20regulates%20metabolic%20and%20cancer%20stem-like%20properties%20of%20breast%20cancer%20cells%20via%20hexosamine%20biosynthetic%20pathway-coupled%20hif-1%20signaling.%20J%20Biol%20Chem.%202016;291:24105%E2%80%9320." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, et al. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res. 2013;73:5277–87.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-13-0549" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23720054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Itkonen%20HM,%20Minner%20S,%20Guldvik%20IJ,%20Sandmann%20MJ,%20Tsourlakis%20MC,%20Berge%20V,%20et%20al.%20O-GlcNAc%20transferase%20integrates%20metabolic%20pathways%20to%20regulate%20the%20stability%20of%20c-MYC%20in%20human%20prostate%20cancer%20cells.%20Cancer%20Res.%202013;73:5277%E2%80%9387." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Fu Y, Ning L, Feng J, Yu X, Guan F, Li X. Dynamic regulation of O-GlcNAcylation and phosphorylation on STAT3 under hypoxia-induced EMT. Cell Signal. 2022;93:110277.
</cite> [<a href="https://doi.org/10.1016/j.cellsig.2022.110277" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35131454/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fu%20Y,%20Ning%20L,%20Feng%20J,%20Yu%20X,%20Guan%20F,%20Li%20X.%20Dynamic%20regulation%20of%20O-GlcNAcylation%20and%20phosphorylation%20on%20STAT3%20under%20hypoxia-induced%20EMT.%20Cell%20Signal.%202022;93:110277." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Manzari B, Kudlow JE, Fardin P, Merello E, Ottaviano C, Puppo M, et al. Induction of macrophage glutamine: fructose-6-phosphate amidotransferase expression by hypoxia and by picolinic acid. Int J Immunopathol Pharmacol. 2007;20:47–58.
</cite> [<a href="https://doi.org/10.1177/039463200702000106" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17346427/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Manzari%20B,%20Kudlow%20JE,%20Fardin%20P,%20Merello%20E,%20Ottaviano%20C,%20Puppo%20M,%20et%20al.%20Induction%20of%20macrophage%20glutamine:%20fructose-6-phosphate%20amidotransferase%20expression%20by%20hypoxia%20and%20by%20picolinic%20acid.%20Int%20J%20Immunopathol%20Pharmacol.%202007;20:47%E2%80%9358." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezène P, et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 2013;110:3919–24.
</cite> [<a href="https://doi.org/10.1073/pnas.1219555110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3593894/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23407165/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guillaumond%20F,%20Leca%20J,%20Olivares%20O,%20Lavaut%20MN,%20Vidal%20N,%20Berthez%C3%A8ne%20P,%20et%20al.%20Strengthened%20glycolysis%20under%20hypoxia%20supports%20tumor%20symbiosis%20and%20hexosamine%20biosynthesis%20in%20pancreatic%20adenocarcinoma.%20Proc%20Natl%20Acad%20Sci%20USA.%202013;110:3919%E2%80%9324." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Wang ZV, Deng Y, Gao N, Pedrozo Z, Li DL, Morales CR, et al. Spliced X-box binding protein 1 couples the unfolded protein response to hexosamine biosynthetic pathway. Cell. 2014;156:1179–92.
</cite> [<a href="https://doi.org/10.1016/j.cell.2014.01.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3959665/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24630721/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20ZV,%20Deng%20Y,%20Gao%20N,%20Pedrozo%20Z,%20Li%20DL,%20Morales%20CR,%20et%20al.%20Spliced%20X-box%20binding%20protein%201%20couples%20the%20unfolded%20protein%20response%20to%20hexosamine%20biosynthetic%20pathway.%20Cell.%202014;156:1179%E2%80%9392." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Qiao D, Skibba M, Xu X, Garofalo RP, Zhao Y, Brasier AR. Paramyxovirus replication induces the hexosamine biosynthetic pathway and mesenchymal transition via the IRE1α-XBP1s arm of the unfolded protein response. Am J Physiol Lung Cell Mol Physiol. 2021;321:L576-L94.</cite> [<a href="https://doi.org/10.1152/ajplung.00127.2021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8461800/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34318710/" class="usa-link">PubMed</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Simpson NE, Tryndyak VP, Beland FA, Pogribny IP. An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression. Breast Cancer Res Treat. 2012;133:959–68.
</cite> [<a href="https://doi.org/10.1007/s10549-011-1871-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22101407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Simpson%20NE,%20Tryndyak%20VP,%20Beland%20FA,%20Pogribny%20IP.%20An%20in%20vitro%20investigation%20of%20metabolically%20sensitive%20biomarkers%20in%20breast%20cancer%20progression.%20Breast%20Cancer%20Res%20Treat.%202012;133:959%E2%80%9368." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Zhang X, Hu C, Ma Z-G, Hu M, Yuan X-P, Yuan Y-P, et al. Tisp40 prevents cardiac ischemia/reperfusion injury through the hexosamine biosynthetic pathway in male mice. Nat Commun. 2023;14:3383.
</cite> [<a href="https://doi.org/10.1038/s41467-023-39159-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10250363/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37291168/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20X,%20Hu%20C,%20Ma%20Z-G,%20Hu%20M,%20Yuan%20X-P,%20Yuan%20Y-P,%20et%20al.%20Tisp40%20prevents%20cardiac%20ischemia/reperfusion%20injury%20through%20the%20hexosamine%20biosynthetic%20pathway%20in%20male%20mice.%20Nat%20Commun.%202023;14:3383." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Huang H, Wang Y, Huang T, Wang L, Liu Y, Wu Q, et al. FOXA2 inhibits doxorubicin-induced apoptosis via transcriptionally activating HBP rate-limiting enzyme GFPT1 in HCC cells. J Physiol Biochem. 2021;77:625–38.
</cite> [<a href="https://doi.org/10.1007/s13105-021-00829-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34291417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20H,%20Wang%20Y,%20Huang%20T,%20Wang%20L,%20Liu%20Y,%20Wu%20Q,%20et%20al.%20FOXA2%20inhibits%20doxorubicin-induced%20apoptosis%20via%20transcriptionally%20activating%20HBP%20rate-limiting%20enzyme%20GFPT1%20in%20HCC%20cells.%20J%20Physiol%20Biochem.%202021;77:625%E2%80%9338." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Szymura SJ, Zaemes JP, Allison DF, Clift SH, D’Innocenzi JM, Gray LG, et al. NF-κB upregulates glutamine-fructose-6-phosphate transaminase 2 to promote migration in non-small cell lung cancer. Cell Commun Signal. 2019;17:24.
</cite> [<a href="https://doi.org/10.1186/s12964-019-0335-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6421657/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30885209/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Szymura%20SJ,%20Zaemes%20JP,%20Allison%20DF,%20Clift%20SH,%20D%E2%80%99Innocenzi%20JM,%20Gray%20LG,%20et%20al.%20NF-%CE%BAB%20upregulates%20glutamine-fructose-6-phosphate%20transaminase%202%20to%20promote%20migration%20in%20non-small%20cell%20lung%20cancer.%20Cell%20Commun%20Signal.%202019;17:24." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Tolwani A, Matusiak M, Bui N, Forgó E, Varma S, Baratto L, et al. Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma. npj Genom Med. 2021;6:30.
</cite> [<a href="https://doi.org/10.1038/s41525-021-00193-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8093268/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33941787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tolwani%20A,%20Matusiak%20M,%20Bui%20N,%20Forg%C3%B3%20E,%20Varma%20S,%20Baratto%20L,%20et%20al.%20Prognostic%20relevance%20of%20the%20hexosamine%20biosynthesis%20pathway%20activation%20in%20leiomyosarcoma.%20npj%20Genom%20Med.%202021;6:30." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35:871–82.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2011.09.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3248798/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22195744/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20R,%20Dillon%20CP,%20Shi%20LZ,%20Milasta%20S,%20Carter%20R,%20Finkelstein%20D,%20et%20al.%20The%20transcription%20factor%20Myc%20controls%20metabolic%20reprogramming%20upon%20T%20lymphocyte%20activation.%20Immunity.%202011;35:871%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656–70.
</cite> [<a href="https://doi.org/10.1016/j.cell.2012.01.058" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3472002/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22541435/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ying%20H,%20Kimmelman%20AC,%20Lyssiotis%20CA,%20Hua%20S,%20Chu%20GC,%20Fletcher-Sananikone%20E,%20et%20al.%20Oncogenic%20Kras%20maintains%20pancreatic%20tumors%20through%20regulation%20of%20anabolic%20glucose%20metabolism.%20Cell.%202012;149:656%E2%80%9370." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Liu B, Huang Z-B, Chen X, See Y-X, Chen Z-K, Yao H-K. Mammalian target of rapamycin 2 (MTOR2) and C-MYC modulate glucosamine-6-phosphate synthesis in glioblastoma (GBM) cells through glutamine: fructose-6-phosphate aminotransferase 1 (GFAT1). Cell Mol Neurobiol. 2019;39:415–34.
</cite> [<a href="https://doi.org/10.1007/s10571-019-00659-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11469801/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30771196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20B,%20Huang%20Z-B,%20Chen%20X,%20See%20Y-X,%20Chen%20Z-K,%20Yao%20H-K.%20Mammalian%20target%20of%20rapamycin%202%20(MTOR2)%20and%20C-MYC%20modulate%20glucosamine-6-phosphate%20synthesis%20in%20glioblastoma%20(GBM)%20cells%20through%20glutamine:%20fructose-6-phosphate%20aminotransferase%201%20(GFAT1).%20Cell%20Mol%20Neurobiol.%202019;39:415%E2%80%9334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Itano N, Iwamoto S. Dysregulation of hexosamine biosynthetic pathway wiring metabolic signaling circuits in cancer. Biochimica Biophysica Acta (BBA) - Gen Subj. 2023;1867:130250.</cite> [<a href="https://doi.org/10.1016/j.bbagen.2022.130250" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36228878/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Itano%20N,%20Iwamoto%20S.%20Dysregulation%20of%20hexosamine%20biosynthetic%20pathway%20wiring%20metabolic%20signaling%20circuits%20in%20cancer.%20Biochimica%20Biophysica%20Acta%20(BBA)%20-%20Gen%20Subj.%202023;1867:130250." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Traxinger RR, Marshall S. Coordinated regulation of glutamine:fructose-6-phosphate amidotransferase activity by insulin, glucose, and glutamine. Role of hexosamine biosynthesis in enzyme regulation. J Biol Chem. 1991;266:10148–54.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/2037571/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Traxinger%20RR,%20Marshall%20S.%20Coordinated%20regulation%20of%20glutamine:fructose-6-phosphate%20amidotransferase%20activity%20by%20insulin,%20glucose,%20and%20glutamine.%20Role%20of%20hexosamine%20biosynthesis%20in%20enzyme%20regulation.%20J%20Biol%20Chem.%201991;266:10148%E2%80%9354." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991;266:4706–12.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/2002019/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marshall%20S,%20Bacote%20V,%20Traxinger%20RR.%20Discovery%20of%20a%20metabolic%20pathway%20mediating%20glucose-induced%20desensitization%20of%20the%20glucose%20transport%20system.%20Role%20of%20hexosamine%20biosynthesis%20in%20the%20induction%20of%20insulin%20resistance.%20J%20Biol%20Chem.%201991;266:4706%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Hebert LF Jr., Daniels MC, Zhou J, Crook ED, Turner RL, Simmons ST, et al. Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Invest. 1996;98:930–6.
</cite> [<a href="https://doi.org/10.1172/JCI118876" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC507507/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8770864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hebert%20LF%20Jr.,%20Daniels%20MC,%20Zhou%20J,%20Crook%20ED,%20Turner%20RL,%20Simmons%20ST,%20et%20al.%20Overexpression%20of%20glutamine:fructose-6-phosphate%20amidotransferase%20in%20transgenic%20mice%20leads%20to%20insulin%20resistance.%20J%20Clin%20Invest.%201996;98:930%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Werstuck GH, Khan MI, Femia G, Kim AJ, Tedesco V, Trigatti B, et al. Glucosamine-induced endoplasmic reticulum dysfunction is associated with accelerated atherosclerosis in a hyperglycemic mouse model. Diabetes. 2006;55:93−101.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/16380481/" class="usa-link">PubMed</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Vasconcelos-dos-Santos A, Loponte HFBR, Mantuano NR, Oliveira IA, de Paula IF, Teixeira LK, et al. Hyperglycemia exacerbates colon cancer malignancy through hexosamine biosynthetic pathway. Oncogenesis. 2017;6:e306–e.
</cite> [<a href="https://doi.org/10.1038/oncsis.2017.2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5533945/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28319096/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vasconcelos-dos-Santos%20A,%20Loponte%20HFBR,%20Mantuano%20NR,%20Oliveira%20IA,%20de%20Paula%20IF,%20Teixeira%20LK,%20et%20al.%20Hyperglycemia%20exacerbates%20colon%20cancer%20malignancy%20through%20hexosamine%20biosynthetic%20pathway.%20Oncogenesis.%202017;6:e306%E2%80%93e." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Phoomak C, Vaeteewoottacharn K, Silsirivanit A, Saengboonmee C, Seubwai W, Sawanyawisuth K, et al. High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation. Sci Rep. 2017;7:43842.
</cite> [<a href="https://doi.org/10.1038/srep43842" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5338328/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28262738/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Phoomak%20C,%20Vaeteewoottacharn%20K,%20Silsirivanit%20A,%20Saengboonmee%20C,%20Seubwai%20W,%20Sawanyawisuth%20K,%20et%20al.%20High%20glucose%20levels%20boost%20the%20aggressiveness%20of%20highly%20metastatic%20cholangiocarcinoma%20cells%20via%20O-GlcNAcylation.%20Sci%20Rep.%202017;7:43842." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Zhou F, Huo J, Liu Y, Liu H, Liu G, Chen Y, et al. Elevated glucose levels impair the WNT/β-catenin pathway via the activation of the hexosamine biosynthesis pathway in endometrial cancer. J steroid Biochem Mol Biol. 2016;159:19–25.
</cite> [<a href="https://doi.org/10.1016/j.jsbmb.2016.02.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26923859/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20F,%20Huo%20J,%20Liu%20Y,%20Liu%20H,%20Liu%20G,%20Chen%20Y,%20et%20al.%20Elevated%20glucose%20levels%20impair%20the%20WNT/%CE%B2-catenin%20pathway%20via%20the%20activation%20of%20the%20hexosamine%20biosynthesis%20pathway%20in%20endometrial%20cancer.%20J%20steroid%20Biochem%20Mol%20Biol.%202016;159:19%E2%80%9325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Eguchi S, Oshiro N, Miyamoto T, Yoshino K, Okamoto S, Ono T, et al. AMP-activated protein kinase phosphorylates glutamine : fructose-6-phosphate amidotransferase 1 at Ser243 to modulate its enzymatic activity. Genes Cells devoted Mol Cell Mech. 2009;14:179–89.</cite> [<a href="https://doi.org/10.1111/j.1365-2443.2008.01260.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19170765/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Eguchi%20S,%20Oshiro%20N,%20Miyamoto%20T,%20Yoshino%20K,%20Okamoto%20S,%20Ono%20T,%20et%20al.%20AMP-activated%20protein%20kinase%20phosphorylates%20glutamine%20:%20fructose-6-phosphate%20amidotransferase%201%20at%20Ser243%20to%20modulate%20its%20enzymatic%20activity.%20Genes%20Cells%20devoted%20Mol%20Cell%20Mech.%202009;14:179%E2%80%9389." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Zibrova D, Vandermoere F, Göransson O, Peggie M, Mariño KV, Knierim A, et al. GFAT1 phosphorylation by AMPK promotes VEGF-induced angiogenesis. Biochem J. 2017;474:983–1001.
</cite> [<a href="https://doi.org/10.1042/BCJ20160980" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28008135/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zibrova%20D,%20Vandermoere%20F,%20G%C3%B6ransson%20O,%20Peggie%20M,%20Mari%C3%B1o%20KV,%20Knierim%20A,%20et%20al.%20GFAT1%20phosphorylation%20by%20AMPK%20promotes%20VEGF-induced%20angiogenesis.%20Biochem%20J.%202017;474:983%E2%80%931001." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Moloughney JG, Vega-Cotto NM, Liu S, Patel C, Kim PK, Wu CC, et al. mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation. J Biol Chem. 2018;293:16464–78.
</cite> [<a href="https://doi.org/10.1074/jbc.RA118.003991" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6200946/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30201609/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Moloughney%20JG,%20Vega-Cotto%20NM,%20Liu%20S,%20Patel%20C,%20Kim%20PK,%20Wu%20CC,%20et%20al.%20mTORC2%20modulates%20the%20amplitude%20and%20duration%20of%20GFAT1%20Ser-243%20phosphorylation%20to%20maintain%20flux%20through%20the%20hexosamine%20pathway%20during%20starvation.%20J%20Biol%20Chem.%202018;293:16464%E2%80%9378." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Moloughney JG, Kim PK, Vega-Cotto NM, Wu CC, Zhang S, Adlam M, et al. mTORC2 responds to glutamine catabolite levels to modulate the hexosamine biosynthesis enzyme GFAT1. Mol Cell. 2016;63:811–26.
</cite> [<a href="https://doi.org/10.1016/j.molcel.2016.07.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5006067/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27570073/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Moloughney%20JG,%20Kim%20PK,%20Vega-Cotto%20NM,%20Wu%20CC,%20Zhang%20S,%20Adlam%20M,%20et%20al.%20mTORC2%20responds%20to%20glutamine%20catabolite%20levels%20to%20modulate%20the%20hexosamine%20biosynthesis%20enzyme%20GFAT1.%20Mol%20Cell.%202016;63:811%E2%80%9326." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR68">
<span class="label">68.</span><cite>Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW, et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev. 2010;24:2784–99.
</cite> [<a href="https://doi.org/10.1101/gad.1985910" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3003197/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21106670/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wellen%20KE,%20Lu%20C,%20Mancuso%20A,%20Lemons%20JM,%20Ryczko%20M,%20Dennis%20JW,%20et%20al.%20The%20hexosamine%20biosynthetic%20pathway%20couples%20growth%20factor-induced%20glutamine%20uptake%20to%20glucose%20metabolism.%20Genes%20Dev.%202010;24:2784%E2%80%9399." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<span class="label">69.</span><cite>Drury J, Geisen ME, Tessmann JW, Rychahou PG, Kelson CO, He D, et al. Overexpression of fatty acid synthase upregulates glutamine-fructose-6-phosphate transaminase 1 and o-linked n-acetylglucosamine transferase to increase o-glcnac protein glycosylation and promote colorectal cancer growth. Int J Mol Sci. 2024;25:4883.</cite> [<a href="https://doi.org/10.3390/ijms25094883" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11084459/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38732103/" class="usa-link">PubMed</a>]</li>
<li id="CR70">
<span class="label">70.</span><cite>Li SY, Liu Y, Sigmon V, McCort A, Ren JJD, obesity, metabolism. High-fat diet enhances visceral advanced glycation end products, nuclear O-Glc-Nac modification, p38 mitogen-activated protein kinase activation and apoptosis. Diabetes Obes Metab. 2005;7:448−54.</cite> [<a href="https://doi.org/10.1111/j.1463-1326.2004.00387.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15955132/" class="usa-link">PubMed</a>]</li>
<li id="CR71">
<span class="label">71.</span><cite>Lockridge A, Hanover JA. A nexus of lipid and O-Glcnac metabolism in physiology and disease. Front Endocrinol (Lausanne). 2022;13:943576.
</cite> [<a href="https://doi.org/10.3389/fendo.2022.943576" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9468787/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36111295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lockridge%20A,%20Hanover%20JA.%20A%20nexus%20of%20lipid%20and%20O-Glcnac%20metabolism%20in%20physiology%20and%20disease.%20Front%20Endocrinol%20(Lausanne).%202022;13:943576." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR72">
<span class="label">72.</span><cite>Medford HM, Chatham JC, Marsh SA. Chronic ingestion of a Western diet increases O-linked-β-N-acetylglucosamine (O-GlcNAc) protein modification in the rat heart. Life Sci. 2012;90:883–8.
</cite> [<a href="https://doi.org/10.1016/j.lfs.2012.04.030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3372663/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22575823/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Medford%20HM,%20Chatham%20JC,%20Marsh%20SA.%20Chronic%20ingestion%20of%20a%20Western%20diet%20increases%20O-linked-%CE%B2-N-acetylglucosamine%20(O-GlcNAc)%20protein%20modification%20in%20the%20rat%20heart.%20Life%20Sci.%202012;90:883%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR73">
<span class="label">73.</span><cite>Cui Y-L, Xue R-Q, Xi H, Ming Z, Yu X-J, Liu L-Z, et al. Cholinergic drugs ameliorate endothelial dysfunction by decreasing O-GlcNAcylation via M3 AChR-AMPK-ER stress signaling. Life Sc.i 2019;222:1–12.</cite> [<a href="https://doi.org/10.1016/j.lfs.2019.02.036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30786250/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cui%20Y-L,%20Xue%20R-Q,%20Xi%20H,%20Ming%20Z,%20Yu%20X-J,%20Liu%20L-Z,%20et%20al.%20Cholinergic%20drugs%20ameliorate%20endothelial%20dysfunction%20by%20decreasing%20O-GlcNAcylation%20via%20M3%20AChR-AMPK-ER%20stress%20signaling.%20Life%20Sc.i%202019;222:1%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR74">
<span class="label">74.</span><cite>Meadus WJ, MacInnis R, Dugan ME. Prolonged dietary treatment with conjugated linoleic acid stimulates porcine muscle peroxisome proliferator activated receptor gamma and glutamine-fructose aminotransferase gene expression in vivo. J Mol Endocrinol. 2002;28:79–86.
</cite> [<a href="https://doi.org/10.1677/jme.0.0280079" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11932205/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Meadus%20WJ,%20MacInnis%20R,%20Dugan%20ME.%20Prolonged%20dietary%20treatment%20with%20conjugated%20linoleic%20acid%20stimulates%20porcine%20muscle%20peroxisome%20proliferator%20activated%20receptor%20gamma%20and%20glutamine-fructose%20aminotransferase%20gene%20expression%20in%20vivo.%20J%20Mol%20Endocrinol.%202002;28:79%E2%80%9386." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR75">
<span class="label">75.</span><cite>Weigert C, Klopfer K, Kausch C, Brodbeck K, Stumvoll M, Häring HU, et al. Palmitate-induced activation of the hexosamine pathway in human myotubes: increased expression of glutamine:fructose-6-phosphate aminotransferase. Diabetes. 2003;52:650–6.
</cite> [<a href="https://doi.org/10.2337/diabetes.52.3.650" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12606504/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Weigert%20C,%20Klopfer%20K,%20Kausch%20C,%20Brodbeck%20K,%20Stumvoll%20M,%20H%C3%A4ring%20HU,%20et%20al.%20Palmitate-induced%20activation%20of%20the%20hexosamine%20pathway%20in%20human%20myotubes:%20increased%20expression%20of%20glutamine:fructose-6-phosphate%20aminotransferase.%20Diabetes.%202003;52:650%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR76">
<span class="label">76.</span><cite>Dai W, Dierschke SK, Toro AL, Dennis MD. Consumption of a high fat diet promotes protein O-GlcNAcylation in mouse retina via NR4A1-dependent GFAT2 expression. BiochimBiophys Acta (BBA) Mol Basis Dis. 2018;1864:3568–76.</cite> [<a href="https://doi.org/10.1016/j.bbadis.2018.09.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6239931/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30254013/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dai%20W,%20Dierschke%20SK,%20Toro%20AL,%20Dennis%20MD.%20Consumption%20of%20a%20high%20fat%20diet%20promotes%20protein%20O-GlcNAcylation%20in%20mouse%20retina%20via%20NR4A1-dependent%20GFAT2%20expression.%20BiochimBiophys%20Acta%20(BBA)%20Mol%20Basis%20Dis.%202018;1864:3568%E2%80%9376." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR77">
<span class="label">77.</span><cite>Dragic H, Barthelaix A, Duret C, Goupil SL, Laprade H, Martin S, et al. The hexosamine pathway and coat complex II promote malignant adaptation to nutrient scarcity. Life Sci Alliance. 2022;5:e202101334.</cite> [<a href="https://doi.org/10.26508/lsa.202101334" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9008580/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35396334/" class="usa-link">PubMed</a>]</li>
<li id="CR78">
<span class="label">78.</span><cite>Chaveroux C, Sarcinelli C, Barbet V, Belfeki S, Barthelaix A, Ferraro-Peyret C, et al. Nutrient shortage triggers the hexosamine biosynthetic pathway via the GCN2-ATF4 signalling pathway. Sci Rep 2016;6:27278.
</cite> [<a href="https://doi.org/10.1038/srep27278" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4891703/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27255611/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chaveroux%20C,%20Sarcinelli%20C,%20Barbet%20V,%20Belfeki%20S,%20Barthelaix%20A,%20Ferraro-Peyret%20C,%20et%20al.%20Nutrient%20shortage%20triggers%20the%20hexosamine%20biosynthetic%20pathway%20via%20the%20GCN2-ATF4%20signalling%20pathway.%20Sci%20Rep%202016;6:27278." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR79">
<span class="label">79.</span><cite>Madden E, Logue SE, Healy SJ, Manie S, Samali A. The role of the unfolded protein response in cancer progression: from oncogenesis to chemoresistance. Biol Cell. 2019;111:1−17.</cite> [<a href="https://doi.org/10.1111/boc.201800050" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30302777/" class="usa-link">PubMed</a>]</li>
<li id="CR80">
<span class="label">80.</span><cite>Hamiel CR, Pinto S, Hau A, Wischmeyer PE. Glutamine enhances heat shock protein 70 expression via increased hexosamine biosynthetic pathway activity. Am J Physiol Cell Physiol 2009;297:C1509–19.
</cite> [<a href="https://doi.org/10.1152/ajpcell.00240.2009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2793053/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19776393/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hamiel%20CR,%20Pinto%20S,%20Hau%20A,%20Wischmeyer%20PE.%20Glutamine%20enhances%20heat%20shock%20protein%2070%20expression%20via%20increased%20hexosamine%20biosynthetic%20pathway%20activity.%20Am%20J%20Physiol%20Cell%20Physiol%202009;297:C1509%E2%80%9319." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR81">
<span class="label">81.</span><cite>Majumdar G, Harrington A, Hungerford J, Martinez-Hernandez A, Gerling IC, Raghow R, et al. Insulin dynamically regulates calmodulin gene expression by sequential o-glycosylation and phosphorylation of sp1 and its subcellular compartmentalization in liver cells. J Biol Chem. 2006;281:3642−50.</cite> [<a href="https://doi.org/10.1074/jbc.M511223200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16332679/" class="usa-link">PubMed</a>]</li>
<li id="CR82">
<span class="label">82.</span><cite>Dey P, Kimmelman AC, DePinho RA. Metabolic codependencies in the tumor microenvironment. Cancer Discov. 2021;11:1067–81.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-20-1211" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8102306/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33504580/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dey%20P,%20Kimmelman%20AC,%20DePinho%20RA.%20Metabolic%20codependencies%20in%20the%20tumor%20microenvironment.%20Cancer%20Discov.%202021;11:1067%E2%80%9381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR83">
<span class="label">83.</span><cite>Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84.
</cite> [<a href="https://doi.org/10.1016/j.cell.2006.01.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16469695/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wullschleger%20S,%20Loewith%20R,%20Hall%20MN.%20TOR%20signaling%20in%20growth%20and%20metabolism.%20Cell.%202006;124:471%E2%80%9384." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR84">
<span class="label">84.</span><cite>Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18:26.
</cite> [<a href="https://doi.org/10.1186/s12943-019-0954-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6379961/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30782187/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20J,%20Nie%20J,%20Ma%20X,%20Wei%20Y,%20Peng%20Y,%20Wei%20X.%20Targeting%20PI3K%20in%20cancer:%20mechanisms%20and%20advances%20in%20clinical%20trials.%20Mol%20Cancer.%202019;18:26." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR85">
<span class="label">85.</span><cite>Very N, Steenackers A, Dubuquoy C, Vermuse J, Dubuquoy L, Lefebvre T, et al. Cross regulation between mTOR signaling and O-GlcNAcylation. J Bioenerg Biomembr. 2018;50:213–22.
</cite> [<a href="https://doi.org/10.1007/s10863-018-9747-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29524020/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Very%20N,%20Steenackers%20A,%20Dubuquoy%20C,%20Vermuse%20J,%20Dubuquoy%20L,%20Lefebvre%20T,%20et%20al.%20Cross%20regulation%20between%20mTOR%20signaling%20and%20O-GlcNAcylation.%20J%20Bioenerg%20Biomembr.%202018;50:213%E2%80%9322." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR86">
<span class="label">86.</span><cite>Makwana V, Rudrawar S, Anoopkumar-Dukie S. Signalling transduction of O-GlcNAcylation and PI3K/AKT/mTOR-axis in prostate cancer. Biochim Biophys Acta Mol Basis Dis. 2021;1867:166129.
</cite> [<a href="https://doi.org/10.1016/j.bbadis.2021.166129" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33744394/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Makwana%20V,%20Rudrawar%20S,%20Anoopkumar-Dukie%20S.%20Signalling%20transduction%20of%20O-GlcNAcylation%20and%20PI3K/AKT/mTOR-axis%20in%20prostate%20cancer.%20Biochim%20Biophys%20Acta%20Mol%20Basis%20Dis.%202021;1867:166129." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR87">
<span class="label">87.</span><cite>Sodi VL, Khaku S, Krutilina R, Schwab LP, Vocadlo DJ, Seagroves TN, et al. mTOR/MYC axis regulates O-GlcNAc transferase expression and O-GlcNAcylation in breast cancer. Mol Cancer Res. 2015;13:923–33.
</cite> [<a href="https://doi.org/10.1158/1541-7786.MCR-14-0536" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4433402/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25636967/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sodi%20VL,%20Khaku%20S,%20Krutilina%20R,%20Schwab%20LP,%20Vocadlo%20DJ,%20Seagroves%20TN,%20et%20al.%20mTOR/MYC%20axis%20regulates%20O-GlcNAc%20transferase%20expression%20and%20O-GlcNAcylation%20in%20breast%20cancer.%20Mol%20Cancer%20Res.%202015;13:923%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR88">
<span class="label">88.</span><cite>Liu Y, Cao Y, Pan X, Shi M, Wu Q, Huang T, et al. O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance. Cell Death Dis. 2018;9:485.
</cite> [<a href="https://doi.org/10.1038/s41419-018-0522-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5924752/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29706631/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20Y,%20Cao%20Y,%20Pan%20X,%20Shi%20M,%20Wu%20Q,%20Huang%20T,%20et%20al.%20O-GlcNAc%20elevation%20through%20activation%20of%20the%20hexosamine%20biosynthetic%20pathway%20enhances%20cancer%20cell%20chemoresistance.%20Cell%20Death%20Dis.%202018;9:485." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR89">
<span class="label">89.</span><cite>Heath JM, Sun Y, Yuan K, Bradley WE, Litovsky S, Dell’Italia LJ, et al. Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitus. Circ Res. 2014;114:1094–102.
</cite> [<a href="https://doi.org/10.1161/CIRCRESAHA.114.302968" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4030422/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24526702/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Heath%20JM,%20Sun%20Y,%20Yuan%20K,%20Bradley%20WE,%20Litovsky%20S,%20Dell%E2%80%99Italia%20LJ,%20et%20al.%20Activation%20of%20AKT%20by%20O-linked%20N-acetylglucosamine%20induces%20vascular%20calcification%20in%20diabetes%20mellitus.%20Circ%20Res.%202014;114:1094%E2%80%93102." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR90">
<span class="label">90.</span><cite>Wang S, Huang X, Sun D, Xin X, Pan Q, Peng S, et al. Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates Akt signaling. PLoS ONE. 2012;7:e37427.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0037427" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3358304/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22629392/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20S,%20Huang%20X,%20Sun%20D,%20Xin%20X,%20Pan%20Q,%20Peng%20S,%20et%20al.%20Extensive%20crosstalk%20between%20O-GlcNAcylation%20and%20phosphorylation%20regulates%20Akt%20signaling.%20PLoS%20ONE.%202012;7:e37427." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR91">
<span class="label">91.</span><cite>Asthana A, Ramakrishnan P, Vicioso Y, Zhang K, Parameswaran R. Hexosamine biosynthetic pathway inhibition leads to AML cell differentiation and cell death. Mol Cancer Therapeutics. 2018;17:2226–37.</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-18-0426" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6168390/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30082471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Asthana%20A,%20Ramakrishnan%20P,%20Vicioso%20Y,%20Zhang%20K,%20Parameswaran%20R.%20Hexosamine%20biosynthetic%20pathway%20inhibition%20leads%20to%20AML%20cell%20differentiation%20and%20cell%20death.%20Mol%20Cancer%20Therapeutics.%202018;17:2226%E2%80%9337." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR92">
<span class="label">92.</span><cite>Vosseller K, Wells L, Lane MD, Hart GW. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci USA. 2002;99:5313–8.
</cite> [<a href="https://doi.org/10.1073/pnas.072072399" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC122766/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11959983/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vosseller%20K,%20Wells%20L,%20Lane%20MD,%20Hart%20GW.%20Elevated%20nucleocytoplasmic%20glycosylation%20by%20O-GlcNAc%20results%20in%20insulin%20resistance%20associated%20with%20defects%20in%20Akt%20activation%20in%203T3-L1%20adipocytes.%20Proc%20Natl%20Acad%20Sci%20USA.%202002;99:5313%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR93">
<span class="label">93.</span><cite>Kang E-S, Han D, Park J, Kwak TK, Oh M-A, Lee S-A, et al. O-GlcNAc modulation at Akt1 Ser473 correlates with apoptosis of murine pancreatic β cells. Exp Cell Res. 2008;314:2238–48.
</cite> [<a href="https://doi.org/10.1016/j.yexcr.2008.04.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18570920/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kang%20E-S,%20Han%20D,%20Park%20J,%20Kwak%20TK,%20Oh%20M-A,%20Lee%20S-A,%20et%20al.%20O-GlcNAc%20modulation%20at%20Akt1%20Ser473%20correlates%20with%20apoptosis%20of%20murine%20pancreatic%20%CE%B2%20cells.%20Exp%20Cell%20Res.%202008;314:2238%E2%80%9348." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR94">
<span class="label">94.</span><cite>Shi J, Wu S, Dai CL, Li Y, Grundke-Iqbal I, Iqbal K, et al. Diverse regulation of AKT and GSK-3β by O-GlcNAcylation in various types of cells. FEBS Lett. 2012;586:2443–50.
</cite> [<a href="https://doi.org/10.1016/j.febslet.2012.05.063" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3407308/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22687243/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shi%20J,%20Wu%20S,%20Dai%20CL,%20Li%20Y,%20Grundke-Iqbal%20I,%20Iqbal%20K,%20et%20al.%20Diverse%20regulation%20of%20AKT%20and%20GSK-3%CE%B2%20by%20O-GlcNAcylation%20in%20various%20types%20of%20cells.%20FEBS%20Lett.%202012;586:2443%E2%80%9350." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR95">
<span class="label">95.</span><cite>Tran DH, May HI, Li Q, Luo X, Huang J, Zhang G, et al. Chronic activation of hexosamine biosynthesis in the heart triggers pathological cardiac remodeling. Nat Commun. 2020;11:1771.
</cite> [<a href="https://doi.org/10.1038/s41467-020-15640-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7156663/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32286306/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tran%20DH,%20May%20HI,%20Li%20Q,%20Luo%20X,%20Huang%20J,%20Zhang%20G,%20et%20al.%20Chronic%20activation%20of%20hexosamine%20biosynthesis%20in%20the%20heart%20triggers%20pathological%20cardiac%20remodeling.%20Nat%20Commun.%202020;11:1771." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR96">
<span class="label">96.</span><cite>Ishikita A, Matsushima S, Ikeda S, Okabe K, Nishimura R, Tadokoro T, et al. GFAT2 mediates cardiac hypertrophy through HBP-O-GlcNAcylation-Akt pathway. iScience. 2021;24:103517.
</cite> [<a href="https://doi.org/10.1016/j.isci.2021.103517" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8661546/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34934932/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ishikita%20A,%20Matsushima%20S,%20Ikeda%20S,%20Okabe%20K,%20Nishimura%20R,%20Tadokoro%20T,%20et%20al.%20GFAT2%20mediates%20cardiac%20hypertrophy%20through%20HBP-O-GlcNAcylation-Akt%20pathway.%20iScience.%202021;24:103517." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR97">
<span class="label">97.</span><cite>Li D, Guan M, Cao X, Zha ZQ, Zhang P, Xiang H, et al. GFPT1 promotes the proliferation of cervical cancer via regulating the ubiquitination and degradation of PTEN. Carcinogenesis. 2022;43:969–79.
</cite> [<a href="https://doi.org/10.1093/carcin/bgac073" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36040914/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20D,%20Guan%20M,%20Cao%20X,%20Zha%20ZQ,%20Zhang%20P,%20Xiang%20H,%20et%20al.%20GFPT1%20promotes%20the%20proliferation%20of%20cervical%20cancer%20via%20regulating%20the%20ubiquitination%20and%20degradation%20of%20PTEN.%20Carcinogenesis.%202022;43:969%E2%80%9379." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR98">
<span class="label">98.</span><cite>Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251–62.
</cite> [<a href="https://doi.org/10.1038/nrm3311" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5726489/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22436748/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hardie%20DG,%20Ross%20FA,%20Hawley%20SA.%20AMPK:%20a%20nutrient%20and%20energy%20sensor%20that%20maintains%20energy%20homeostasis.%20Nat%20Rev%20Mol%20Cell%20Biol.%202012;13:251%E2%80%9362." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR99">
<span class="label">99.</span><cite>Yuan HX, Xiong Y, Guan KL. Nutrient sensing, metabolism, and cell growth control. Mol Cell. 2013;49:379–87.
</cite> [<a href="https://doi.org/10.1016/j.molcel.2013.01.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3587157/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23395268/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yuan%20HX,%20Xiong%20Y,%20Guan%20KL.%20Nutrient%20sensing,%20metabolism,%20and%20cell%20growth%20control.%20Mol%20Cell.%202013;49:379%E2%80%9387." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR100">
<span class="label">100.</span><cite>Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä TP, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol. 2003;2:28.
</cite> [<a href="https://doi.org/10.1186/1475-4924-2-28" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC333410/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14511394/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hawley%20SA,%20Boudeau%20J,%20Reid%20JL,%20Mustard%20KJ,%20Udd%20L,%20M%C3%A4kel%C3%A4%20TP,%20et%20al.%20Complexes%20between%20the%20LKB1%20tumor%20suppressor,%20STRAD%20alpha/beta%20and%20MO25%20alpha/beta%20are%20upstream%20kinases%20in%20the%20AMP-activated%20protein%20kinase%20cascade.%20J%20Biol.%202003;2:28." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR101">
<span class="label">101.</span><cite>Cork GK, Thompson J, Slawson C. Real talk: the inter-play between the mTOR, AMPK, and hexosamine biosynthetic pathways in cell signaling. Front Endocrinol (Lausanne). 2018;9:522.
</cite> [<a href="https://doi.org/10.3389/fendo.2018.00522" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6136272/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30237786/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cork%20GK,%20Thompson%20J,%20Slawson%20C.%20Real%20talk:%20the%20inter-play%20between%20the%20mTOR,%20AMPK,%20and%20hexosamine%20biosynthetic%20pathways%20in%20cell%20signaling.%20Front%20Endocrinol%20(Lausanne).%202018;9:522." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR102">
<span class="label">102.</span><cite>Luo B, Parker GJ, Cooksey RC, Soesanto Y, Evans M, Jones D, et al. Chronic hexosamine flux stimulates fatty acid oxidation by activating AMP-activated protein kinase in adipocytes. J Biol Chem. 2007;282:7172–80.
</cite> [<a href="https://doi.org/10.1074/jbc.M607362200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17227772/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Luo%20B,%20Parker%20GJ,%20Cooksey%20RC,%20Soesanto%20Y,%20Evans%20M,%20Jones%20D,%20et%20al.%20Chronic%20hexosamine%20flux%20stimulates%20fatty%20acid%20oxidation%20by%20activating%20AMP-activated%20protein%20kinase%20in%20adipocytes.%20J%20Biol%20Chem.%202007;282:7172%E2%80%9380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR103">
<span class="label">103.</span><cite>Ishimura E, Nakagawa T, Moriwaki K, Hirano S, Matsumori Y, Asahi M. Augmented O-GlcNAcylation of AMP-activated kinase promotes the proliferation of LoVo cells, a colon cancer cell line. Cancer Sci. 2017;108:2373–82.
</cite> [<a href="https://doi.org/10.1111/cas.13412" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5715261/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28973823/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ishimura%20E,%20Nakagawa%20T,%20Moriwaki%20K,%20Hirano%20S,%20Matsumori%20Y,%20Asahi%20M.%20Augmented%20O-GlcNAcylation%20of%20AMP-activated%20kinase%20promotes%20the%20proliferation%20of%20LoVo%20cells,%20a%20colon%20cancer%20cell%20line.%20Cancer%20Sci.%202017;108:2373%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR104">
<span class="label">104.</span><cite>Jin L, Yuan F, Dai G, Yao Q, Xiang H, Wang L, et al. Blockage of O-linked GlcNAcylation induces AMPK-dependent autophagy in bladder cancer cells. Cell Mol Biol Lett. 2020;25:17.
</cite> [<a href="https://doi.org/10.1186/s11658-020-00208-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7063793/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32174982/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jin%20L,%20Yuan%20F,%20Dai%20G,%20Yao%20Q,%20Xiang%20H,%20Wang%20L,%20et%20al.%20Blockage%20of%20O-linked%20GlcNAcylation%20induces%20AMPK-dependent%20autophagy%20in%20bladder%20cancer%20cells.%20Cell%20Mol%20Biol%20Lett.%202020;25:17." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR105">
<span class="label">105.</span><cite>Xu Q, Yang C, Du Y, Chen Y, Liu H, Deng M, et al. AMPK regulates histone H2B O-GlcNAcylation. Nucleic Acids Res. 2014;42:5594–604.
</cite> [<a href="https://doi.org/10.1093/nar/gku236" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4027166/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24692660/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20Q,%20Yang%20C,%20Du%20Y,%20Chen%20Y,%20Liu%20H,%20Deng%20M,%20et%20al.%20AMPK%20regulates%20histone%20H2B%20O-GlcNAcylation.%20Nucleic%20Acids%20Res.%202014;42:5594%E2%80%93604." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR106">
<span class="label">106.</span><cite>Bullen JW, Balsbaugh JL, Chanda D, Shabanowitz J, Hunt DF, Neumann D, et al. Cross-talk between two essential nutrient-sensitive enzymes: O-GlcNAc transferase (OGT) and AMP-activated protein kinase (AMPK). J Biol Chem. 2014;289:10592–606.
</cite> [<a href="https://doi.org/10.1074/jbc.M113.523068" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4036179/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24563466/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bullen%20JW,%20Balsbaugh%20JL,%20Chanda%20D,%20Shabanowitz%20J,%20Hunt%20DF,%20Neumann%20D,%20et%20al.%20Cross-talk%20between%20two%20essential%20nutrient-sensitive%20enzymes:%20O-GlcNAc%20transferase%20(OGT)%20and%20AMP-activated%20protein%20kinase%20(AMPK).%20J%20Biol%20Chem.%202014;289:10592%E2%80%93606." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR107">
<span class="label">107.</span><cite>Ishino K, Kudo M, Peng WX, Kure S, Kawahara K, Teduka K, et al. 2-Deoxy-d-glucose increases GFAT1 phosphorylation resulting in endoplasmic reticulum-related apoptosis via disruption of protein N-glycosylation in pancreatic cancer cells. Biochem Biophys Res Commun. 2018;501:668–73.
</cite> [<a href="https://doi.org/10.1016/j.bbrc.2018.05.041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29753740/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ishino%20K,%20Kudo%20M,%20Peng%20WX,%20Kure%20S,%20Kawahara%20K,%20Teduka%20K,%20et%20al.%202-Deoxy-d-glucose%20increases%20GFAT1%20phosphorylation%20resulting%20in%20endoplasmic%20reticulum-related%20apoptosis%20via%20disruption%20of%20protein%20N-glycosylation%20in%20pancreatic%20cancer%20cells.%20Biochem%20Biophys%20Res%20Commun.%202018;501:668%E2%80%9373." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR108">
<span class="label">108.</span><cite>Gélinas R, Mailleux F, Dontaine J, Bultot L, Demeulder B, Ginion A, et al. AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. Nat Commun. 2018;9:374.
</cite> [<a href="https://doi.org/10.1038/s41467-017-02795-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5785516/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29371602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?G%C3%A9linas%20R,%20Mailleux%20F,%20Dontaine%20J,%20Bultot%20L,%20Demeulder%20B,%20Ginion%20A,%20et%20al.%20AMPK%20activation%20counteracts%20cardiac%20hypertrophy%20by%20reducing%20O-GlcNAcylation.%20Nat%20Commun.%202018;9:374." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR109">
<span class="label">109.</span><cite>Li Y, Roux C, Lazereg S, LeCaer J-P, Laprévote O, Badet B, et al. Identification of a novel serine phosphorylation site in human glutamine:fructose-6-phosphate amidotransferase isoform 1. Biochemistry. 2007;46:13163–9.
</cite> [<a href="https://doi.org/10.1021/bi700694c" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17941647/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20Y,%20Roux%20C,%20Lazereg%20S,%20LeCaer%20J-P,%20Lapr%C3%A9vote%20O,%20Badet%20B,%20et%20al.%20Identification%20of%20a%20novel%20serine%20phosphorylation%20site%20in%20human%20glutamine:fructose-6-phosphate%20amidotransferase%20isoform%201.%20Biochemistry.%202007;46:13163%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR110">
<span class="label">110.</span><cite>Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9:517–31.
</cite> [<a href="https://doi.org/10.1038/nrm2438" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3915522/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18568040/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Karnoub%20AE,%20Weinberg%20RA.%20Ras%20oncogenes:%20split%20personalities.%20Nat%20Rev%20Mol%20Cell%20Biol.%202008;9:517%E2%80%9331." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR111">
<span class="label">111.</span><cite>Lim K-H, Counter CMJCc. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell. 2005;8:381−92.</cite> [<a href="https://doi.org/10.1016/j.ccr.2005.10.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16286246/" class="usa-link">PubMed</a>]</li>
<li id="CR112">
<span class="label">112.</span><cite>Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39:91–100.
</cite> [<a href="https://doi.org/10.1016/j.tibs.2013.12.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3955735/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24388967/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bryant%20KL,%20Mancias%20JD,%20Kimmelman%20AC,%20Der%20CJ.%20KRAS:%20feeding%20pancreatic%20cancer%20proliferation.%20Trends%20Biochem%20Sci.%202014;39:91%E2%80%93100." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR113">
<span class="label">113.</span><cite>Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325:1555–9.
</cite> [<a href="https://doi.org/10.1126/science.1174229" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2820374/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19661383/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yun%20J,%20Rago%20C,%20Cheong%20I,%20Pagliarini%20R,%20Angenendt%20P,%20Rajagopalan%20H,%20et%20al.%20Glucose%20deprivation%20contributes%20to%20the%20development%20of%20KRAS%20pathway%20mutations%20in%20tumor%20cells.%20Science.%202009;325:1555%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR114">
<span class="label">114.</span><cite>Wei S, Zhao Q, Zheng K, Liu P, Sha N, Li Y, et al. GFAT1-linked TAB1 glutamylation sustains p38 MAPK activation and promotes lung cancer cell survival under glucose starvation. Cell Discov. 2022;8:77.
</cite> [<a href="https://doi.org/10.1038/s41421-022-00423-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9363421/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35945223/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wei%20S,%20Zhao%20Q,%20Zheng%20K,%20Liu%20P,%20Sha%20N,%20Li%20Y,%20et%20al.%20GFAT1-linked%20TAB1%20glutamylation%20sustains%20p38%20MAPK%20activation%20and%20promotes%20lung%20cancer%20cell%20survival%20under%20glucose%20starvation.%20Cell%20Discov.%202022;8:77." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR115">
<span class="label">115.</span><cite>Taparra K, Wang H, Malek R, Lafargue A, Barbhuiya MA, Wang X, et al. O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. J Clin Invest. 2018;128:4924–37.
</cite> [<a href="https://doi.org/10.1172/JCI94844" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6205381/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30130254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Taparra%20K,%20Wang%20H,%20Malek%20R,%20Lafargue%20A,%20Barbhuiya%20MA,%20Wang%20X,%20et%20al.%20O-GlcNAcylation%20is%20required%20for%20mutant%20KRAS-induced%20lung%20tumorigenesis.%20J%20Clin%20Invest.%202018;128:4924%E2%80%9337." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR116">
<span class="label">116.</span><cite>Kim J, Lee HM, Cai F, Ko B, Yang C, Lieu EL, et al. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Nat Metab. 2020;2:1401–12.
</cite> [<a href="https://doi.org/10.1038/s42255-020-00316-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7744327/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33257855/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim%20J,%20Lee%20HM,%20Cai%20F,%20Ko%20B,%20Yang%20C,%20Lieu%20EL,%20et%20al.%20The%20hexosamine%20biosynthesis%20pathway%20is%20a%20targetable%20liability%20in%20KRAS/LKB1%20mutant%20lung%20cancer.%20Nat%20Metab.%202020;2:1401%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR117">
<span class="label">117.</span><cite>Gwinn DM, Lee AG, Briones-Martin-Del-Campo M, Conn CS, Simpson DR, Scott AI, et al. Oncogenic KRAS regulates amino acid homeostasis and asparagine biosynthesis via ATF4 and alters sensitivity to L-asparaginase. Cancer Cell. 2018;33:91–107.e6.
</cite> [<a href="https://doi.org/10.1016/j.ccell.2017.12.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5761662/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29316436/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gwinn%20DM,%20Lee%20AG,%20Briones-Martin-Del-Campo%20M,%20Conn%20CS,%20Simpson%20DR,%20Scott%20AI,%20et%20al.%20Oncogenic%20KRAS%20regulates%20amino%20acid%20homeostasis%20and%20asparagine%20biosynthesis%20via%20ATF4%20and%20alters%20sensitivity%20to%20L-asparaginase.%20Cancer%20Cell.%202018;33:91%E2%80%93107.e6." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR118">
<span class="label">118.</span><cite>Ye J, Kumanova M, Hart LS, Sloane K, Zhang H, De Panis DN, et al. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. Embo J. 2010;29:2082–96.
</cite> [<a href="https://doi.org/10.1038/emboj.2010.81" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2892366/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20473272/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ye%20J,%20Kumanova%20M,%20Hart%20LS,%20Sloane%20K,%20Zhang%20H,%20De%20Panis%20DN,%20et%20al.%20The%20GCN2-ATF4%20pathway%20is%20critical%20for%20tumour%20cell%20survival%20and%20proliferation%20in%20response%20to%20nutrient%20deprivation.%20Embo%20J.%202010;29:2082%E2%80%9396." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR119">
<span class="label">119.</span><cite>Ricciardiello F, Bergamaschi L, De Vitto H, Gang Y, Zhang T, Palorini R. et al. Suppression of the HBP function increases pancreatic cancer cell sensitivity to a Pan-RAS inhibitor. Cells. 2021;10:431.</cite> [<a href="https://doi.org/10.3390/cells10020431" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7923121/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33670598/" class="usa-link">PubMed</a>]</li>
<li id="CR120">
<span class="label">120.</span><cite>Djouder N, Tuerk RD, Suter M, Salvioni P, Thali RF, Scholz R, et al. PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis. Embo J. 2010;29:469–81.
</cite> [<a href="https://doi.org/10.1038/emboj.2009.339" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2824464/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19942859/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Djouder%20N,%20Tuerk%20RD,%20Suter%20M,%20Salvioni%20P,%20Thali%20RF,%20Scholz%20R,%20et%20al.%20PKA%20phosphorylates%20and%20inactivates%20AMPKalpha%20to%20promote%20efficient%20lipolysis.%20Embo%20J.%202010;29:469%E2%80%9381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR121">
<span class="label">121.</span><cite>Yang H, Yang L. Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy. J Mol Endocrinol. 2016;57:R93–r108.
</cite> [<a href="https://doi.org/10.1530/JME-15-0316" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27194812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20H,%20Yang%20L.%20Targeting%20cAMP/PKA%20pathway%20for%20glycemic%20control%20and%20type%202%20diabetes%20therapy.%20J%20Mol%20Endocrinol.%202016;57:R93%E2%80%93r108." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR122">
<span class="label">122.</span><cite>Palorini R, Votta G, Pirola Y, De Vitto H, De Palma S, Airoldi C, et al. Protein kinase A activation promotes cancer cell resistance to glucose starvation and anoikis. PLoS Genet. 2016;12:e1005931.
</cite> [<a href="https://doi.org/10.1371/journal.pgen.1005931" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4792400/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26978032/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Palorini%20R,%20Votta%20G,%20Pirola%20Y,%20De%20Vitto%20H,%20De%20Palma%20S,%20Airoldi%20C,%20et%20al.%20Protein%20kinase%20A%20activation%20promotes%20cancer%20cell%20resistance%20to%20glucose%20starvation%20and%20anoikis.%20PLoS%20Genet.%202016;12:e1005931." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR123">
<span class="label">123.</span><cite>Chang Q, Su K, Baker JR, Yang X, Paterson AJ, Kudlow JE. Phosphorylation of human glutamine:fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase at serine 205 blocks the enzyme activity. J Biol Chem. 2000;275:21981–7.
</cite> [<a href="https://doi.org/10.1074/jbc.M001049200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10806197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chang%20Q,%20Su%20K,%20Baker%20JR,%20Yang%20X,%20Paterson%20AJ,%20Kudlow%20JE.%20Phosphorylation%20of%20human%20glutamine:fructose-6-phosphate%20amidotransferase%20by%20cAMP-dependent%20protein%20kinase%20at%20serine%20205%20blocks%20the%20enzyme%20activity.%20J%20Biol%20Chem.%202000;275:21981%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR124">
<span class="label">124.</span><cite>Zhou J, Huynh QK, Hoffman RT, Crook ED, Daniels MC, Gulve EA, et al. Regulation of glutamine:fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase. Diabetes. 1998;47:1836–40.
</cite> [<a href="https://doi.org/10.2337/diabetes.47.12.1836" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9836513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20J,%20Huynh%20QK,%20Hoffman%20RT,%20Crook%20ED,%20Daniels%20MC,%20Gulve%20EA,%20et%20al.%20Regulation%20of%20glutamine:fructose-6-phosphate%20amidotransferase%20by%20cAMP-dependent%20protein%20kinase.%20Diabetes.%201998;47:1836%E2%80%9340." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR125">
<span class="label">125.</span><cite>Hu Y, Riesland L, Paterson AJ, Kudlow JE. Phosphorylation of mouse glutamine-fructose-6-phosphate amidotransferase 2 (GFAT2) by cAMP-dependent protein kinase Increases the Enzyme Activity*. J Biol Chem. 2004;279:29988–93.
</cite> [<a href="https://doi.org/10.1074/jbc.M401547200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15133036/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hu%20Y,%20Riesland%20L,%20Paterson%20AJ,%20Kudlow%20JE.%20Phosphorylation%20of%20mouse%20glutamine-fructose-6-phosphate%20amidotransferase%202%20(GFAT2)%20by%20cAMP-dependent%20protein%20kinase%20Increases%20the%20Enzyme%20Activity*.%20J%20Biol%20Chem.%202004;279:29988%E2%80%9393." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR126">
<span class="label">126.</span><cite>Graack HR, Cinque U, Kress H. Functional regulation of glutamine:fructose-6-phosphate aminotransferase 1 (GFAT1) of drosophila melanogaster in a UDP-N-acetylglucosamine and cAMP-dependent manner. Biochem J. 2001;360:401–12.
</cite> [<a href="https://doi.org/10.1042/0264-6021:3600401" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1222241/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11716769/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Graack%20HR,%20Cinque%20U,%20Kress%20H.%20Functional%20regulation%20of%20glutamine:fructose-6-phosphate%20aminotransferase%201%20(GFAT1)%20of%20drosophila%20melanogaster%20in%20a%20UDP-N-acetylglucosamine%20and%20cAMP-dependent%20manner.%20Biochem%20J.%202001;360:401%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR127">
<span class="label">127.</span><cite>Ruegenberg S, Mayr FAMC, Atanassov I, Baumann U, Denzel MS. Protein kinase A controls the hexosamine pathway by tuning the feedback inhibition of GFAT-1. Nat Commun. 2021;12:2176.
</cite> [<a href="https://doi.org/10.1038/s41467-021-22320-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8041777/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33846315/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ruegenberg%20S,%20Mayr%20FAMC,%20Atanassov%20I,%20Baumann%20U,%20Denzel%20MS.%20Protein%20kinase%20A%20controls%20the%20hexosamine%20pathway%20by%20tuning%20the%20feedback%20inhibition%20of%20GFAT-1.%20Nat%20Commun.%202021;12:2176." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR128">
<span class="label">128.</span><cite>Ishibashi Y, Hirabayashi Y. AMP-activated protein kinase suppresses biosynthesis of glucosylceramide by reducing intracellular sugar nucleotides. J Biol Chem. 2015;290:18245–60.
</cite> [<a href="https://doi.org/10.1074/jbc.M115.658948" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4505067/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26048992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ishibashi%20Y,%20Hirabayashi%20Y.%20AMP-activated%20protein%20kinase%20suppresses%20biosynthesis%20of%20glucosylceramide%20by%20reducing%20intracellular%20sugar%20nucleotides.%20J%20Biol%20Chem.%202015;290:18245%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR129">
<span class="label">129.</span><cite>Kazyken D, Magnuson B, Bodur C, Acosta-Jaquez HA, Zhang D, Tong X. et al. AMPK directly activates mTORC2 to promote cell survival during acute energetic stress. Sci Signal. 2019;12:eaav3249.</cite> [<a href="https://doi.org/10.1126/scisignal.aav3249" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6935248/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31186373/" class="usa-link">PubMed</a>]</li>
<li id="CR130">
<span class="label">130.</span><cite>Stichelen SO-V, Guinez C, Mir A-M, Perez-Cervera Y, Liu C, Michalski J-C. et al. The hexosamine biosynthetic pathway and O-GlcNAcylation drive the expression of β-catenin and cell proliferation. Am J Physiol Endocrinol Metab. 2012;302:E417-E24.</cite> [<a href="https://doi.org/10.1152/ajpendo.00390.2011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22114026/" class="usa-link">PubMed</a>]</li>
<li id="CR131">
<span class="label">131.</span><cite>Ding X, Liu H, Yuan Y, Zhong Q, Zhong X. Roles of GFPT2 expression levels on the prognosis and tumor microenvironment of colon cancer. Front Oncol. 2022;12:811559.
</cite> [<a href="https://doi.org/10.3389/fonc.2022.811559" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8940194/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35330716/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ding%20X,%20Liu%20H,%20Yuan%20Y,%20Zhong%20Q,%20Zhong%20X.%20Roles%20of%20GFPT2%20expression%20levels%20on%20the%20prognosis%20and%20tumor%20microenvironment%20of%20colon%20cancer.%20Front%20Oncol.%202022;12:811559." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR132">
<span class="label">132.</span><cite>Gong Y, Qian Y, Luo G, Liu Y, Wang R, Deng S, et al. High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. World J Surg Oncol. 2021;19:35.
</cite> [<a href="https://doi.org/10.1186/s12957-021-02147-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7849098/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33517899/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gong%20Y,%20Qian%20Y,%20Luo%20G,%20Liu%20Y,%20Wang%20R,%20Deng%20S,%20et%20al.%20High%20GFPT1%20expression%20predicts%20unfavorable%20outcomes%20in%20patients%20with%20resectable%20pancreatic%20ductal%20adenocarcinoma.%20World%20J%20Surg%20Oncol.%202021;19:35." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR133">
<span class="label">133.</span><cite>Li L, Shao M, Peng P, Yang C, Song S, Duan F, et al. High expression of GFAT1 predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget. 2017;8:19205–17.
</cite> [<a href="https://doi.org/10.18632/oncotarget.15164" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5386678/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28186970/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20L,%20Shao%20M,%20Peng%20P,%20Yang%20C,%20Song%20S,%20Duan%20F,%20et%20al.%20High%20expression%20of%20GFAT1%20predicts%20unfavorable%20prognosis%20in%20patients%20with%20hepatocellular%20carcinoma.%20Oncotarget.%202017;8:19205%E2%80%9317." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR134">
<span class="label">134.</span><cite>Jia C, Li H, Fu D, Lan Y. GFAT1/HBP/O-GlcNAcylation axis regulates β-catenin activity to promote pancreatic cancer aggressiveness. BioMed Res Int. 2020;2020:1921609.
</cite> [<a href="https://doi.org/10.1155/2020/1921609" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7048922/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32149084/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jia%20C,%20Li%20H,%20Fu%20D,%20Lan%20Y.%20GFAT1/HBP/O-GlcNAcylation%20axis%20regulates%20%CE%B2-catenin%20activity%20to%20promote%20pancreatic%20cancer%20aggressiveness.%20BioMed%20Res%20Int.%202020;2020:1921609." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR135">
<span class="label">135.</span><cite>Walter LA, Lin YH, Halbrook CJ, Chuh KN, He L, Pedowitz NJ, et al. Inhibiting the hexosamine biosynthetic pathway lowers O-GlcNAcylation levels and sensitizes cancer to environmental stress. Biochemistry. 2020;59:3169–79.
</cite> [<a href="https://doi.org/10.1021/acs.biochem.9b00560" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7231633/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31625393/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Walter%20LA,%20Lin%20YH,%20Halbrook%20CJ,%20Chuh%20KN,%20He%20L,%20Pedowitz%20NJ,%20et%20al.%20Inhibiting%20the%20hexosamine%20biosynthetic%20pathway%20lowers%20O-GlcNAcylation%20levels%20and%20sensitizes%20cancer%20to%20environmental%20stress.%20Biochemistry.%202020;59:3169%E2%80%9379." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR136">
<span class="label">136.</span><cite>Dong T, Kang X, Liu Z, Zhao S, Ma W, Xuan Q. et al. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer. Tumour Biol. 2016;37:8159−68.</cite> [<a href="https://doi.org/10.1007/s13277-015-4729-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26715276/" class="usa-link">PubMed</a>]</li>
<li id="CR137">
<span class="label">137.</span><cite>Zhang W, Bouchard G, Yu A, Shafiq M, Jamali M, Shrager JB, et al. GFPT2-Expressing cancer-associated fibroblasts mediate metabolic reprogramming in human lung adenocarcinoma. Cancer Res. 2018;78:3445–57.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-17-2928" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6030462/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29760045/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20W,%20Bouchard%20G,%20Yu%20A,%20Shafiq%20M,%20Jamali%20M,%20Shrager%20JB,%20et%20al.%20GFPT2-Expressing%20cancer-associated%20fibroblasts%20mediate%20metabolic%20reprogramming%20in%20human%20lung%20adenocarcinoma.%20Cancer%20Res.%202018;78:3445%E2%80%9357." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR138">
<span class="label">138.</span><cite>van IJzendoorn DGP, Matusiak M, Charville GW, Spierenburg G, Varma S, Colburg DRC, et al. Interactions in CSF1-driven tenosynovial giant cell tumors. Clin Cancer Res. 2022;28:4934–46.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-22-1898" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9660542/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36007098/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?van%20IJzendoorn%20DGP,%20Matusiak%20M,%20Charville%20GW,%20Spierenburg%20G,%20Varma%20S,%20Colburg%20DRC,%20et%20al.%20Interactions%20in%20CSF1-driven%20tenosynovial%20giant%20cell%20tumors.%20Clin%20Cancer%20Res.%202022;28:4934%E2%80%9346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR139">
<span class="label">139.</span><cite>Zitzler J, Link D, Schafer R, Liebetrau W, Kazinski M, Bonin-Debs A. et al. High-throughput functional genomics identifies genes that ameliorate toxicity due to oxidative stress in neuronal HT-22 cells: GFPT2 protects cells against peroxide. Mol Cell Proteomic. 2004;3:834−40.</cite> [<a href="https://doi.org/10.1074/mcp.M400054-MCP200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15181156/" class="usa-link">PubMed</a>]</li>
<li id="CR140">
<span class="label">140.</span><cite>Wang Q, Karvelsson ST, Kotronoulas A, Gudjonsson T, Halldorsson S, Rolfsson O. Glutamine-fructose-6-Phosphate transaminase 2 (GFPT2) is upregulated in breast epithelial-mesenchymal transition and responds to oxidative stress. Mol Cell Proteom : MCP. 2022;21:100185.
</cite> [<a href="https://doi.org/10.1016/j.mcpro.2021.100185" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8803663/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34923141/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Q,%20Karvelsson%20ST,%20Kotronoulas%20A,%20Gudjonsson%20T,%20Halldorsson%20S,%20Rolfsson%20O.%20Glutamine-fructose-6-Phosphate%20transaminase%202%20(GFPT2)%20is%20upregulated%20in%20breast%20epithelial-mesenchymal%20transition%20and%20responds%20to%20oxidative%20stress.%20Mol%20Cell%20Proteom%20:%20MCP.%202022;21:100185." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR141">
<span class="label">141.</span><cite>Palorini R, Cammarata FP, Balestrieri C, Monestiroli A, Vasso M, Gelfi C, et al. Glucose starvation induces cell death in K-ras-transformed cells by interfering with the hexosamine biosynthesis pathway and activating the unfolded protein response. Cell Death Dis. 2013;4:e732–e.
</cite> [<a href="https://doi.org/10.1038/cddis.2013.257" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3730427/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23868065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Palorini%20R,%20Cammarata%20FP,%20Balestrieri%20C,%20Monestiroli%20A,%20Vasso%20M,%20Gelfi%20C,%20et%20al.%20Glucose%20starvation%20induces%20cell%20death%20in%20K-ras-transformed%20cells%20by%20interfering%20with%20the%20hexosamine%20biosynthesis%20pathway%20and%20activating%20the%20unfolded%20protein%20response.%20Cell%20Death%20Dis.%202013;4:e732%E2%80%93e." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR142">
<span class="label">142.</span><cite>Wang Z, Kuang T, Wu W, Wang D, Lou W, Jin D, et al. GFAT1 is highly expressed in cancer stem cells of pancreatic cancer. Ann Transl Med. 2022;10:544.
</cite> [<a href="https://doi.org/10.21037/atm-22-1946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9201171/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35722419/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Z,%20Kuang%20T,%20Wu%20W,%20Wang%20D,%20Lou%20W,%20Jin%20D,%20et%20al.%20GFAT1%20is%20highly%20expressed%20in%20cancer%20stem%20cells%20of%20pancreatic%20cancer.%20Ann%20Transl%20Med.%202022;10:544." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR143">
<span class="label">143.</span><cite>Nishiyama M, Tsunedomi R, Yoshimura K, Hashimoto N, Matsukuma S, Ogihara H. et al. Metastatic ability and the epithelial-mesenchymal transition in induced cancer stem-like hepatoma cells. Cancer Sci. 2018;109:1101−9.</cite> [<a href="https://doi.org/10.1111/cas.13527" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5891178/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29417690/" class="usa-link">PubMed</a>]</li>
<li id="CR144">
<span class="label">144.</span><cite>Shimizu M, Tanaka N. IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells. Oncogene. 2019;38:1520–33.
</cite> [<a href="https://doi.org/10.1038/s41388-018-0533-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30305725/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shimizu%20M,%20Tanaka%20N.%20IL-8-induced%20O-GlcNAc%20modification%20via%20GLUT3%20and%20GFAT%20regulates%20cancer%20stem%20cell-like%20properties%20in%20colon%20and%20lung%20cancer%20cells.%20Oncogene.%202019;38:1520%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR145">
<span class="label">145.</span><cite>Chen W, Do KC, Saxton B, Leng S, Filipczak P, Tessema M, et al. Inhibition of the hexosamine biosynthesis pathway potentiates cisplatin cytotoxicity by decreasing BiP expression in non-small-cell lung cancer cells. Mol Carcinogenesis. 2019;58:1046–55.</cite> [<a href="https://doi.org/10.1002/mc.22992" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6525013/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30790354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20W,%20Do%20KC,%20Saxton%20B,%20Leng%20S,%20Filipczak%20P,%20Tessema%20M,%20et%20al.%20Inhibition%20of%20the%20hexosamine%20biosynthesis%20pathway%20potentiates%20cisplatin%20cytotoxicity%20by%20decreasing%20BiP%20expression%20in%20non-small-cell%20lung%20cancer%20cells.%20Mol%20Carcinogenesis.%202019;58:1046%E2%80%9355." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR146">
<span class="label">146.</span><cite>Johansson HJ, Sanchez BC, Forshed J, Stål O, Fohlin H, Lewensohn R, et al. Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. Clin Proteom. 2015;12:8.</cite> [<a href="https://doi.org/10.1186/s12014-015-9080-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4389343/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25878567/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Johansson%20HJ,%20Sanchez%20BC,%20Forshed%20J,%20St%C3%A5l%20O,%20Fohlin%20H,%20Lewensohn%20R,%20et%20al.%20Proteomics%20profiling%20identify%20CAPS%20as%20a%20potential%20predictive%20marker%20of%20tamoxifen%20resistance%20in%20estrogen%20receptor%20positive%20breast%20cancer.%20Clin%20Proteom.%202015;12:8." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR147">
<span class="label">147.</span><cite>Miyazaki K, Ariake K, Sato S, Miura T, Xun J, Douchi D, et al. GFPT2 expression is induced by gemcitabine administration and enhances invasion by activating the hexosamine biosynthetic pathway in pancreatic cancer. Clin Exp Metastasis. 2024;41:777–89.
</cite> [<a href="https://doi.org/10.1007/s10585-024-10298-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11499537/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38888874/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Miyazaki%20K,%20Ariake%20K,%20Sato%20S,%20Miura%20T,%20Xun%20J,%20Douchi%20D,%20et%20al.%20GFPT2%20expression%20is%20induced%20by%20gemcitabine%20administration%20and%20enhances%20invasion%20by%20activating%20the%20hexosamine%20biosynthetic%20pathway%20in%20pancreatic%20cancer.%20Clin%20Exp%20Metastasis.%202024;41:777%E2%80%9389." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR148">
<span class="label">148.</span><cite>Yang S, Li G, Yin X, Wang Y, Jiang X, Bian X, et al. Cancer-associated fibroblast expression of glutamine fructose-6-phosphate aminotransferase 2 (GFPT2) is a prognostic marker in gastric cancer. J Pathol Clin Res. 2023;9:391–408.
</cite> [<a href="https://doi.org/10.1002/cjp2.333" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10397376/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37395335/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20S,%20Li%20G,%20Yin%20X,%20Wang%20Y,%20Jiang%20X,%20Bian%20X,%20et%20al.%20Cancer-associated%20fibroblast%20expression%20of%20glutamine%20fructose-6-phosphate%20aminotransferase%202%20(GFPT2)%20is%20a%20prognostic%20marker%20in%20gastric%20cancer.%20J%20Pathol%20Clin%20Res.%202023;9:391%E2%80%93408." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR149">
<span class="label">149.</span><cite>Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117–34.
</cite> [<a href="https://doi.org/10.1007/s10911-010-9178-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2886089/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20490631/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Micalizzi%20DS,%20Farabaugh%20SM,%20Ford%20HL.%20Epithelial-mesenchymal%20transition%20in%20cancer:%20parallels%20between%20normal%20development%20and%20tumor%20progression.%20J%20Mammary%20Gland%20Biol%20Neoplasia.%202010;15:117%E2%80%9334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR150">
<span class="label">150.</span><cite>Taparra K, Tran PT, Zachara NE. Hexosamine biosynthetic pathway to promote EMT-mediated neoplastic phenotypes. Front Oncol. 2016;6:85.</cite> [<a href="https://doi.org/10.3389/fonc.2016.00085" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4834358/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27148477/" class="usa-link">PubMed</a>]</li>
<li id="CR151">
<span class="label">151.</span><cite>Lucena MC, Carvalho-Cruz P, Donadio JL, Oliveira IA, de Queiroz RM, Marinho-Carvalho MM, et al. Epithelial mesenchymal transition induces aberrant glycosylation through hexosamine biosynthetic pathway activation. J Biol Chem. 2016;291:12917–29.
</cite> [<a href="https://doi.org/10.1074/jbc.M116.729236" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4933211/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27129262/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lucena%20MC,%20Carvalho-Cruz%20P,%20Donadio%20JL,%20Oliveira%20IA,%20de%20Queiroz%20RM,%20Marinho-Carvalho%20MM,%20et%20al.%20Epithelial%20mesenchymal%20transition%20induces%20aberrant%20glycosylation%20through%20hexosamine%20biosynthetic%20pathway%20activation.%20J%20Biol%20Chem.%202016;291:12917%E2%80%9329." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR152">
<span class="label">152.</span><cite>Zou Y, Liu Z, Liu W, Liu Z. Current knowledge and potential intervention of hexosamine biosynthesis pathway in lung cancer. World J surgical Oncol. 2023;21:334.</cite> [<a href="https://doi.org/10.1186/s12957-023-03226-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10601224/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37880766/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zou%20Y,%20Liu%20Z,%20Liu%20W,%20Liu%20Z.%20Current%20knowledge%20and%20potential%20intervention%20of%20hexosamine%20biosynthesis%20pathway%20in%20lung%20cancer.%20World%20J%20surgical%20Oncol.%202023;21:334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR153">
<span class="label">153.</span><cite>De Queiroz RM, Oliveira IA, Piva B, Bouchuid Catão F, da Costa Rodrigues B, da Costa Pascoal A. et al. Hexosamine biosynthetic pathway and glycosylation regulate cell migration in melanoma cells. Front Oncol. 2019;9:116.</cite> [<a href="https://doi.org/10.3389/fonc.2019.00116" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6411693/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30891426/" class="usa-link">PubMed</a>]</li>
<li id="CR154">
<span class="label">154.</span><cite>Zhang N, Zhu T, Yu K, Shi M, Wang X, Wang L. et al. Elevation of O-GlcNAc and GFAT expression by nicotine exposure promotes epithelial-mesenchymal transition and invasion in breast cancer cells. Cell Death Dis. 2019;10:343.</cite> [<a href="https://doi.org/10.1038/s41419-019-1577-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6482138/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31019204/" class="usa-link">PubMed</a>]</li>
<li id="CR155">
<span class="label">155.</span><cite>Li X, Wang X, Tan Z, Chen S, Guan F. Role of glycans in cancer cells undergoing epithelial–mesenchymal transition. Front Oncol. 2016;6:33.</cite> [<a href="https://doi.org/10.3389/fonc.2016.00033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4756103/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26925388/" class="usa-link">PubMed</a>]</li>
<li id="CR156">
<span class="label">156.</span><cite>Carvalho-Cruz P, Alisson-Silva F, Todeschini AR, Dias WB. Cellular glycosylation senses metabolic changes and modulates cell plasticity during epithelial to mesenchymal transition. Dev Dyn Publ Am Assoc Anatomists. 2018;247:481–91.</cite> [<a href="https://doi.org/10.1002/dvdy.24553" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28722313/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Carvalho-Cruz%20P,%20Alisson-Silva%20F,%20Todeschini%20AR,%20Dias%20WB.%20Cellular%20glycosylation%20senses%20metabolic%20changes%20and%20modulates%20cell%20plasticity%20during%20epithelial%20to%20mesenchymal%20transition.%20Dev%20Dyn%20Publ%20Am%20Assoc%20Anatomists.%202018;247:481%E2%80%9391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR157">
<span class="label">157.</span><cite>Carvalho S, Catarino TA, Dias AM, Kato M, Almeida A, Hessling B, et al. Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer. Oncogene. 2016;35:1619–31.
</cite> [<a href="https://doi.org/10.1038/onc.2015.225" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4856288/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26189796/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Carvalho%20S,%20Catarino%20TA,%20Dias%20AM,%20Kato%20M,%20Almeida%20A,%20Hessling%20B,%20et%20al.%20Preventing%20E-cadherin%20aberrant%20N-glycosylation%20at%20Asn-554%20improves%20its%20critical%20function%20in%20gastric%20cancer.%20Oncogene.%202016;35:1619%E2%80%9331." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR158">
<span class="label">158.</span><cite>Jin F-z, Yu C, Zhao D-z, Wu M-j, Yang Z. A correlation between altered O-GlcNAcylation, migration and with changes in E-cadherin levels in ovarian cancer cells. Exp Cell Res. 2013;319:1482–90.
</cite> [<a href="https://doi.org/10.1016/j.yexcr.2013.03.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23524144/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jin%20F-z,%20Yu%20C,%20Zhao%20D-z,%20Wu%20M-j,%20Yang%20Z.%20A%20correlation%20between%20altered%20O-GlcNAcylation,%20migration%20and%20with%20changes%20in%20E-cadherin%20levels%20in%20ovarian%20cancer%20cells.%20Exp%20Cell%20Res.%202013;319:1482%E2%80%9390." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR159">
<span class="label">159.</span><cite>Oikari S, Makkonen K, Deen AJ, Tyni I, Kärnä R, Tammi RH, et al. Hexosamine biosynthesis in keratinocytes: roles of GFAT and GNPDA enzymes in the maintenance of UDP-GlcNAc content and hyaluronan synthesis. Glycobiology. 2016;26:710–22.
</cite> [<a href="https://doi.org/10.1093/glycob/cww019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26887390/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Oikari%20S,%20Makkonen%20K,%20Deen%20AJ,%20Tyni%20I,%20K%C3%A4rn%C3%A4%20R,%20Tammi%20RH,%20et%20al.%20Hexosamine%20biosynthesis%20in%20keratinocytes:%20roles%20of%20GFAT%20and%20GNPDA%20enzymes%20in%20the%20maintenance%20of%20UDP-GlcNAc%20content%20and%20hyaluronan%20synthesis.%20Glycobiology.%202016;26:710%E2%80%9322." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR160">
<span class="label">160.</span><cite>Shaul YoavD, Freinkman E, Comb WilliamC, Cantor JasonR, Tam WaiL, Thiru P, et al. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell. 2014;158:1094–109.
</cite> [<a href="https://doi.org/10.1016/j.cell.2014.07.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4250222/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25171410/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shaul%20YoavD,%20Freinkman%20E,%20Comb%20WilliamC,%20Cantor%20JasonR,%20Tam%20WaiL,%20Thiru%20P,%20et%20al.%20Dihydropyrimidine%20accumulation%20is%20required%20for%20the%20epithelial-mesenchymal%20transition.%20Cell.%202014;158:1094%E2%80%93109." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR161">
<span class="label">161.</span><cite>Chao D, Ariake K, Sato S, Ohtsuka H, Takadate T, Ishida M. et al. Stomatin‑like protein 2 induces metastasis by regulating the expression of a rate‑limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer. Oncol Rep. 2021;45:90.</cite> [<a href="https://doi.org/10.3892/or.2021.8041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8042670/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33846782/" class="usa-link">PubMed</a>]</li>
<li id="CR162">
<span class="label">162.</span><cite>Duan F, Jia D, Zhao J, Wu W, Min L, Song S. et al. Loss of GFAT1 promotes epithelial-to-mesenchymal transition and predicts unfavorable prognosis in gastric cancer. Oncotarget. 2016;7:38427–39.</cite> [<a href="https://doi.org/10.18632/oncotarget.9538" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5122401/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27509259/" class="usa-link">PubMed</a>]</li>
<li id="CR163">
<span class="label">163.</span><cite>Cui Y, Feng H, Liu J, Wu J, Zhu R, Huang R, et al. Identification of hexosamine biosynthesis pathway as a novel prognostic signature and its correlation with immune infiltration in bladder cancer. Front Mol Biosci. 2022;9:1009168.
</cite> [<a href="https://doi.org/10.3389/fmolb.2022.1009168" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9493074/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36158580/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cui%20Y,%20Feng%20H,%20Liu%20J,%20Wu%20J,%20Zhu%20R,%20Huang%20R,%20et%20al.%20Identification%20of%20hexosamine%20biosynthesis%20pathway%20as%20a%20novel%20prognostic%20signature%20and%20its%20correlation%20with%20immune%20infiltration%20in%20bladder%20cancer.%20Front%20Mol%20Biosci.%202022;9:1009168." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR164">
<span class="label">164.</span><cite>Zhang J, Wang T, Wei S, Chen S, Bi J. GFPT2 pan-cancer analysis and its prognostic and tumor microenvironment associations*. Oncol Transl Med. 2021;7:286−93.</cite>
</li>
<li id="CR165">
<span class="label">165.</span><cite>Sharma NS, Gupta VK, Garrido VT, Hadad R, Durden BC, Kesh K, et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 2020;130:451–65.
</cite> [<a href="https://doi.org/10.1172/JCI127515" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6934212/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31613799/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sharma%20NS,%20Gupta%20VK,%20Garrido%20VT,%20Hadad%20R,%20Durden%20BC,%20Kesh%20K,%20et%20al.%20Targeting%20tumor-intrinsic%20hexosamine%20biosynthesis%20sensitizes%20pancreatic%20cancer%20to%20anti-PD1%20therapy.%20J%20Clin%20Invest.%202020;130:451%E2%80%9365." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR166">
<span class="label">166.</span><cite>Ao L, Jia W, Gong Q, Cui J, Wang J, Yu Y. et al. Targeting GFPT2 to reinvigorate immunotherapy in EGFR-mutated NSCLC. bioRxiv. 2024:2024.03.01.582888.</cite>
</li>
<li id="CR167">
<span class="label">167.</span><cite>Chen W, Saxton B, Tessema M, Belinsky SA. Inhibition of GFAT1 in lung cancer cells destabilizes PD-L1 protein. Carcinogenesis. 2021;42:1171–8.
</cite> [<a href="https://doi.org/10.1093/carcin/bgab063" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8491135/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34270713/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20W,%20Saxton%20B,%20Tessema%20M,%20Belinsky%20SA.%20Inhibition%20of%20GFAT1%20in%20lung%20cancer%20cells%20destabilizes%20PD-L1%20protein.%20Carcinogenesis.%202021;42:1171%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR168">
<span class="label">168.</span><cite>Jiang Y, Huang T, Chen L, Gao YF, Cai Y, Chou KC. Signal propagation in protein interaction network during colorectal cancer progression. BioMed Res Int. 2013;2013:287019.
</cite> [<a href="https://doi.org/10.1155/2013/287019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3615629/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23586028/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jiang%20Y,%20Huang%20T,%20Chen%20L,%20Gao%20YF,%20Cai%20Y,%20Chou%20KC.%20Signal%20propagation%20in%20protein%20interaction%20network%20during%20colorectal%20cancer%20progression.%20BioMed%20Res%20Int.%202013;2013:287019." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR169">
<span class="label">169.</span><cite>Connelly AR, Jeong BM, Coden ME, Cao JY, Chirkova T, Rosas-Salazar C. et al. Metabolic reprogramming of nasal airway epithelial cells following infant respiratory syncytial virus. Viruses. 2021;13:2055.</cite> [<a href="https://doi.org/10.3390/v13102055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8538412/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34696488/" class="usa-link">PubMed</a>]</li>
<li id="CR170">
<span class="label">170.</span><cite>Xu X, Qiao D, Pan L, Boldogh I, Zhao Y, Brasier AR. RELA∙8-oxoguanine DNA glycosylase1 is an epigenetic regulatory complex coordinating the hexosamine biosynthetic pathway in RSV infection. Cells. 2022;11:2210.</cite> [<a href="https://doi.org/10.3390/cells11142210" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9319012/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35883652/" class="usa-link">PubMed</a>]</li>
<li id="CR171">
<span class="label">171.</span><cite>Zhang H-R, Li T-J, Yu X-J, Liu C, Wu W-D, Ye L-Y, et al. The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer. Cell Death Dis. 2024;15:244.
</cite> [<a href="https://doi.org/10.1038/s41419-024-06589-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10995196/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38575607/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20H-R,%20Li%20T-J,%20Yu%20X-J,%20Liu%20C,%20Wu%20W-D,%20Ye%20L-Y,%20et%20al.%20The%20GFPT2-O-GlcNAcylation-YBX1%20axis%20promotes%20IL-18%20secretion%20to%20regulate%20the%20tumor%20immune%20microenvironment%20in%20pancreatic%20cancer.%20Cell%20Death%20Dis.%202024;15:244." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR172">
<span class="label">172.</span><cite>Al-Mukh H, Baudoin L, Bouaboud A, Sanchez-Salgado J-L, Maraqa N, Khair M, et al. Lipopolysaccharide induces GFAT2 expression to promote O-linked β-N-acetylglucosaminylation and attenuate inflammation in macrophages. J Immunol. 2020;205:2499–510.
</cite> [<a href="https://doi.org/10.4049/jimmunol.2000345" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32978282/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Al-Mukh%20H,%20Baudoin%20L,%20Bouaboud%20A,%20Sanchez-Salgado%20J-L,%20Maraqa%20N,%20Khair%20M,%20et%20al.%20Lipopolysaccharide%20induces%20GFAT2%20expression%20to%20promote%20O-linked%20%CE%B2-N-acetylglucosaminylation%20and%20attenuate%20inflammation%20in%20macrophages.%20J%20Immunol.%202020;205:2499%E2%80%93510." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR173">
<span class="label">173.</span><cite>Stefaniak J, Nowak MG, Wojciechowski M, Milewski S, Skwarecki AS. Inhibitors of glucosamine-6-phosphate synthase as potential antimicrobials or antidiabetics - synthesis and properties. J Enzym Inhib Med Chem. 2022;37:1928–56.</cite> [<a href="https://doi.org/10.1080/14756366.2022.2096018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9272926/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35801410/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Stefaniak%20J,%20Nowak%20MG,%20Wojciechowski%20M,%20Milewski%20S,%20Skwarecki%20AS.%20Inhibitors%20of%20glucosamine-6-phosphate%20synthase%20as%20potential%20antimicrobials%20or%20antidiabetics%20-%20synthesis%20and%20properties.%20J%20Enzym%20Inhib%20Med%20Chem.%202022;37:1928%E2%80%9356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR174">
<span class="label">174.</span><cite>Wojciechowski M, Milewski S, Mazerski J, Borowski E. Glucosamine-6-phosphate synthase, a novel target for antifungal agents. Molecular modelling studies in drug design. Acta Biochim Pol. 2005;52:647–53.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/16082410/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wojciechowski%20M,%20Milewski%20S,%20Mazerski%20J,%20Borowski%20E.%20Glucosamine-6-phosphate%20synthase,%20a%20novel%20target%20for%20antifungal%20agents.%20Molecular%20modelling%20studies%20in%20drug%20design.%20Acta%20Biochim%20Pol.%202005;52:647%E2%80%9353." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR175">
<span class="label">175.</span><cite>Milewski S, Janiak A, Wojciechowski M. Structural analogues of reactive intermediates as inhibitors of glucosamine-6-phosphate synthase and phosphoglucose isomerase. Arch Biochem Biophys. 2006;450:39–49.
</cite> [<a href="https://doi.org/10.1016/j.abb.2006.03.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16631105/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Milewski%20S,%20Janiak%20A,%20Wojciechowski%20M.%20Structural%20analogues%20of%20reactive%20intermediates%20as%20inhibitors%20of%20glucosamine-6-phosphate%20synthase%20and%20phosphoglucose%20isomerase.%20Arch%20Biochem%20Biophys.%202006;450:39%E2%80%9349." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR176">
<span class="label">176.</span><cite>Bearne SL, Blouin C. Inhibition of Escherichia coli glucosamine-6-phosphate synthase by reactive intermediate analogues: the role of the 2-amino function in catalysis*. J Biol Chem. 2000;275:135–40.
</cite> [<a href="https://doi.org/10.1074/jbc.275.1.135" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10617596/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bearne%20SL,%20Blouin%20C.%20Inhibition%20of%20Escherichia%20coli%20glucosamine-6-phosphate%20synthase%20by%20reactive%20intermediate%20analogues:%20the%20role%20of%20the%202-amino%20function%20in%20catalysis*.%20J%20Biol%20Chem.%202000;275:135%E2%80%9340." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR177">
<span class="label">177.</span><cite>Kucharczyk N, Denisot MA, Le Goffic F, Badet B. Glucosamine-6-phosphate synthase from Escherichia coli: determination of the mechanism of inactivation by N3-fumaroyl-L-2,3-diaminopropionic derivatives. Biochemistry. 1990;29:3668–76.
</cite> [<a href="https://doi.org/10.1021/bi00467a012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2111163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kucharczyk%20N,%20Denisot%20MA,%20Le%20Goffic%20F,%20Badet%20B.%20Glucosamine-6-phosphate%20synthase%20from%20Escherichia%20coli:%20determination%20of%20the%20mechanism%20of%20inactivation%20by%20N3-fumaroyl-L-2,3-diaminopropionic%20derivatives.%20Biochemistry.%201990;29:3668%E2%80%9376." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR178">
<span class="label">178.</span><cite>Qian Y, Ahmad M, Chen S, Gillespie P, Le N, Mennona F, et al. Discovery of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors. Bioorg Med Chem Lett. 2011;21:6264–9.
</cite> [<a href="https://doi.org/10.1016/j.bmcl.2011.09.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21958546/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qian%20Y,%20Ahmad%20M,%20Chen%20S,%20Gillespie%20P,%20Le%20N,%20Mennona%20F,%20et%20al.%20Discovery%20of%201-arylcarbonyl-6,7-dimethoxyisoquinoline%20derivatives%20as%20glutamine%20fructose-6-phosphate%20amidotransferase%20(GFAT)%20inhibitors.%20Bioorg%20Med%20Chem%20Lett.%202011;21:6264%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR179">
<span class="label">179.</span><cite>Andruszkiewicz R, Chmara H, Milewski S, Borowski E. Synthesis and biological properties of N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid dipeptides, a novel group of antimicrobial agents. J Med Chem. 1987;30:1715–9.
</cite> [<a href="https://doi.org/10.1021/jm00393a005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3309312/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Andruszkiewicz%20R,%20Chmara%20H,%20Milewski%20S,%20Borowski%20E.%20Synthesis%20and%20biological%20properties%20of%20N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic%20acid%20dipeptides,%20a%20novel%20group%20of%20antimicrobial%20agents.%20J%20Med%20Chem.%201987;30:1715%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR180">
<span class="label">180.</span><cite>Lyons SD, Sant ME, Christopherson RI. Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia. J Biol Chem. 1990;265:11377–81.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/2358467/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lyons%20SD,%20Sant%20ME,%20Christopherson%20RI.%20Cytotoxic%20mechanisms%20of%20glutamine%20antagonists%20in%20mouse%20L1210%20leukemia.%20J%20Biol%20Chem.%201990;265:11377%E2%80%9381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR181">
<span class="label">181.</span><cite>Prajda N. Enzyme targets of antiglutamine agents in cancer chemotherapy. Adv Enzym Regul. 1985;24:207–23.</cite> [<a href="https://doi.org/10.1016/0065-2571(85)90077-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2424283/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Prajda%20N.%20Enzyme%20targets%20of%20antiglutamine%20agents%20in%20cancer%20chemotherapy.%20Adv%20Enzym%20Regul.%201985;24:207%E2%80%9323." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR182">
<span class="label">182.</span><cite>Pittillo RF, Hunt DE. Azaserine and 6-diazo-5 -oxo-L-norleucine (DON). In: Gottlieb D, Shaw PD, editors. Antibiotics: Volume I Mechanism of Action. Berlin, Heidelberg: Springer Berlin Heidelberg; 1967. pp. 481−93.</cite>
</li>
<li id="CR183">
<span class="label">183.</span><cite>Magill GB, Myers WP, Reilly HC, Putnam RC, Magill JW, Sykes MP, et al. Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-1-norleucine (DON) in human neoplastic disease. Cancer. 1957;10:1138–50.
</cite> [<a href="https://doi.org/10.1002/1097-0142(195711/12)10:6&lt;1138::aid-cncr2820100608&gt;3.0.co;2-k" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/13489662/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Magill%20GB,%20Myers%20WP,%20Reilly%20HC,%20Putnam%20RC,%20Magill%20JW,%20Sykes%20MP,%20et%20al.%20Pharmacological%20and%20initial%20therapeutic%20observations%20on%206-diazo-5-oxo-1-norleucine%20(DON)%20in%20human%20neoplastic%20disease.%20Cancer.%201957;10:1138%E2%80%9350." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR184">
<span class="label">184.</span><cite>Catane R, Von Hoff DD, Glaubiger DL, Muggia FM. Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity. Cancer Treat Rep. 1979;63:1033–8.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/380801/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Catane%20R,%20Von%20Hoff%20DD,%20Glaubiger%20DL,%20Muggia%20FM.%20Azaserine,%20DON,%20and%20azotomycin:%20three%20diazo%20analogs%20of%20L-glutamine%20with%20clinical%20antitumor%20activity.%20Cancer%20Treat%20Rep.%201979;63:1033%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR185">
<span class="label">185.</span><cite>DeWald HA, Moore AM. 6-diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance.1a preparation of L-, D- and DL-forms1b. J Am Chem Soc. 1958;80:3941–5.</cite> [<a href="https://scholar.google.com/scholar_lookup?DeWald%20HA,%20Moore%20AM.%206-diazo-5-oxo-L-norleucine,%20a%20new%20tumor-inhibitory%20substance.1a%20preparation%20of%20L-,%20D-%20and%20DL-forms1b.%20J%20Am%20Chem%20Soc.%201958;80:3941%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR186">
<span class="label">186.</span><cite>Pettit GR, Nelson PS. Synthesis of amino acid diazoketones. Can J Chem. 1986;64:2097–102.</cite> [<a href="https://scholar.google.com/scholar_lookup?Pettit%20GR,%20Nelson%20PS.%20Synthesis%20of%20amino%20acid%20diazoketones.%20Can%20J%20Chem.%201986;64:2097%E2%80%93102." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR187">
<span class="label">187.</span><cite>Nicolaides ED, Westland RD, Wittle EL. Azaserine, synthetic studies. II. J Am Chem Soc. 1954;76:2887–91.</cite> [<a href="https://scholar.google.com/scholar_lookup?Nicolaides%20ED,%20Westland%20RD,%20Wittle%20EL.%20Azaserine,%20synthetic%20studies.%20II.%20J%20Am%20Chem%20Soc.%201954;76:2887%E2%80%9391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR188">
<span class="label">188.</span><cite>Curphey TJ, Daniel DS. New synthesis of azaserine. J Org Chem. 1978;43:4666–8.</cite> [<a href="https://scholar.google.com/scholar_lookup?Curphey%20TJ,%20Daniel%20DS.%20New%20synthesis%20of%20azaserine.%20J%20Org%20Chem.%201978;43:4666%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR189">
<span class="label">189.</span><cite>Alt J, Potter MC, Rojas C, Slusher BS. Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry. Anal Biochem. 2015;474:28–34.
</cite> [<a href="https://doi.org/10.1016/j.ab.2015.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4357560/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25584882/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Alt%20J,%20Potter%20MC,%20Rojas%20C,%20Slusher%20BS.%20Bioanalysis%20of%206-diazo-5-oxo-l-norleucine%20in%20plasma%20and%20brain%20by%20ultra-performance%20liquid%20chromatography%20mass%20spectrometry.%20Anal%20Biochem.%202015;474:28%E2%80%9334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR190">
<span class="label">190.</span><cite>Green SP, Wheelhouse KM, Payne AD, Hallett JP, Miller PW, Bull JA. Thermal stability and explosive hazard assessment of diazo compounds and diazo transfer reagents. Org Process Res Dev. 2020;24:67–84.
</cite> [<a href="https://doi.org/10.1021/acs.oprd.9b00422" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6972035/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31983869/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Green%20SP,%20Wheelhouse%20KM,%20Payne%20AD,%20Hallett%20JP,%20Miller%20PW,%20Bull%20JA.%20Thermal%20stability%20and%20explosive%20hazard%20assessment%20of%20diazo%20compounds%20and%20diazo%20transfer%20reagents.%20Org%20Process%20Res%20Dev.%202020;24:67%E2%80%9384." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR191">
<span class="label">191.</span><cite>Lewis CE. Diazomethane poisoning. report of a case suggesting sensitization reaction. J Occup Med. 1964;6:91–2.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/14116291/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lewis%20CE.%20Diazomethane%20poisoning.%20report%20of%20a%20case%20suggesting%20sensitization%20reaction.%20J%20Occup%20Med.%201964;6:91%E2%80%932." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR192">
<span class="label">192.</span><cite>Schoental R. Carcinogenic action of diazomethane and of nitroso-n-methyl urethane. Nature. 1960;188:420–1.
</cite> [<a href="https://doi.org/10.1038/188420b0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/13748420/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schoental%20R.%20Carcinogenic%20action%20of%20diazomethane%20and%20of%20nitroso-n-methyl%20urethane.%20Nature.%201960;188:420%E2%80%931." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR193">
<span class="label">193.</span><cite>Van Cura D, Ng TL, Huang J, Hager H, Hartwig JF, Keasling JD, et al. Discovery of the azaserine biosynthetic pathway uncovers a biological route for α-diazoester production. Angew Chem Int Ed. 2023;62:e202304646.</cite> [<a href="https://doi.org/10.1002/anie.202304646" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10330308/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37151182/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Van%20Cura%20D,%20Ng%20TL,%20Huang%20J,%20Hager%20H,%20Hartwig%20JF,%20Keasling%20JD,%20et%20al.%20Discovery%20of%20the%20azaserine%20biosynthetic%20pathway%20uncovers%20a%20biological%20route%20for%20%CE%B1-diazoester%20production.%20Angew%20Chem%20Int%20Ed.%202023;62:e202304646." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR194">
<span class="label">194.</span><cite>Kawai S, Sugaya Y, Hagihara R, Tomita H, Katsuyama Y, Ohnishi Y. Complete biosynthetic pathway of alazopeptin, a tripeptide consisting of two molecules of 6-diazo-5-oxo-l-norleucine and one molecule of alanine. Angew Chem Int Ed. 2021;60:10319–25.</cite> [<a href="https://doi.org/10.1002/anie.202100462" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33624374/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kawai%20S,%20Sugaya%20Y,%20Hagihara%20R,%20Tomita%20H,%20Katsuyama%20Y,%20Ohnishi%20Y.%20Complete%20biosynthetic%20pathway%20of%20alazopeptin,%20a%20tripeptide%20consisting%20of%20two%20molecules%20of%206-diazo-5-oxo-l-norleucine%20and%20one%20molecule%20of%20alanine.%20Angew%20Chem%20Int%20Ed.%202021;60:10319%E2%80%9325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR195">
<span class="label">195.</span><cite>Mix KA, Aronoff MR, Raines RT. Diazo compounds: versatile tools for chemical biology. ACS Chem Biol. 2016;11:3233–44.
</cite> [<a href="https://doi.org/10.1021/acschembio.6b00810" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5161546/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27739661/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mix%20KA,%20Aronoff%20MR,%20Raines%20RT.%20Diazo%20compounds:%20versatile%20tools%20for%20chemical%20biology.%20ACS%20Chem%20Biol.%202016;11:3233%E2%80%9344." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR196">
<span class="label">196.</span><cite>Terzyan SS, Cook PF, Heroux A, Hanigan MH. Structure of 6-diazo-5-oxo-norleucine-bound human gamma-glutamyl transpeptidase 1, a novel mechanism of inactivation. Protein Sci. 2017;26:1196–205.
</cite> [<a href="https://doi.org/10.1002/pro.3172" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5441403/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28378915/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Terzyan%20SS,%20Cook%20PF,%20Heroux%20A,%20Hanigan%20MH.%20Structure%20of%206-diazo-5-oxo-norleucine-bound%20human%20gamma-glutamyl%20transpeptidase%201,%20a%20novel%20mechanism%20of%20inactivation.%20Protein%20Sci.%202017;26:1196%E2%80%93205." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR197">
<span class="label">197.</span><cite>Wada K, Hiratake J, Irie M, Okada T, Yamada C, Kumagai H, et al. Crystal structures of escherichia coli γ-glutamyltranspeptidase in complex with azaserine and acivicin: novel mechanistic implication for inhibition by glutamine antagonists. J Mol Biol. 2008;380:361–72.
</cite> [<a href="https://doi.org/10.1016/j.jmb.2008.05.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18555071/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wada%20K,%20Hiratake%20J,%20Irie%20M,%20Okada%20T,%20Yamada%20C,%20Kumagai%20H,%20et%20al.%20Crystal%20structures%20of%20escherichia%20coli%20%CE%B3-glutamyltranspeptidase%20in%20complex%20with%20azaserine%20and%20acivicin:%20novel%20mechanistic%20implication%20for%20inhibition%20by%20glutamine%20antagonists.%20J%20Mol%20Biol.%202008;380:361%E2%80%9372." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR198">
<span class="label">198.</span><cite>Lemberg KM, Vornov JJ, Rais R, Slusher BS. We’re not “DON” yet: optimal dosing and prodrug delivery of 6-diazo-5-oxo-L-norleucine. Mol Cancer Therap. 2018;17:1824–32.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-17-1148" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6130910/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30181331/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lemberg%20KM,%20Vornov%20JJ,%20Rais%20R,%20Slusher%20BS.%20We%E2%80%99re%20not%20%E2%80%9CDON%E2%80%9D%20yet:%20optimal%20dosing%20and%20prodrug%20delivery%20of%206-diazo-5-oxo-L-norleucine.%20Mol%20Cancer%20Therap.%202018;17:1824%E2%80%9332." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR199">
<span class="label">199.</span><cite>Cervantes-Madrid D, Romero Y, Dueñas-González A. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to be used in combination for metabolic cancer therapy. BioMed Res Int. 2015;2015:690492.
</cite> [<a href="https://doi.org/10.1155/2015/690492" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4575731/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26425550/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cervantes-Madrid%20D,%20Romero%20Y,%20Due%C3%B1as-Gonz%C3%A1lez%20A.%20Reviving%20Lonidamine%20and%206-Diazo-5-oxo-L-norleucine%20to%20be%20used%20in%20combination%20for%20metabolic%20cancer%20therapy.%20BioMed%20Res%20Int.%202015;2015:690492." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR200">
<span class="label">200.</span><cite>Schroeder JM, Ansfield FJ, Curreri AR, Lepage GA. Toxicity and clinical trial of azaserine and 6-thioguanine in advanced solid malignant neoplasms. Br J cancer. 1964;13:449–58.
</cite> [<a href="https://doi.org/10.1038/bjc.1964.51" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2071098/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14219537/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schroeder%20JM,%20Ansfield%20FJ,%20Curreri%20AR,%20Lepage%20GA.%20Toxicity%20and%20clinical%20trial%20of%20azaserine%20and%206-thioguanine%20in%20advanced%20solid%20malignant%20neoplasms.%20Br%20J%20cancer.%201964;13:449%E2%80%9358." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR201">
<span class="label">201.</span><cite>Ansfield FJ. Phase I study of azotomycin (NSC-56654). Cancer Chemother Rep. 1965;46:37–40.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/14327551/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ansfield%20FJ.%20Phase%20I%20study%20of%20azotomycin%20(NSC-56654).%20Cancer%20Chemother%20Rep.%201965;46:37%E2%80%9340." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR202">
<span class="label">202.</span><cite>Mueller C, Al-Batran S, Jaeger E, Schmidt B, Bausch M, Unger C, et al. A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors. J Clin Oncol. 2008;26:2533.</cite> [<a href="https://scholar.google.com/scholar_lookup?Mueller%20C,%20Al-Batran%20S,%20Jaeger%20E,%20Schmidt%20B,%20Bausch%20M,%20Unger%20C,%20et%20al.%20A%20phase%20IIa%20study%20of%20PEGylated%20glutaminase%20(PEG-PGA)%20plus%206-diazo-5-oxo-L-norleucine%20(DON)%20in%20patients%20with%20advanced%20refractory%20solid%20tumors.%20J%20Clin%20Oncol.%202008;26:2533." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR203">
<span class="label">203.</span><cite>Sullivan MP, Nelson JA, Feldman S, Van Nguyen B. Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. Cancer Chemother Pharm. 1988;21:78–84.</cite> [<a href="https://doi.org/10.1007/BF00262746" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3342470/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sullivan%20MP,%20Nelson%20JA,%20Feldman%20S,%20Van%20Nguyen%20B.%20Pharmacokinetic%20and%20phase%20I%20study%20of%20intravenous%20DON%20(6-diazo-5-oxo-L-norleucine)%20in%20children.%20Cancer%20Chemother%20Pharm.%201988;21:78%E2%80%9384." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR204">
<span class="label">204.</span><cite>Lynch G, Kemeny N, Casper E. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1982;5:541–3.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/7180833/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lynch%20G,%20Kemeny%20N,%20Casper%20E.%20Phase%20II%20evaluation%20of%20DON%20(6-diazo-5-oxo-L-norleucine)%20in%20patients%20with%20advanced%20colorectal%20carcinoma.%20Am%20J%20Clin%20Oncol.%201982;5:541%E2%80%933." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR205">
<span class="label">205.</span><cite>Rais R, Jančařík A, Tenora L, Nedelcovych M, Alt J, Englert J, et al. Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with enhanced CSF delivery in monkeys: a potential treatment for glioblastoma. J Med Chem. 2016;59:8621–33.
</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.6b01069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27560860/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rais%20R,%20Jan%C4%8Da%C5%99%C3%ADk%20A,%20Tenora%20L,%20Nedelcovych%20M,%20Alt%20J,%20Englert%20J,%20et%20al.%20Discovery%20of%206-Diazo-5-oxo-l-norleucine%20(DON)%20Prodrugs%20with%20enhanced%20CSF%20delivery%20in%20monkeys:%20a%20potential%20treatment%20for%20glioblastoma.%20J%20Med%20Chem.%202016;59:8621%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR206">
<span class="label">206.</span><cite>Tenora L, Alt J, Dash RP, Gadiano AJ, Novotná K, Veeravalli V, et al. Tumor-targeted delivery of 6-diazo-5-oxo-l-norleucine (DON) using substituted acetylated lysine prodrugs. J Med Chem. 2019;62:3524–38.
</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.8b02009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8025739/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30892035/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tenora%20L,%20Alt%20J,%20Dash%20RP,%20Gadiano%20AJ,%20Novotn%C3%A1%20K,%20Veeravalli%20V,%20et%20al.%20Tumor-targeted%20delivery%20of%206-diazo-5-oxo-l-norleucine%20(DON)%20using%20substituted%20acetylated%20lysine%20prodrugs.%20J%20Med%20Chem.%202019;62:3524%E2%80%9338." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR207">
<span class="label">207.</span><cite>Pham K, Maxwell MJ, Sweeney H, Alt J, Rais R, Eberhart CG, et al. Novel glutamine antagonist JHU395 suppresses MYC-driven medulloblastoma growth and induces apoptosis. J Neuropathol Exp Neurol. 2021;80:336–44.
</cite> [<a href="https://doi.org/10.1093/jnen/nlab018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7985826/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33712838/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pham%20K,%20Maxwell%20MJ,%20Sweeney%20H,%20Alt%20J,%20Rais%20R,%20Eberhart%20CG,%20et%20al.%20Novel%20glutamine%20antagonist%20JHU395%20suppresses%20MYC-driven%20medulloblastoma%20growth%20and%20induces%20apoptosis.%20J%20Neuropathol%20Exp%20Neurol.%202021;80:336%E2%80%9344." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR208">
<span class="label">208.</span><cite>Hanaford AR, Alt J, Rais R, Wang SZ, Kaur H, Thorek DLJ, et al. Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Transl Oncol. 2019;12:1314–22.
</cite> [<a href="https://doi.org/10.1016/j.tranon.2019.05.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6657308/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31340195/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hanaford%20AR,%20Alt%20J,%20Rais%20R,%20Wang%20SZ,%20Kaur%20H,%20Thorek%20DLJ,%20et%20al.%20Orally%20bioavailable%20glutamine%20antagonist%20prodrug%20JHU-083%20penetrates%20mouse%20brain%20and%20suppresses%20the%20growth%20of%20MYC-driven%20medulloblastoma.%20Transl%20Oncol.%202019;12:1314%E2%80%9322." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR209">
<span class="label">209.</span><cite>Rais R, Lemberg KM, Tenora L, Arwood ML, Pal A, Alt J, et al. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug. Sci Adv. 2022;8:eabq5925.
</cite> [<a href="https://doi.org/10.1126/sciadv.abq5925" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9668306/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36383674/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rais%20R,%20Lemberg%20KM,%20Tenora%20L,%20Arwood%20ML,%20Pal%20A,%20Alt%20J,%20et%20al.%20Discovery%20of%20DRP-104,%20a%20tumor-targeted%20metabolic%20inhibitor%20prodrug.%20Sci%20Adv.%202022;8:eabq5925." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR210">
<span class="label">210.</span><cite>Xu H, Zheng M, Yang C, Wang K, Lv Z, Liu Z, et al. Azo-based hypoxic-activated 6-diazo-5-oxo-L-norleucine (DON) prodrug combined with vascular disrupting agent nanoparticles for tumor-selective glutamine metabolism blockade. Chem Eng J. 2024;481:148281.</cite> [<a href="https://scholar.google.com/scholar_lookup?Xu%20H,%20Zheng%20M,%20Yang%20C,%20Wang%20K,%20Lv%20Z,%20Liu%20Z,%20et%20al.%20Azo-based%20hypoxic-activated%206-diazo-5-oxo-L-norleucine%20(DON)%20prodrug%20combined%20with%20vascular%20disrupting%20agent%20nanoparticles%20for%20tumor-selective%20glutamine%20metabolism%20blockade.%20Chem%20Eng%20J.%202024;481:148281." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR211">
<span class="label">211.</span><cite>Kroef V, Ruegenberg S, Horn M, Allmeroth K, Ebert L, Bozkus S. et al. GFPT2/GFAT2 and AMDHD2 act in tandem to control the hexosamine pathway. Elife. 2022;11:e69223.</cite> [<a href="https://doi.org/10.7554/eLife.69223" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8970586/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35229715/" class="usa-link">PubMed</a>]</li>
<li id="CR212">
<span class="label">212.</span><cite>Issop Y, Hathazi D, Khan MM, Rudolf R, Weis J, Spendiff S, et al. GFPT1 deficiency in muscle leads to myasthenia and myopathy in mice. Hum Mol Genet. 2018;27:3218–32.
</cite> [<a href="https://doi.org/10.1093/hmg/ddy225" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6121184/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29905857/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Issop%20Y,%20Hathazi%20D,%20Khan%20MM,%20Rudolf%20R,%20Weis%20J,%20Spendiff%20S,%20et%20al.%20GFPT1%20deficiency%20in%20muscle%20leads%20to%20myasthenia%20and%20myopathy%20in%20mice.%20Hum%20Mol%20Genet.%202018;27:3218%E2%80%9332." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR213">
<span class="label">213.</span><cite>Nabeebaccus AA, Verma S, Zoccarato A, Emanuelli G, Santos CX, Streckfuss-Bömeke K, et al. Cardiomyocyte protein O-GlcNAcylation is regulated by GFAT1 not GFAT2. Biochem Biophys Res Commun. 2021;583:121–7.
</cite> [<a href="https://doi.org/10.1016/j.bbrc.2021.10.056" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8606754/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34735873/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nabeebaccus%20AA,%20Verma%20S,%20Zoccarato%20A,%20Emanuelli%20G,%20Santos%20CX,%20Streckfuss-B%C3%B6meke%20K,%20et%20al.%20Cardiomyocyte%20protein%20O-GlcNAcylation%20is%20regulated%20by%20GFAT1%20not%20GFAT2.%20Biochem%20Biophys%20Res%20Commun.%202021;583:121%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR214">
<span class="label">214.</span><cite>Wang R, Zhu G. A narrative review for the Hippo-YAP pathway in cancer survival and immunity: the Yin-Yang dynamics. Transl cancer Res. 2022;11:262–75.
</cite> [<a href="https://doi.org/10.21037/tcr-21-1843" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8841479/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35261902/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20R,%20Zhu%20G.%20A%20narrative%20review%20for%20the%20Hippo-YAP%20pathway%20in%20cancer%20survival%20and%20immunity:%20the%20Yin-Yang%20dynamics.%20Transl%20cancer%20Res.%202022;11:262%E2%80%9375." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR215">
<span class="label">215.</span><cite>Yamashita AS, da Costa Rosa M, Stumpo V, Rais R, Slusher BS, Riggins GJ. The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling. Neurooncol Adv. 2021;3:vdaa149.
</cite> [<a href="https://doi.org/10.1093/noajnl/vdaa149" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7920530/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33681764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yamashita%20AS,%20da%20Costa%20Rosa%20M,%20Stumpo%20V,%20Rais%20R,%20Slusher%20BS,%20Riggins%20GJ.%20The%20glutamine%20antagonist%20prodrug%20JHU-083%20slows%20malignant%20glioma%20growth%20and%20disrupts%20mTOR%20signaling.%20Neurooncol%20Adv.%202021;3:vdaa149." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR216">
<span class="label">216.</span><cite>Lemberg KM, Zhao L, Wu Y, Veeravalli V, Alt J, Aguilar JMH, et al. The novel glutamine antagonist prodrug JHU395 has antitumor activity in malignant peripheral nerve sheath tumor. Mol Cancer Therap. 2020;19:397–408.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-19-0319" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7007868/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31594823/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lemberg%20KM,%20Zhao%20L,%20Wu%20Y,%20Veeravalli%20V,%20Alt%20J,%20Aguilar%20JMH,%20et%20al.%20The%20novel%20glutamine%20antagonist%20prodrug%20JHU395%20has%20antitumor%20activity%20in%20malignant%20peripheral%20nerve%20sheath%20tumor.%20Mol%20Cancer%20Therap.%202020;19:397%E2%80%93408." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR217">
<span class="label">217.</span><cite>Novotná K, Tenora L, Prchalová E, Paule J, Alt J, Veeravalli V, et al. Discovery of tert-Butyl ester based 6-Diazo-5-oxo-l-norleucine prodrugs for enhanced metabolic stability and tumor delivery. J Med Chem. 2023;66:15493–510.
</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.3c01681" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10683027/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37949450/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Novotn%C3%A1%20K,%20Tenora%20L,%20Prchalov%C3%A1%20E,%20Paule%20J,%20Alt%20J,%20Veeravalli%20V,%20et%20al.%20Discovery%20of%20tert-Butyl%20ester%20based%206-Diazo-5-oxo-l-norleucine%20prodrugs%20for%20enhanced%20metabolic%20stability%20and%20tumor%20delivery.%20J%20Med%20Chem.%202023;66:15493%E2%80%93510." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR218">
<span class="label">218.</span><cite>Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102.
</cite> [<a href="https://doi.org/10.1093/nar/gkx247" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5570223/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28407145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tang%20Z,%20Li%20C,%20Kang%20B,%20Gao%20G,%20Li%20C,%20Zhang%20Z.%20GEPIA:%20a%20web%20server%20for%20cancer%20and%20normal%20gene%20expression%20profiling%20and%20interactive%20analyses.%20Nucleic%20Acids%20Res.%202017;45:W98%E2%80%93W102." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR219">
<span class="label">219.</span><cite>Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108–e10.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-17-0307" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6042652/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29092952/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20T,%20Fan%20J,%20Wang%20B,%20Traugh%20N,%20Chen%20Q,%20Liu%20JS,%20et%20al.%20TIMER:%20A%20web%20server%20for%20comprehensive%20analysis%20of%20tumor-infiltrating%20immune%20cells.%20Cancer%20Res.%202017;77:e108%E2%80%93e10." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Cell Death Discovery are provided here courtesy of <strong>Nature Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1038/s41420-025-02687-3"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/41420_2025_Article_2687.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.0 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12365115/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12365115/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365115%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365115/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12365115/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12365115/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40830088/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12365115/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40830088/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12365115/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12365115/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="Q1aFbiu9EEbwJc3AGEjGySBoJ6ts5jzw2KSbSwPbDX6taZn6buRpctpBGscOyOhb">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
